|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/3 ¤W¤È 09:45:15²Ä 5827 ½g¦^À³
|
©Ò¿×ªºASLAN004 2b ¸Ñª¼¦p预´Á ´N¬O¦p1b mITT IGA0,1=45% vs 15%(¹ï·Ó组) ®t²§30% (¹êÅç组16¶g¦³¤j¾÷·|¹F50%~60%) EASI75=69% vs 15%(¹ï·Ó组) ®t²§54% (2bªº¹ï·Ó组16¶gEASI75ªñ 24%, ¹êÅç²Õ ¬ù65%,®t²§45%¥H¤W¡B¤~²Å¦X¥«³õ预´Á) ASLAN004 2b IGA0,1¤ÎEASI75 ©M¹ï·Ó组ªº®t²§Àu©óLebrikizumab10% ¤~²Å¦X¥«³õ预´Á,³Ì°ª¨é°Ó¥Ø¼Ð»ù7¬ü¤¸/ªÑ ¡K¡K¡K¡K¡K Lebrikizumab 2b Q2W EASI75=61% vs24%(¹ï·Ó组)¡B®t²§37% IGA0,1=45% vs 15%(),®t²§30% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/2 ¤U¤È 05:48:40²Ä 5826 ½g¦^À³
|
Lebrikizumab 2b 1.Percent Change From Baseline in Eczema Area and Severity Index (EASI) Q2W 72% vs 41%(¹ï·Ó²Õ) P=0.0005 Q4W 69% vs41% P=0.0022 2.IGA0,1 Q2W 45%vs15%(¹ï·Ó组) P=0.0023 Q4W 34%vs 15% P=0.0392 (Lebrikizumab ¤T´ÁÁ{§É¨Ã¥¼°µ1-16¶gªºQ4W) clinicaltrials.gov/ct2/show/results/NCT03443024 |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/1/2 ¤W¤È 10:32:17²Ä 5825 ½g¦^À³
|
·s¦~·s°ø±æ 1.§Æ±æ¶V§Ö¶V¦n¦³¥¿¦V´Á¤¤¼Æ¾Ú¨Ñ°Ñ¦Ò¡A§Yªí¥Ü¤U°ø±æ¦¨¥\¾÷·|¤j¡C 2.¸Ñª¼®É¾ãÅéPȤp©ó0.05 3.¥|¶g¤@°w¸ÕÅç²Õ§CªÅ§C©ó0.05§Y¥i 4.¦Ü¤Ö¤@ªÑ4.5¶ô¼W¸ê |
|
|
·|û¡GDHL10147526 µoªí®É¶¡:2023/1/1 ¤W¤È 09:05:44²Ä 5824 ½g¦^À³
|
·s¦~·s§Æ±æ ¨È·à±d ¸Ñª¼¦¨¥\¡A¼W¸ê¶¶§Q¡A¤j®aµo¤j°]¡I ¯¬¤j®a·s¦~§Ö¼Ö¡I°]·½ºuºu¡I¨Åé°·±d¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/1 ¤W¤È 08:56:12²Ä 5823 ½g¦^À³
|
2023/01/31 ªÑªF·|¡B¸ê¥»额¼W¤@¿¡D ¦ô2¤ë¤¤¦¯~3¤ë¤W¦¯¡B¤½¥q·|¥ý¸Ñª¼. ±µµÛ¨p¶Ò 4¤ë¤½¥¬¸Ñª¼¼Æ¾Ú¡B ¥]¾P ¡K¤j¶Ò¸ê¡D ¤@¤Á¨Ì¸Ñª¼¼Æ¾Ú²Å¦X预´Á¬°¥²n±ø¥ó¡D ¥un400mg*Q2W(¤G¶g¤@°w)¦X¥G预´Á§Y¥i¡D |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/31 ¤W¤È 07:30:25²Ä 5822 ½g¦^À³
|
§Ö¯}«e§C¡AÁÙ¦³±Ï¶Ü ·sªº¤@¦~³Ì«áªº¾÷·| ¯¬¦U¦ì·s¦~·s§Æ±æ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/23 ¤U¤È 07:18:11²Ä 5821 ½g¦^À³
|
×¥¿¤@¡B ASLAN004 VS Lebrikizumab ®Ä²vPK//2b ¥DnÀø®Ä«ü¼Ð´Á±æÈ Lebrikizumab 2Ó¤T´Á: ¨C¤G¶g¤@°w. www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de ASLAN004 1b mITT :¨C¶g¤@°w aslanpharma.com/wp-content/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf ¤@.Àø®Ä®Ä²v²Ä¤K¶g¤§PK(¦©°£¹ï·Ó²Õ) 1.EASI75 ASLAN004 69%-15%=54%-----A VS LEB. 50%-15%=35%,-----B Leb. ªºEASI75 ¦b²Ä8¶g´î±Ó®Ä²v¶È ASLAN004 ªº65% (B:35%/A:54%=65% ) ***ASLAN004 ªýÂ_IL4 & IL13 °T¸¹¯à¤O±j¦b²Ä8¶gªºEASI75Àø®Ä69%ªí²{¤ñLebrikizumab,16¶g59%Àu(8¶g=50%). ***Lebrikizumab,IGA0,1 ,Àø®Ä ²Ä8¶g30%. 16¶g43%. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/23 ¤U¤È 04:52:42²Ä 5820 ½g¦^À³
|
ASLAN004 VS Lebrikizumab ®Ä²vPK//2b ¥DnÀø®Ä«ü¼Ð´Á±æÈ Lebrikizumab 2Ó¤T´Á: ¨C¤G¶g¤@°w. www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de ASLAN004 1b mITT :¨C¶g¤@°w aslanpharma.com/wp-content/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf ¤@.Àø®Ä®Ä²v²Ä¤K¶g¤§PK(¦©°£¹ï·Ó²Õ) 1.EASI75 ASLAN004 69%-15%=54%-----A VS LEB. 50%-15%=30%,-----B Leb. ªºEASI75 ¦b²Ä8¶g´î±Ó®Ä²v¶È ASLAN004 ªº55% (B:30%/A:54%=55% ) ***ASLAN004 ªýÂ_IL4 & IL13 °T¸¹¯à¤O±j¦b²Ä8¶gªºEASI75Àø®Ä69%ªí²{¤ñLebrikizumab,16¶g59%Àu(8¶g=50%). ***Lebrikizumab,IGA0,1 ,Àø®Ä ²Ä8¶g30%. 16¶g43%. ASLAN004 2bÁ{§É «e¤T°w, «e26¤Ñ~29¤Ñ«Oµý§¹¥þ§í¨îIL13Ra1ªºª¬ªp¤U, ¦ô¨Ï¾ãÅ骺¤ÏÀ³¥§¡°EASI¹Fªñ60%~65%¤U,EASI75¦ôªñ50%. (¬Û·í©óLebrikizumab ²Ä¤K¶gªºÀø®Ä.), ¦ôIGA0,1 ¥i°¦Ü30%. ---TRAC¤w»â¥ý¤U°¶W¹L70%. ASLAN004 2b *Q2W*300mg /400mg ²Ä29¤Ñ(²Ä¥|¶g)~112¤Ñ(²Ä16¶g),¦ô±N¨Ï (1)¥§¡EASI¥Ñ²Ä¥|¶g60%~65%¤U°¨ì²Ä16¶gªº85%¥ª¥k, (2)EASI75¥Ñ²Ä¥|¶g50%¤U°¦Ü²Ä16¶gªº69%~73% (3)³Ì«nªºIGA0,1 ,¥Ñ²Ä¥|¶g30%¤U°¦Ü²Ä16¶g, 53%~60%. ***Lebrikizumab,IGA0,1 ,Àø®Ä ²Ä8¶g30%. 16¶g43%. ¦³¥t¥~ªº12¶g(6°w)ªº®É¶¡¥R¤À¤ÏÀ³,¥i¨ÏIGA0,1(ªñEASI88~85)Àø®Ä¹F¥Ø¼Ð53%~60% ------------------------------------------ ASLAN004 2b Q2W ¥Ø¼Ð¥DnÀø®Ä«ü¼Ð´Á±æÈ EASI75 69%~73%//24%(¹ï·Ó²Õ) IGA0,1 53%~60%//15%(¹ï·Ó²Õ) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/22 ¤U¤È 05:56:32²Ä 5819 ½g¦^À³
|
Lebrikizumab + TCS ,2022/10/18 , ¶}©l 3 ´ÁÁ{§É, 0.5~17·³*N=300¤H clinicaltrials.gov/ct2/show/NCT05158023 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Actual Study Start Date : October 18, 2022 Estimated Primary Completion Date : July 15, 2024 Estimated Study Completion Date : August 15, 2025 1.Experimental: Lebrikizumab (Cohort 1) Participants who are 6 years to <18 years of age, 12 years to <18 years of age who weigh <40 kilogram (kg) or 6 years to <12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS). Dosing will be based on weight. Drug: Lebrikizumab Administered SC Other Names: LY3650150 DRM06 Drug: Topical corticosteroid Topical corticosteroid 2.Experimental: Lebrikizumab (Cohort 2) Participants who are 6 months to <6 years of age, 2 years to <6 years of age or 6 months to <2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS. Dosing will be based on weight. Drug: Lebrikizumab Administered SC Other Names: LY3650150 DRM06 Drug: Topical corticosteroid Topical corticosteroid 3.Placebo Comparator: Placebo Participants will receive placebo matching lebrikizumab by SC injections with a TCS. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/22 ¤W¤È 09:12:01²Ä 5818 ½g¦^À³
|
2021/¤¸¤ë/29 ¤é ´£¥X1»õ5¥a¸U¬ü¤¸ªº¶Ò¸êp¹º,¦p¤W ir.aslanpharma.com/static-files/a3f199f7-f90f-43e0-8068-18a04a09edc5 2021/02/24 ¨p¶Ò3.52¬ü¤¸/ªÑ ir.aslanpharma.com/static-files/8e211cfa-512e-4f27-b382-dea0efcc2e14 2021/03/01 ¤½§G1b´Á¤¤¼Æ¾Ú ir.aslanpharma.com/static-files/73f9ba3a-6822-48e5-ba31-886e0617b68d 2021/03/02 ¥]¾P4¬ü¤¸/ªÑ ir.aslanpharma.com/static-files/3e007d02-a765-4a15-83c3-47aa257d8f49 ¦ôp¤¸¤ë©³¥H«e,¤w¥ý¸Ñª¼1b´Á¤¤¼Æ¾Ú. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/22 ¤W¤È 06:22:33²Ä 5817 ½g¦^À³
|
¨Ì®Éµ{ ²Ä¤@µ§¨p¶Ò±N¦b2023¦~3¤ë15¤é¥H«e§¹¦¨¡B§_«h¥²¶·´î¸ê¡D »ù®æ¡G7*80%*92%=5.15¬ü¤¸/ªÑ ³o¬O2021/02©³ªº¼Ò¦¡ 5x80%x92%=3.68....¨p¶Ò 2021/03/3...4¬ü¤¸¥]销 ¦Ó·í®É¤¸¤ë©³¶}©lº¦¡D ¦ô¤½¥q¦b¥|¤ëªì¤½§G2b¼Æ¾Ú¡B¨Ã¥]销¨é°Ó¶Ò¥H«á¤T´Á¸êª÷¡D ³Q¨ÖÁʮɾ÷¦b©ú¦~©³! ¦³¸êª÷°µ¤T´ÁÁ{§É¤~·|¦³¦nªº³Q¨ÖÁÊ»ùÈ¡D ¥H¤WÓ¤H¬Ýªk! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/21 ¤U¤È 09:45:29²Ä 5816 ½g¦^À³
|
¤jx¥¼°Ê¡B³¯ó¥ý¦æ! ¤½¥q»ùÈ´N¦b15~25¬ü¤¸/ªÑ¤§¶¡¾÷·|¤j¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/21 ¤U¤È 09:35:39²Ä 5815 ½g¦^À³
|
¦p³Q¨ÖÁÊ»ù40»õ¬ü¤¸ 20¸UªÑADRªÑ¥» ¨CªÑ³Ñ20¬ü¤¸¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/21 ¤U¤È 09:28:10²Ä 5814 ½g¦^À³
|
¦n®ø®§¡I ¤£·|´î¸ê¤F¡C ¤@¤@¤@¤@ ©M¥H«e¤@¼Ë¡A¼W¥[¤@¿¸ê¥»ÃB¡A ADR±q10¸U¤dªÑ¼W¬°20¸U¤dªÑ¡C ¥Ø«e¤wµo¦æªñ7¸UªÑ¤dªÑADR ¡]¤½¥q¤º³¡¤Hû奬Ày¤@¸UªÑ¡^ ¥i¹ï¥~¶Ò12¸UªÑ¤d¤dªÑADR ¦p¨é°Ó¥Ø¼Ð»ù7¬ü¤¸¡C ¥]¾P»ù5.6¬ü¤¸¡C 5.6¬ü¤¸x12¸U¤dªÑ¡×ªñ6»õ7¤d¸U¬ü¤¸¡]¤@¦¸¶Ò§¹¡^ ¶Ò¸ê5¡ã6»õ¬ü¤¸°µ¤T´Á¤Î¥ICSL3¤d¸U¬ü¤¸ªºqª÷¤Q ÁÙ·s¥[©Y°]¬F³¡ªºÉ´Ú¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/21 ¤U¤È 09:03:32²Ä 5813 ½g¦^À³
|
2023¦~1¤ë31¤é¥l¶}Á{®ÉªÑªF¤j·|ªº³qª¾¤½§i 2022 ¦~ 12 ¤ë 21 ¤é¡AASLAN Pharmaceuticals Limited¡]¡§¤½¥q¡¨¡^µo¥XÁ{®ÉªÑªF¤j·|³qª¾¡]¡§³qª¾¡¨¡^±N©ó·í¦a®É¶¡ 2023 ¦~ 1 ¤ë 31 ¤é¤W¤È 9 ÂI¦b 3 Temasek Avenue Á|¦æ , Level 18 Centennial Tower, Singapore 039190 ¬°¦Ò¼{¨Ã°u±¡³q¹L¥H¤UªÑªF¨Mij¡G ¨Mij 1¡G (i) §@¬°¤@¶µ´¶³q¨Mij¡A¼W¥[¤½¥qªºªk©wªÑ¥»¡G (A) ¨Ó¦Û¡G5,000,000 ¬ü¤¸¤À¬° 500,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±È©Î±È¬° 0.01 ¬ü¤¸¡C (B) TO¡G10,000,000 ¬ü¤¸¤À¬° 1,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ±È©Î±È¬° 0.01 ¬ü¤¸¡C ¨Mij 2¡G (ii) §@¬°¤@¶µ¯S§O¨Mij¡A¤½¥q²{¦³ªº²Õ´³¹µ{¤jºõ©M²Ó«h¡]§Y¤½¥qªº²Ä¤Q¦¸×q©M«zªº²Õ´³¹µ{¤jºõ©M²Ó«h¡^¥þ³¡¥Ñ·sªº²Õ´³¹µ{¤jºõ©M²Ó«h¡] ¬O¤½¥qªº²Ä¤Q¤@¦¸×q©M«z²Õ´³¹µ{¤jºõ©M²Ó«h¡^¡C Ãö©ó¨Mij 2 ªº¸ÑÄÀ¡G¹ï¤½¥q²Õ´¤jºõ©M²Ó«hªºÀÀijקï¶È©ó¥H¤U¤º®e¡G (a) Åܧ󤽥q³¹µ{¤jºõ²Ä 7 ±ø¡A»¡©ú¤½¥q¸ê¥»¡A¥H¤Ï¬M¤Wzªk©wªÑ¥»ªº¼W¥[¡F ©M (b) ¨C¦¸³q½g¨Ï¥Î§ó·s«áªºµu»y¡§¤½¥qªk¡¨¥N´À¡§¤½¥qªk¡¨¡C ¸Ó³qª¾ªº°Æ¥»§@¬°ªþ¥ó 99.1 ªþ¦b¦¹³B¡AÀÀijªº²Ä¤Q¤@¦¸×q©M«zªº¤½¥q²Õ´³¹µ{¤jºõ©M²Ó«hªº°Æ¥»§@¬°ªþ¥ó 99.2 ªþ¦b¦¹³B¡A¦¹Ãþªþ¥ó³q¹L¤Þ¥Î¨Ö¤J¥»¤å¡C¥»¤å¥ó¤¤¥]§tªº«H®§ ªí®æ 6-K ¯S¦¹³q¹L¤Þ¥Î¯Ç¤J¤½¥qªí®æ F-3 ªºµù¥UÁn©ú¡]¤å¥ó½s¸¹ 333-252575¡^¡Bªí®æ F-3 ªºµù¥UÁn©ú¡]¤å¥ó½s¸¹ 333-254768¡^¡Bªí®æ S- ªºµù¥UÁn©ú 8¡]¤å¥ó½s¸¹ 333-252118¡^©Mªí®æ S-8 ¤Wªºµù¥UÁn©ú¡]¤å¥ó½s¸¹ 333-263843¡^¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/19 ¤U¤È 12:48:18²Ä 5812 ½g¦^À³
|
¸Ø±i¤j¡C ¥Ø«e°ê»Úªº¦ôºâ»Ý¥ý¦©°£¹ï·Ó²ÕªºÀø®Ä¦A¤ñ¸û¤èªk¸û¦h¡G EASI75 69% vs 24%(¹ï·Ó²Õ¡^¡A¡]¦©°£¹ï·Ó²Õ69%-24%=45%¡^ IGA0,1 53% vs 15%(¹ï·Ó²Õ¡^¡A¡]¦©°£¹ï·Ó²Õ53%-15%=38%¡^ Dupilumab 2Ó¤T´Á.¦©°£¹ï·Ó²Õ«á EASI75=36% IGA0,1=28% ASLAN004 vs Dupilumab EASI75 45%¡þ36%=125% IGA0,1 38%/28%=135% µ²½×¡G¤T´ÁÁ{§Éªº¥Dn«ü¼Ð¡AASLAN004¦³Ä¹¹LDupilumab ¼Ð·ÇÀøªk25%¡ã35%ªºÁͶաC |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/12/19 ¤U¤È 12:04:02²Ä 5811 ½g¦^À³
|
¥»¤å¥ýº¡¨¬¨â±ø¥ó¡G 1.©ú¦~¤G´Á¸Ñª¼¼Æ¾Ú¥¿¦V¡C 2.·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤U¤È 04:00:38 ¥Ø«e§ä¤£¨ìÃÄÃÒ¤£¹Lªº²z¥Ñ¡I (©ú¦~¤G´Á¸Ñª¼¼Æ¾Ú)EASI75ªºÀø®ÄASLAN004Àu©óDupilumab40%¡]69%/48.5¢H¡^¡A¨º004ªºÃÄÃÒ»ùÈ´N«D±`¡B«D±`°ª¡C ----------------------------------------------------------------------ÅÞ¿è°Q½×¦p¤U--------------------------------------------------------------------- ¤£§@TREK-DX¤§«e¡A¨ä¹êTREK-ADªº¸Ñª¼¼Æ¾Ú´N°÷Ãļt¤U¨ÖÁʨMµ¦¤F¡A ·f°t©ú¦~²Ä¤@©uÁɿյ᤽¥¬Dupilumab ¤µ(111)¦~¾P°âÃB(111¦~¥þ²y«e¤Q¤jºZ¾PÃÄ)¡A Ãļt®Ú¥»¤£»ÝnTREK-DXªº¸Ñª¼¼Æ¾Ú¡A (TREK-DXªº¸Ñª¼¼Æ¾Ú¡A¬OÅý¨È·à±d´£°ª³Q¨ÖÁʪ÷ÃB¥Îªº) YTREK-DX¼Æ¾Ú¥¼¤½¥¬«e´N³Q¨Ö¡A¨È·à±d¤]·|§âTREK-DX¼Æ¾Ú¸Ó¦³ªº»ùÈ¥[¦b¨ÖÁʪ÷¸Ì±(Ãļt¤]·|»{¦P)¡C (¤£¬Û«H©Ò¦³Ãļtªº¯à¤O³£nµ¥TREK-DXªº¸Ñª¼¼Æ¾Ú¥X¨Ó) YEASI75ªºÀø®ÄASLAN004Àu©óDupilumab20%¥H¤W¡AÃļt¨ä¹ê´N¥i¥H¨ÖÁʨȷà±d¤F¡A (®Ú¥»¤£¥Î¦Ò¼{TREK-DX·|¸Ñª¼¦¨¥\©Î¥¢±Ñ)¡A (TREK-DX¸Ñª¼¦¨¥\¡GÀ³¸Óªº¡C¹ï¶H³£¬O¶Ç²Î«¬¯f±w) (TREK-DX¸Ñª¼¥¢±Ñ¡GÃļt¥H«á¥é³æ¥[µùĵ»y¡G¸T¥Î¹ï¶H¬°´¿¨Ï¥ÎDupilumab¯f±w) Ãļt¥unª¾¹DASLAN004Àø®Ä¡B¼Ú¬w°Ï±ÂÅvª÷ÃB©MDupilumab¤µ(111)¦~¾P°âÃB´N°÷¤F¡C ©Ò¥H¨È·à±d³Ì¦³¥i¯à³Q¨ÖÁʮɶ¡¡GTREK-AD¼Æ¾Ú¤½¥¬«á¦ÜTREK-DX¼Æ¾Ú¤½¥¬«e¡C (Åwªï¦U¦ì¤j¤j¤@¦P°Q½×) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/19 ¤W¤È 11:01:52²Ä 5810 ½g¦^À³
|
¥xÁÞ¤j Dupilumab 2b ¦³´ú300mg ¥|¶g¤@°w¡A¨äIGA0,1¶È2¶g¤@针x300mgªº70%. ¡]Dupilumab ¤@°wªºPK¥i¶W¹L29¤Ñ¡C¡^ ASLAN004 1A x¤@°w¡A600mg x6¤H¡]¨ä¤¤5¤H¶È15¤Ñªº§¹¥þ§í¨î¡A¡^ ¨ä¤¤2¤H²Ä28¤Ñ§¹¥þ§í¨î ¨ä¤¤1¤H¥i¹F25¤Ñ§¹¥þ§í¨î ¨ä¤¤2¤H¡A¥i¹F18¤Ñ§¹¥þ§í¨î ¨ä¤¤1¤H¡A¥i¨ì13¤Ñ§¹¥þ§í¨î Q4wx600mg IGA¦³Q2W ªº50%´Nºâ¼F®`¤F¡C ¥H¤WÓ¤H±À´ú¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/12/19 ¤W¤È 10:31:51²Ä 5809 ½g¦^À³
|
¤Ñ©R¤j ¤½¥q¦³´ú¸Õ300mg 400mg¨â¶g£¸°w»P400mg 600mg¥|¶g£¸°w , ¥|¶g£¸°w¥Ø«eÁÙ¨S¦³ÃĪ«¤W¥« , ¬D¾Ô¬Ý¬Ý¦A»¡ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/19 ¤W¤È 10:11:34²Ä 5808 ½g¦^À³
|
±À½× ¤@¡BASLAN004 2bxQ2W 0/1/2°wx300mg ¦ô¥i°EASI,²Ä¥|¶g(²Ä29¤Ñ) **¨Ì1b 400mgxQ1Wx6¤H结ªG±À¦ô¡B 65%x2¤H 63%x2¤H 61%x1¤H 59%x1¤H ¥§¡EASI ¤U°62% ¤G¡B2b 400mgxQ2W¦ô ¡B²Ä29¤Ñ 65%*4¤H 63%x1¤H 61%x1¤H ¥§¡EASI ¤U°64% ¥H¤W300mg/400mg ¦b²Ä¥|¶g(²Ä29¤Ñ)¥´²Ä¥|°w¡B¦b²Ä¤»¶g(²Ä43¤Ñ)¥i¸É¦^«e±3%/1%ªº¸¨®t¡D EASI ¥§¡°¦Ü71%. ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb Q2WªºÀø®Ä¥i´Á¡B¦³°ª¾÷·|¶W¶V1bªº8¶gªvÀøªºÀø®Ä¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/19 ¤W¤È 08:19:59²Ä 5807 ½g¦^À³
|
¸É¥R¤G¡B patents.google.com/patent/WO2020197502A1 ¹Ï10 scx300mg ÃĮľÇÁͶչÏx6¤H 2¤H§¹¥þ§í¨î¨ì²Ä15¤Ñ¡B¦ô³Ì°ª¨ì18¤Ñ 2¤H§¹¥þ§í¨î¨ì²Ä14¤Ñ, ²Ä14¤ÑªºSTART6¤U´åÁͶդÀ¤l¤Ï¼u15%,ÃĮľÇPK³Ñ85%. 1¤H§¹¥þ§í¨î¨ì²Ä13¤Ñ, ²Öp2¤ÑSTART6¼Æ¶q¤Ï¼u45%,ÃĮľÇPK³Ñ55%. 1¤H§¹¥þ§í¨î¨ì²Ä12¤Ñ¡B²Öp3¤ÑSTART6¼Æ¶q¤@¤Ï¼u90%,ÃĮľÇPK³Ñ10%. ¥H¤WÆ[¹î¡BÃĮľÇPK¨C¤Ñ15%¤Ï¼u¡D²Öp3¤Ñªñ90%ªºÃĮķl¥¢¡B¶È¯à§í¨î10%. ASLAN004 SC¥Ö¤Uª`®gªº¥Í¦¨²v¤j¬ù¶È30%(¥´¤J¨Å骺ÃĶq³Ì«á¶i¤J¦åºÞªº¤ñ²v¶È30%.Dupilumab¬ù50%) ASLSN004§¹¥þ§í¨î¦åºÞ¤¤ÃĶq=1mg/L=1000ng/ml ¹Ï12b«Ü«n¡BSC ¦U¾¯¶qªºPK¥Í©R¹Ï¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/18 ¤W¤È 05:11:29²Ä 5806 ½g¦^À³
|
IV10mg/kg: ÀR¯ßª`®g¡BÅ髨C¤½¤ç¥´10mg. 60¤½¤ç¥´¤J¦åºÞ¤¤ÃĶq10x60=600mg 70¤½¤ç¥´¤JÃĶq700mg SC600mg:¥Ö¤Uª`®g600mg °²³]¶i¤J¦åºÞÃĶq50%(¥Í¦¨²v),¨ä¥L³Q¨Åé§l¦¬¡D 600*50%=300mg¶i¤J¦åºÞ ¥B¤£ºÞ§AÅ髦h¤Ö¡B¥´¤J¨ÅéÃĶq©T©w¡D ¤@Ó±wªÌSC600mg,¶i¤J¦åºÞÃĶq¬ù300mg (sc¥Í¦¨²v°²³]50%)¡B¬Û·í¥´ IV5mg/kg¦Ó¤w¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/18 ¤W¤È 03:33:18²Ä 5805 ½g¦^À³
|
¥xÁÞ¤j¡B IV 10mg/kg ¥i§¹¥þ§í¨î29¤Ñªº³ø§i¬O¥¿½Tªº¡D ¦ýSC 600mg ªº§¹¥þ§í¨î¦b³ø§i¤¤6¤H¡B¶È5¤H¨ì²Ä15¤Ñ¡B¥t¤@¤H¨ì²Ä8¤Ñ¡B ¹Ï12b¦³dupilumab vs aslan004 Sc pk ÁÍ¶Õ¹Ï ±z¥i¥h¬Ý¬Ý! ¹Ï12a¬OIV dupilumab vs aslan004 Pk ÁÍ¶Õ¹Ï 2b ³]p¥Î0/1/2¶g¦U¤@°w¨Ó¤j°EASI¦Ü²Ä¥|¶g¬ù60%,³Ñ¤Uªº10%~20%¥i³Q´î±Ó°ÝÃD¡B ¾a«á±ªº°w¼Æ¨Ó¸É¡D §Ú¹ïQ2W*400mgªº«H¤ß³Ì±j¡B Q4WªºIGA ??? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/12/17 ¤U¤È 11:19:43²Ä 5804 ½g¦^À³
|
¤Ñ©R¤j ¤£¥Î¾á¤ßÅé«°ÝÃD ³o½g±M§Q¬O2020¦~10¤ë1¤é¨ú±o---¦¬®×¬O2021¦~3¤ë16¤é¶}©l ÃĪ«°Ê¤O¾Ç¤è±¤½¥q¤£¥i¯à¨S¦³´x´¤ 2b Á{§É¤~´±¥ÎSC¥Ö¤Uª`®g ¤£¨ü²z½×ªº§ô¿£¡A¥»±M§Qµo©ú¤H»{¬°¡A»P Dupilumab ¬Û¤ñ¡AASLAN004 ¥i¥H¹ê²{¸û§Cªº C through¡A¦]¬° ASLAN004 ¹v¦V IL-13Ra1¡A¦Ó Dupilumab ¹v¦V IL-4Ra¡C¦bÅ餺¡AIL-13Ra1 ªº¼Æ¶q¤j¤j¶W¹L IL-4Ra ªº¼Æ¶q¡C (¦^¥h¬Ý2021¦~4¤ë¤½¥q²³ø P 11¤w´£¨Ñ¹v¦V¤£¦P¨üÅ骺¿¼Æ¼Æ¾Ú ( 60¿:3¿ ) ³o·N¨ýµÛASLAN004»Ýn¸û§C¤ô¥ªº§ÜÅé¡A¦]¦¹ASLAN004 ªºÃĮľǯS¼xªí©ú ASLAN004 »P Dupliumab ¬Û¤ñ«D±`¦³§Q¡A¨Ãªí©ú ASLAN004 ¨C¤ëµ¹ÃĪvÀøª¢¯g©Ê¯e¯f¡]¦p²§¦ì©Ê¥Ö½§ª¢¡^ªº¼ç¤O ·í¤j©ó©Îµ¥©ó 600mg ªº ASLAN004 ³QÀR¯ß¤ºµ¹ÃÄ (10mg/kg) ®É¡A¥¦Åã¥Ü¥X 100% ªº¨üÅé¦û¾Ú©M¦bµ¹Ãīᤣ¨ì 1 ¤p®É¤º§¹¥þ§í¨î STAT6 ÁC»Ä¤Æ¡C³o¨Ç®ÄªG¦b³æ¾¯¶q ASLAN004 «áºû«ù¶W¹L 29 ¤Ñ¡Aªí©ú¨C¤ëµ¹ÃÄ¥i¯à¬O¥i¥H¹ê²{ªº¡C ASLAN004 ¹ï IL-4 ©M IL-13 «H¸¹ªº§Ö³t§í¨î¤]¥i¯à¾ÉP²§¦ì©Ê¥Ö½§ª¢©M¹L±Ó©Êý³Ý±wªÌªº¯gª¬§Ö³t½w¸Ñ¡C ¥H¤W¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/17 ¤U¤È 10:23:46²Ä 5803 ½g¦^À³
|
¸É¥R¡G 1a 600mgx6¤H¸É¥R ¦³2¤H¡B¥i§¹¥þ§í¨î¦ô28¤Ñ ¦³1¤H¡B¥i§¹§í¨î¨ì25¤Ñ¡D ¦³2¤H¡B¥i§¹¥þ§í¨î¨ì18¤Ñ ³Ì«á1¤H¡B¥i§¹¥þ§í¨î¨ì13¤Ñ¡D ¦b¥H¤Uºô§}¤W¡B¥i¤U¸üÀɮסD¦³¦UºØÁÍ¶Õ¹Ï patents.google.com/patent/WO2020197502A1 ¸g¹L0/1/2¶g¨C¶g¤@°w¡BÀ°§U¬Æ¤j¡B´X¥G¥i§¹¥þ¤ÏÀ³¨ì²Ä28¤Ñ¡D 300/400mg*Q2W ¡B·ÀI¤pÀ³¦³¤£¿ùªºÀø®Ä¡B¤×¨ä¬O400mg. Q4W,600mg¥i¥u |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/17 ¤W¤È 11:22:51²Ä 5802 ½g¦^À³
|
ASLAN004 1A °·±d¤Hx¥´¤@°wªºµ²ªG¡G¡]³ø§i¤¤¦³SCx600mgx6¤H¸Ô²Ó¨C¤H³ø§i¡^ pSTAT6 ©M RO ¡]IL13Ra1)´ú©wªºµ²ªG¦p¹Ï 2 ¦Ü 11 ©Ò¥Ü¡C ÀR¯ß¤º (IV) ¶¤¦Cªºµ²ªG¡]¹Ï 2 ¦Ü 6¡^ ªí©ú 0.1 mg/kg ¾¯¶q¯à°÷¦b 1 ¤p®É¤º¹ê²{´X¥G¥þ³¡¨üÅé¦û¾Ú ASLAN004 ªººÞ²z¡C µM¦Ó¡A³oºØ®ÄªG¨Ã¥¼«ùÄò¡ApSTAT6 ©M´åÂ÷¨üÅé¤ô¥¦Ê¤À¤ñ¦¹«á¤£¤[¶}©l¤W¤É¡C 0.3 mg/kg ¾¯¶qªí²{µy¦n¡A¹ê²{§¹¥þ¨üÅé§í¨î¡A«ùÄò¬ù 24 ¤p®É¡C µM¦Ó¡A¦¹«á pSTAT6 ©M´åÂ÷¨üÅé¤ô¥¦A¦¸Ã©w¤W¤É¡C ¬Û¤Ï¡A¦b 1 mg/kg ¾¯¶q¤ô¥¤U¡A¦b¥Î ASLAN004 ªvÀø«áÆ[¹î¨ì pSTAT6 ©M´åÂ÷¨üÅé¤ô¥«ùÄò§í¨î¬ù 1 ¶g¡]²Ä 8 ¤Ñ¡^¡C ±N¾¯¶q´£°ª¨ì 3 mg/kg ¶i¤@¨B±N³oºØ®ÄªG©µªø¦Ü¬ù 2 ¶g¡]²Ä 15 ¤Ñ¡^¡C ³oºØÁ`ÅéÁͶզb 10 mg/kg ¾¯¶q¤ô¥¤UÄ~Äò¡A¨ä¤¤¹ê²{¤F¤j¬ù 4 ¶g¡]²Ä 29 ¤Ñ¡^ªº§¹¥þ§í¨î¡C ¹ï©ó¥Ö¤U (SC) ¶¤¦C¡]¹Ï 8 ¦Ü 11¡^¡Aµ²ªGªí©ú 75 mg ¾¯¶q¯à°÷¦b¬I¥Î ASLAN004 «á 24 ¤p®É¤º¹ê²{´X¥G¥þ³¡¨üÅé¦û¾Ú¡C µM¦Ó¡A³oºØ®ÄªG¨Ã¥¼«ùÄò¡ApSTAT6 ©M´åÂ÷¨üÅé¤ô¥¦Ê¤À¤ñ¦¹«á¤£¤[¶}©l¤W¤É¡C µM¦Ó¡A¦b ¡]SC¡^150 mg ¾¯¶q¤ô¥¤U¡A¦b¥Î ASLAN004 ªvÀø«áÆ[¹î¨ì pSTAT6 ©M´åÂ÷¨üÅé¤ô¥«ùÄò§í¨î¬ù 1 ¶g¡]²Ä 8 ¤Ñ¡^¡C ±N¾¯¶q´£°ª¨ì 300 ²@§J¶i¤@¨B±N³oºØ®ÄªG©µªø¦Ü¬ù 2 ¶g¡]²Ä 15 ¤Ñ¡^¡C ¹ï©ó 600 mg SC ¾¯¶q¤]Æ[¹î¨ìÃþ¦üªºµ²ªG¡C ¤UªíÅã¥Ü¤F±µ¨ü 600 mg SC µ¹ÃĪº¨ü¸ÕªÌÅ髹ï PD ªº¼vÅT¡G ªí 2 ¡V ¨ü¸ÕªÌÅ髹ï PD ªº¼vÅT¡G600 mg SC PD:Pharmacodynamic ÃÄ®Ä SC¡G¥Ö¤Uª`®g IV¡GÀR¯ßª`®g 1¡A55085(½s¸¹¡^¡þ70.6¡]Åé«¡þ¤½¤ç¡^¡þFull PD response to¡]§¹¥þ§í¨î¨ì¡^15¤Ñ¡APD lost by day 29) ²Ä29¤Ñ®ÉÃĮĺɥ¢¡C§í¨î¯à¤OÂk¹s¡C 2¡B55088/65.3kg/15¤Ñ¡Apartial PD to day 29 ²Ä29¤Ñ®É¤´¦³³¡¥÷§í¨î.¦³³¡¥÷ÃĮġC 3¡B55092/76.3kg/15¤Ñ.PD lost by to day 29 ²Ä29¤Ñ®É¡AÃĮĬ°¹s§í¨î¯à¤OÂk¹s 4¡B55095/82.3kg/§¹¥þ§í¨î¨ì²Ä8¤Ñ¡Apartial PD to 15day ²Ä15¤Ñ®É¡A¦³³¡¥÷ÃĮġC 5¡B550958/76.3kg/15¤Ñ¡Apartial PD to 29day ²Ä29¤Ñ¤´¦³³¡¥÷ÃĮġC 6¡B55101/68.8kg/§¹¥þ§í¨î¨ì²Ä15¤Ñ¡C ³o¨Çµ²ªG¥i¯àªí©ú¼W¥[¨ü¸ÕªÌÅé«·|¹ï PD «ùÄò®É¶¡²£¥Ít±¼vÅT¡C These results may suggest that increasing subject weight negatively impacts on PD duration. The results of the pSTAT6 and RO assays are shown in Figures 2 to 11. The results for the intravenous (IV) cohorts (Figures 2 to 6) suggest that the 0.1 mg/kg dose was able to achieve almost total receptor occupancy within 1 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter. The 0.3 mg/kg dose performed slightly better, achieving complete receptor inhibition, which lasted for about 24 hours. However, pSTAT6 and % free receptor levels again steadily rise after this. In contrast, at the 1 mg/kg dosage level, a sustained inhibition of pSTAT6 and %free receptor levels was observed for about 1 week (Day 8) following treatment with ASLAN004. Raising the dosage to 3 mg/kg further extended this effect to about 2 weeks (Day 15). This general trend continued with the 10 mg/kg dosage level wherein complete inhibition was achieved for around 4 weeks (Day 29). For the subcutaneous (SC) cohorts (Figures 8 to 11), the results suggest that the 75 mg dose was able to achieve almost total receptor occupancy within 24 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter. However, at the 150 mg dosage level, a sustained inhibition of pSTAT6 and %free receptor levels was observed for about 1 week (Day 8) following treatment with ASLAN004. Raising the dosage to 300 mg further extended this effect to about 2 weeks (Day 15). A similar result was also observed for the 600 mg SC dose. The table below shows the influence of subject weight on PD for subjects dosed with 600 mg SC: Table 2¡V influence of subject weight on PD: 600 mg SC patents.google.com/patent/WO2020197502A1 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/17 ¤W¤È 07:41:57²Ä 5801 ½g¦^À³
|
ASLAN004¤§Q4W(¥|¶g¤@°w) Y¨ÌASLAN004 1a°·±d¤H¸ê®Æ±À¦ô 400¤@600mg¦ô¶È¥i§¹¥þ§í¨î¬ù12.5~13.5¤Ñ 0/1/2/6/10/14¶gx¦Xp6°w ¥H¤U004®£©ñ¶}«°ªù¡B¦³·ÀI¡D ²Ä28~42¤Ñ(²Ä¥|~¤»¶g) ²Ä55~72¤Ñ(²Ä¤K~¤Q¶g) ²Ä83~93¤Ñ(²Ä¤Q¤G~¤Q¥|¶g) IGA0,1/IEASI90µ¥Àø®Ä¤ñ¸û§xÃø¹F¦¨¡D ¥Ø«eY¥¼¸Ñª¼ªºIGA0,1¥§¡¤£¬Æ²z·Q¡B³Ì¥i¯à¥X²{°ÝÃDªº´N¥i¯à¦b¨âÓQ4WÁ{§É¡D Q2W·ÀI«D±`¤p¡D |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/16 ¤U¤È 08:16:31²Ä 5800 ½g¦^À³
|
¨È·à±d¤Sn°Ñ¥[°ê»Ú·|ij ¥Íª«¦X§@·|ij ASLAN Pharmaceuticals ºÞ²z¼h±N¥X®u©ó2023¦~1¤ë9¤é¦Ü13¤é¦bª÷¤s Marriott Marquis Á|¦æªº¥»¦¸·|ij¡A¨Ã³q¹L BIO Partnering ¦b½u¦X§@¥¥x°Ñ¥[»P§ë¸êªÌ©M¼ç¦b¦X§@¹Ù¦ñªº¤@¹ï¤@·|ij¡C n¦b¥»¦¸·|ij¤Wµù¥U»PºÞ²z¼h·|±¡A½Ð³X°Ý¦¹Ãì±µ¡C ²Ä 12 ©¡¦~«× LifeSci ¦X§@¹Ù¦ñ¥ø·~ã¤J¬¡°Ê ASLAN Pharmaceuticals ºÞ²z¼h±N©ó 2023 ¦~ 1 ¤ë 10 ¤é¦bª÷¤s°Ñ¥[¦¹¦¸¬¡°Ê¡A¨Ã»P¾÷ºc§ë¸êªÌÁ|¦æ¤@¹ï¤@·|ij¡C |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/12/16 ¤U¤È 06:07:20²Ä 5799 ½g¦^À³
|
ªYÄ£¤]¬O©|¥¼©MÃļt©|¥¼±ÂÅv´N¥ýñq¦³Àv¦X©ó |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/12/16 ¤U¤È 06:02:40²Ä 5798 ½g¦^À³
|
©Î³\¶V¬O¸Ô²Ó¯u¹êªº¼Æ¾Ú¤~¯àµ¹¥X ¦w¥þ¤£¦YÁ«ªº»ù¿ú |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/12/16 ¤U¤È 05:09:19²Ä 5797 ½g¦^À³
|
05/06¤½¥q¤½§i¦¨¥ß36Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A111/12/06¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C ¤½¥q¤â¤W¦³¼Æ¾Ú¤F¡A¦Ó¥BÃÒ©ú§@TREK-DX ¦¨¥\ªº¾÷²v«Ü°ª¡C (§Y©ú¦~4¤ëTREK-AD¸Ñª¼¼Æ¾Ú¥¿¦Vªº¾÷·|«Ü¤j¡A¤~·|Äò§@TREK-DX) (Ãļtª¾¹DTREK-AD¸Ñª¼¼Æ¾Ú¥¿¦V¦Ó¤£¨ÖÁÊ??n©ì¨ìTREK-DX¸Ñª¼¼Æ¾Ú¥¿¦V¡A¤~¨Ó¥[»ù¨ÖÁÊ???Å޿褣¹ï) ¦b¬ü§@TREK-ADªº¦¬®×¤¤¤ß¡Aª½±µ®³¨Ó§@TREK-DX¡A§Y¬Ù¥h¦A§ä¦¬®×¤¤¤ßªº®É¶¡??? |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/12/16 ¤U¤È 04:28:33²Ä 5796 ½g¦^À³
|
À³¸Ó¬O¦³¼Æ¾ÚÃÒ©ú¦³¾÷·|°µ³o¼Ë ªºÁ{§É·|¦¨¥\¤~³W¹ºªº ¦Ó¥BÁ{§Éªº¸êª÷¬O¦³³æ¦ì¥þÃB¸ê§U ?·|¬O¼ç¦bªº¶R®a?ÁÙ¬O·sªºª÷¥D §ÚÁÙ¬O¼ÖÆ[¬Ý«Ý³o¥ó¨Æ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/12/16 ¤W¤È 11:03:21²Ä 5795 ½g¦^À³
|
³¯¤j¡A±j¯PÃhºÃ¤½¥q¥u·Qºû«ù¦b0.5¥H¤W¡AÃø¥H¤Wº¦¶W¹L1¶ô¡A«Ý2023/3/26«á¦A¼W¸ê¡A¥Hµ}ÄÀ¨È¬wªÑÅv¤ñ¨Ò¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/16 ¤W¤È 09:43:49²Ä 5794 ½g¦^À³
|
«Ó¤j ¬ü°êªÑ¥«¤jº¦¡A¥L¤]¨S¸òµÛ¤ÏÀ³¡A ¬üªÑ¤j¶^®É¥L¸òµÛ¶^¡A²{¦bªÑ»ù¤@ª½±r «Þ¾ú¥v§CÂI¡A ¥L̬һ⦳¤½¥qÁ~¤ô¡A¦ÛÀ³¾¨¥»¤À¼®¤O±q¤½¡A³o¬O¥L̬°¦Û¤v¤Î¤½¥qÀ³°µªº¨Æ±¡ ¨C·í¤½¥q¤½¥¬°T®§©Î°Ñ¥[°ê»Ú·|ij»¡©ú«á¡A ªÑ»ù¬Ò¬O¤Ï¦V¤ÏÀ³¡A¥«³õªº¸ÑŪ§¹¥þ¤£¦P¡A¥O¤H¶O¸Ñ¡A |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/12/16 ¤W¤È 07:46:27²Ä 5793 ½g¦^À³
|
ÁöµM§Ú¤]¹ï¨È·à±d«Ü¥¢±æ ¦ý¬Q¤Ñ¯uªº¬O«D¾Ô¤§¸o ¬üªÑ¼É¶^¡A¤p«¬ªÑ³£¤£¦n ¬Û¤Ï¦a§Úı±o¨È·à±d¦³½T¹ê¤½§i·s»D¬O¦nªº ¦Ü¤Ö¤½¥qÁÙ¦³¦b§V¤O¡A§Æ±æ¤´¦b |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/16 ¤W¤È 01:24:55²Ä 5792 ½g¦^À³
|
¤S¬O¤@¼Ë±¡§Î ¨È·à±d¤½¥q«Å¥¬«n°T®§ ·í¤ÑªÑ»ù¤@©w«®À ¤µ¤Ñ¤£¨Ò¥~«ÅºÙ¤wµn¿ý¬ã¨s²Ä¤@¦ì¯f¤H ²{¦bªÑ»ù«®À10%¥H¤W ¯u¬O¼Ð·Ç韮µæ¦¬³ÎªÑ¡A³Î¦n³Îº¡ ¼Ð·ÇªÅ´ß¤½¥q |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/15 ¤U¤È 08:38:09²Ä 5791 ½g¦^À³
|
ASLAN Pharmaceuticals «Å§G¦b Dupilumab ¸g¾úªº¯SÀ³©Ê¥Öª¢±wªÌ¤¤¶i¦æ Eblasakimab ¬ã¨s¿z¿ïº¦ì±wªÌ ¨È´µÄõ»sÃĦ³¤½¥q 2022 ¦~ 12 ¤ë 15 ¤é¬P´Á¥|±ß¤W 8:00¡P7 ¤ÀÄÁ¾\Ū ¨È´µÄõ»sÃĦ³¤½¥q ¦b Dupilumab ¦³¸gÅ窺¯SÀ³©Ê¥Öª¢±wªÌ (TREK-DX) ¬ã¨s¤¤¨Ï¥Î Eblasakimab ªº¸ÕÅç±N¦b´X¥G¨S¦³¦w¥þªvÀø¿ï¾Üªº±wªÌ¸sÅ餤µû¦ô eblasakimab ¸Ó¬ã¨s±N¦b¥_¬ü©Û¶Ò 75 ¦W±wªÌ¡A¹wp±N¦b 2024 ¦~²Ä¤@©u«×Àò±o³»½uµ²ªG ¬ã¨s¸êª÷¥R¨¬¡A¹ï¤§«e³ø§iªº²{ª÷¶]¹D¨S¦³¼vÅT ¨Ó¦Û TREK-DX ©M TREK-AD ªº¼Æ¾Ú¥i¥H¤ä«ù eblasakimab ¥Î©ó¥Íª«¾Çªìªv©M¦³¸gÅ窺 AD ±wªÌ ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients ASLAN PHARMACEUTICALS LIMITED Thu, December 15, 2022 at 8:00 PM¡P7 min read ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options The study will enroll 75 patients in North America with topline results expected in the first quarter of 2024 Study is fully funded with no impact on previously reported cash runway Data from TREK-DX and TREK-AD could support the use of eblasakimab for both biologic naïve and experienced AD patients |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/15 ¤U¤È 05:07:29²Ä 5790 ½g¦^À³
|
2b Á{§É 400mg xQ2W¡A¼ÒÀÀ 2b ®Ú¾ÚASLAN004 1b 400mg x8¶gx¤@°w¡þ¶g¡A¦@8°w¡AN=6 (2021/03/1¤½¥¬¸ê®Æ¡^ ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb 1.¥§¡EASI°´T⋯¡]lb=2b) ²Ä¤@¶g¡]²Ä8¤Ñ ¡^15% ²Ä¤G¶g¡]²Ä15¤Ñ¡^ 45% ²Ä¤T¶g¡]²Ä22¤Ñ¡^ 55%⋯¡]TRAC°´T¤w¹F¬Û¹ï§CÂI¬ù73%¡^ ⋯⋯¤@¤@¤@ 2b Á{§É¡A²Ä23¤Ñ¡ã²Ä30¤Ñ¡A¼ÒÀÀ 300mg ¦b°·±d¤H1aÁ{§É²Ä8¤ÑIL13Ra1=0%¡A²Ä15¤Ñ=30%¡]¦ôp§¹¥þ§í¨î¤O逹²Ä13¤Ñ¡^ 600mg ¦b²Ä8¤ÑIL13Ra1=0%,²Ä15¤Ñ10%(¦ôp§¹¥þ§í¨î¤O逹²Ä14¡P4¤Ñ¡^ 400mg¦b1A ²Ä8¤ÑIL13Ra1=0%,²Ä14¤Ñ¦å²G¤¤¥i¯à¦³23%ªº¡A¡]¦ôp§¹¥þ§í¨î¤O逹13¡P5¤Ñ¡^ «h2bÁ{§É400mg§¹¥þ§í¨î¥i¥Ñ²Ä0¤Ñ¡ã²Ä27¡P5¤Ñ¡A¦å²G¤¤ªºIL13Ra1¥i«O«ù0%ª¬ºA¡C ¥§¡ªºEASI°´T¦ô62%¡AEASI50¦ô¤w¹F80%⋯⋯⋯⋯EASI75¦ôp>50% ¥Ñ©ó80%ªº±wªÌ¤w¸g¹FEASI50¡A,«h²Ä29¤ÑªºÀø®Ä³Ì¤j¥i¯à´N°±¯d¦b²Ä27¡P5¤Ñ¡A¦p²Ä8¶g¡ã11¶gªºTRAC´X¥Gºû«ù¦b§CÀÉ¡C ¦b²Ä29¤Ñªº²Ä¥|°w¬I¥´«á«Ü§Ö´N¦^´_§¹¥þ§í¨î¡C µ²½×¡G2b ²Ä29¤ÑªºÀø®Ä¡AEASI¥§¡°´T¦ôp¥u´î3%¥ª¥k¡A¥i¹F°62%¡C ¨Ì¦¹Ãþ±À 2b ²Ä¤¶g¡]36¤Ñ¡^68% 2b ²Ä¤»¶g¡]43¤Ñ¡^71%(À³¸Ó¥i¸É¨¬¤§«e¬y¥¢ªº¤Ö¶qÀø®Ä¡A¦^¨ìIbªº¤ô·Ç¡C ⋯⋯⋯⋯ 1b ²Ä¥|¶g¡]²Ä29¤Ñ¡^65%⋯¡]¦ôEASI50 ¤w¹F83%¡^ ²Ä¤¶g¡]²Ä36¤Ñ¡^71%⋯¡]¬Û¹ï§CÂI¡AEASI75¦ô67%¡^ ¡K¡K¡K¡K 1b=2b ²Ä¤»¶g¡]²Ä43¤Ñ¡^73%⋯ ²Ä¤C¶g¡]²Ä50¤Ñ¡^75%⋯¡]³Ì§CÂI¡AEASI90¦ô¤w¹F67%¡^ ²Ä¤K¶g¡]²Ä57¤Ñ¡^74% 2.¨ä¥L«ü¼ÐÀø®Ä¡G EASI50=83% EASI75=67% EASI90=67% TRAC°´T¡G aslanpharma.com/wp-content/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/12 ¤U¤È 07:52:46²Ä 5764 ½g¦^À³ Lebrikizumab 2b ¦PÀø®Äªº¹F¦¨³t«×§C©óDupilumab 2a ,¦ý²Ä16¶g¦³¬ÛªñªºÀø®Ä¡C ASLAN004 ¨C¶g¤@°w¡A«e8¶gEASI¤U°Àø®Ä³t«×©MDupilumab¬Ûªñ¡C ¤@¤@¤@¤@ Dupilumab 2a N=110 QWx12¶g Vs Lebrikizumab 2b Q2Wx16¶gN¡×75:52 1¡AEASI50 Dupilumab.//Lebrikizumab ²Ä¤T¶g 55%// ²Ä¥|¶g 65%//52% ²Ä¤¶g 85%¡]¨£°ªÂI¡^// ²Ä¤»¶g 85%// ²Ä¤K¶g 85%//70% ²Ä¤Q¤G¶g85%//81%¡]¨£°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//81% Dupilumab ¥i¦P®Éªý¾×Âù¼Ð¹vIL4/IL13¡A©Ò¥H¦b²Ä¤¶gEASI50´N¹F°ªÂI85%¦ÓLebrikizumab¥u¯àªýÀÉIL13¤Î³¡¤ÀlL4©Ò¥Hª½¨ì²Ä¤Q¤G¶g¤~¹F81%°ªÂI¡C ¤G¡AEASI75 Dupilumab.//Lebrikizumab ²Ä¥|¶g 35%//30% ²Ä¤K¶g ¡X//42% ²Ä¤Q¤G¶g62%//62%¡]°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//61% ¤T¡BIGA 0,1 Dupilumab.//Lebrikizumab ²Ä¥|¶g 18%//18% ²Ä¤K¶g ¤@¤@//30% ²Ä¤Q¤G¶g40%//41% ²Ä¤Q¤»¶g¡X¡X//43%¡]°ªÂI¡^ Lebrikizumab ªý¾×°T®§¯à¤O®Ä¯à¸û®t¡A¦ý®É¶¡©Ôªø¨ì16¶g¡A¤´¥i¸É¨¬IGA0,1ªºÀø®Ä¡C www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@ Dupilumab www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg ¹Ï¤G¡þªí¤G Lebrikizumab |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/13 ¤U¤È 08:11:50²Ä 5789 ½g¦^À³
|
aslanpharma.com/news/?cat=publications ASLAN004 1b mITT ¦U¶µ«ü¼Ð¬ù¦b²Ä¤¡ã¤»¶g¨£³Ì¨Î¸¨ÂI¡C¥B¬Ò赢¹LLebrikizumab ²Ä16¶gªº¼Æ¾Ú¡C ¥H¤W¸É¥R»¡©ú¡C ¦ÓLebrikizumab¡]µLªk§¹¥þ«ÊªýIL4/IL13¬G¡^ «n«ü¼Ð³Ì¨Î¸¨ÂI¤j¦h¥X²{¨ì²Ä12¡ã16¶g¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/13 ¤U¤È 05:42:09²Ä 5788 ½g¦^À³
|
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de Lebrikizuma 2Ó¤T´ÁÁ{§É,¨C¨â¶gªºÁͶչÏ(2022/03/30)---Almirall ¤½¥q(¼Ú¬w°Ï¾P°â¤½¥q) °ª峄¾P°â:4.5»õ¼Ú¤¸ ¥Dn«ü¼Ð:EASI75//IGA0,1 ¦¸n«ü¼Ð:EASI90 //Pruritus NRS ≥4-point improvementa from baseline //Sleep loss NRS ≥2-point improvementa from baseline //Quality of life: DLQI ≥4-point improvementa from baseline --------------------------------------------------------------------------- ¤ñ¹ïASLAN004 1b MITT ¹Ï«á,¹ïASLAN004 2B Á{§Éµ²ªG·|§ó¦³«H¤ß. §ÚÌ«e¤T¶g¬Ò¤j´T»â¥ý¦]¬°§¹¥þ«ÊªýIL4/IL13°T®§¶Ç»¼, ²Ä¥|¶g«áÁͶÕÀ³·|©MLebrikizumab ¨«¶Õ¬Ûªñ.¦]¬°ASLAN004¨C¤G¶g¥i¯à¶È§¹¥þ«ÊÂê7¤Ñªº³¡¥÷«Êªý, ¦ý¦]«eASLAN004´Á3~4¶g,¤w¤j´T´î±Óªñ50%,¥B¥Íª««ü¼ÐTRACC¤w°¦Ü©³ÂI(³Ì°ª°ªñ80%). ²Ä¥|¶g«áASLN004 2B À³¦p¯à¦pLebrikizumab ¦b(¥þµ{)³¡¥÷«ÊÂꪺª¬ªp¤U,¦U«ü¼Ð¯à³v¨B©Ô°ª,¹FÀ³¦³¤ô·Ç. ³Ì«á¦p¤½¥q©Ò¹w´úÀø®Ä(IGA 0,1)8% °ª©óDupilumab 2¶g¼Ð·ÇªvÀø¾÷·|°ª. ¥Ø¼Ð»ù¦pú³°Ó:4~7¬ü¤¸/ªÑ¾÷·|°ª |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/13 ¤U¤È 02:43:54²Ä 5787 ½g¦^À³
|
¥x¤jÂå°|¥Ö½§¬ì¥D¥ô¦¶®a·ì¡@¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¡@±`¨£ªº5¤j¯gª¬ ¥x¤jÂå°|¥Ö½§¬ì¥D¥ô¦¶®a·ìÂå®vªí¥Ü¡A¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¦³5¤j¯gª¬¡AÅý¥¦ÌÅܦ¨¡u§ì¨g²§±Ú¡v¡C 1. Äo¡G¬ã¨s³ø§i«ü¥X6¦¨¥H¤W¤¤««×±wªÌ¥Ö½§¦b¤@¤Ñ¤¤µoÄo¶W¹L12¤p®É¡A«ùÄòµoÄoÅý57%±wªÌ·P¨ì§ì¨g¡C 2. µh¡G¬ã¨s«ü¥X¶W¹L75%¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ·|·P¨ì¤¤«×¦ÜÄY«ªº¯kµh»P¤£¾A¡C 3. ¬y¦å¡G¬ã¨sÅã¥Ü¬ù4¦¨±wªÌ¦b¹L¥h¤@¶g¦Ü¤Ö¦³¤@¤Ñ¥Ö½§¬y²Õ´²G©Î¬y¦å¡C 4. ¥¢¯v¡G¬ã¨sÅã¥Ü¥b¼Æ±wªÌ¦b¹L¥h¤@¶g¦Ü¤Ö¦³¤@¤ÑºÎ¯v¨ü¨ì¼vÅT¡C 5. ¥¢±±¡G¬ã¨sÅã¥Ü2¦W««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤¤´N¦³1¦W¡A¨C¤Ñ¤ÏÂШü¨ì¯e¯f¯gª¬©ÒW¡A25%±wªÌı±o¥L̪º¯e¯f¥¢±±¡A¬Æ¦Ü30%ªº±wªÌ¦]¬°©Ó¨üµÛ¥¨¤jªº¤ß²zÀ£¤O¦Ó³´¤J¼~Æ{¡C °£¤F¥H¤Wªº5ÂI¥~¡A¥Ö½§·|¬y¦å¤Î²Õ´²GÅý±wªÌ·P¨ìÀª§¼¡A·Qn¾B±»¦Û¤vªº±w³¡©ÎÁקK¶â¥L¤HªÏÅ鱵IJ¡C ¥xÆW²§¦ì©Ê¥Ö½§ª¢±wªÌ¡@¥Í¬¡«~½è½Õ¬d ¦¶®a·ìÂå®v¤À¨É¡A¤µ¦~°w¹ï¥xÆW²§¦ì©Ê¥Ö½§ª¢±wªÌ¶i¦æªº¥Í¬¡«~½è½Õ¬d¤]µo²{Ãþ¦üµ²ªG¡A¤ÀªR150¦ì¦¨¤H±wªÌªº³X°Ý«á¡Aµo²{²§¦ì©Ê¥Ö½§ª¢ÄY«¼vÅT¦U¥Í¬¡±¦V¡A¦p¤é±`¬¡°Ê¡B¤u§@¾Ç²ß¡B¤H»ÚÃö«Yµ¥¡A¯fªp¶VÄY«¡B¥Í¬¡«~½è¶V®t¡C©Ò¦³±wªÌªººÎ¯v«~½è³£¤£¦n¡A¥ÎÃÄÀ°§U¤JºÎªº¤ñ¨Ò¬O°ê¤Hªº1.5¿12¡A¥B¤u§@¥Í²£¤O¤]¨ü¼vÅT¡A4¦W±wªÌ´N¦³1¦W¨S¤u§@¡A¥¢·~²v¬°¥þ°ê¥§¡ªº7¿¡C¤£¦ý¨S¦¬¤J¡A75%±wªÌÁÙ·|±µ¨ü¶Ç²ÎÀøªk¡B°·±d¹«~µ¥¨ä¥L¤èªk¡A§ó¬O¥[«±wªÌªºt¾á¡C ¤¤««×²§¦ì©Ê¥Ö½§ª¢ªvÀø¤T³¡¦± ¦¶®a·ìÂå®vªí¥Ü¡A¤¤««×²§¦ì©Ê¥Ö½§ª¢ªvÀø¦³¤T³¡¦±¡F²Ä¤@³¡³q±`·|¥ý«Øij±wªÌ¨Ï¥Î¨Å²G¡B«OÀ㾯¤Î¥~¥ÎÃþ©T¾JÃĪ«©M§Ü²Õ´ÓiÃĪ«¡A¦ý52%ªº±wªÌ¤£º¡·N¥~¥ÎÃþ©T¾J¹ï¯gª¬±±¨îªº®ÄªG¡A¥Bªø´Á¨Ï¥Î«á·|¦³¨Ï¥Ö½§ÅÜÁ¡ªº°Æ§@¥Î¡C ²Ä¤G³¡³q±`·|¨Ï¥Î§K¬Ì§í¨î¾¯ÃÄ»I¤Î·Ó¥úªvÀøµ¥¤èªk¡A«eªÌ·|³y¦¨¥Ö½§ªº¨`¼ö·P»P·kÄo¡A¦³40%ªº±wªÌ·P¨ì¦³°Æ§@¥Î¤Î63%±wªÌ¤£º¡·N§K¬Ì§í¨î¾¯ÃÄ»I¹ï¯gª¬±±¨îªº®ÄªG¡F«áªÌ¦³60%ªº±wªÌ¤£º¡·N·Ó¥úªvÀø±±¨îªº®ÄªG¡C ²Ä¤T³¡«h¨Ï¥Î¤F§K¬Ì½Õ¸`¾¯¨Ó±±¨îµoª¢©Î¹L±Ó¤ÏÀ³¡A¦ýªø´Á¨Ï¥Î§K§í¨î¾¯¥i¯à·|¼vÅT¨x¡BµÇ¥\¯à¡A¶·§@©w´Áªº¦å²GÀˬd¡C¦b¨Ï¥Î§K¬Ì½Õ¸`¾¯ªº±wªÌ¤¤¡A¤´¦³53.4%ªº¤ñ¨Ò¡A¯fªp³QÂå®vÂkÃþ¬°±±¨î¤£¨}¡C¦Ó8¦¨ªº²§¦ì©Ê¥Ö½§ª¢±wªÌ¹ï©óªvÀø¨Ã¤£º¡·N¡A§ó¦³4¦¨±wªÌ§ä¹L5Ó¥H¤WÂå®v¡C¦Ó³Ì·sªº¥Íª«»s¾¯ÁöµM¦³®Ä¡A¦ý¤@°w»Ýn28000¡A¹ï±wªÌ¨Ó»¡¬O¤@µ§¤£¤pªºt¾á¡C §ì¨g²§±Ú¡G»{ÃѤ¤««×²§¦ì©Ê¥Ö½§ª¢ - Heho°·±d heho.com.tw/archives/28443 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/13 ¤U¤È 01:06:24²Ä 5786 ½g¦^À³
|
¥Ñ¥H¤U¬ü°ê¾÷ºc(¹ï¨R°òª÷),¹ïASLN 100¤dªÑ¥H¤W«ùªÑ 2022Q3 VS 2021Q1(¥]¾P4¬ü¤¸/ªÑ) ²Îp 21,750¤dªÑ VS 27,000 ¤dªÑ ½æ¶W: 5,250¤dªÑ, ½æ¶W¦û¾÷ºc«ùªÑ5,250/27000=19.4%, ½æ¶W¦ûªÑ¥»5,250/70,000=7.6% ¨ä¤¤¶R¶W³Ì¦hªº¬O : TANG CAPITAL MANAGEMENT LLC 5,654,925 CITADEL ADVISORS LLC ¬ù2,000,000 -------------------------------------------- ¨ä¤¤½æ¶W³Ì¦hªº¬O ORBIMED ADVISORS LLC 2,520,000 LOGOS GLOBAL MANAGEMENT LP 2,300,000(½æ¥ú) MANGROVE PARTNERS 2,178,063(½æ¥ú) LUMINUS MANAGEMENT LLC 1,753,800(½æ¥ú) ASYMMETRY CAPITAL MANAGEMENT, L.P. 1,352,57(½æ¥ú) whalewisdom.com/stock/asln ¤@.2022//Q3 ¬ü°ê¾÷ºc¹ïASLN «ùªÑ TANG CAPITAL MANAGEMENT LLC 5,654,925 RTW INVESTMENTS, LP 3,015,987 VIVO CAPITAL, LLC 2,840,909 CITADEL ADVISORS LLC 2,665,139 TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075 MILLENNIUM MANAGEMENT LLC 1,589,369 SIO CAPITAL MANAGEMENT, LLC 1,270,758 IKARIAN CAPITAL, LLC 820,455 SABBY MANAGEMENT, LLC 499,045 BARCLAYS PLC 471,270 RENAISSANCE TECHNOLOGIES LLC 365,800 WATERFRONT WEALTH INC. 360,500 MORGAN STANLEY 150,983 MYDA ADVISORS LLC 150,000 PLATINUM INVESTMENT MANAGEMENT LTD145,558 ¦Xp¬ù 21,750,000 ¤G.·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/5/19 ¤U¤È 03:50:19²Ä 4214 ½g¦^À³ 2021¦~3¤ë31¤é ¦b¬ü¾÷ºc§ë¸êASLN ADR ©ú²Óªí whalewisdom.com/stock/asln RTW INVESTMENTS, LP 3,250,000 VIVO CAPITAL, LLC 2,840,909 ORBIMED ADVISORS LLC 2,520,000 LOGOS GLOBAL MANAGEMENT LP 2,300,000 MANGROVE PARTNERS 2,178,063 LUMINUS MANAGEMENT LLC 1,753,800 TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075 SIO CAPITAL MANAGEMENT, LLC 1,448,508 ASYMMETRY CAPITAL MANAGEMENT, L.P. 1,352,57 MILLENNIUM MANAGEMENT LLC 1,246,275 IKARIAN CAPITAL, LLC 1,224,516 SABBY MANAGEMENT, LLC 817,165 DAFNA CAPITAL MANAGEMENT LLC 677,500 CITADEL ADVISORS LLC 652,511 PLATINUM INVESTMENT MANAGEMENT LTD 514,984 KNOTT DAVID M 437,412 MONASHEE INVESTMENT MANAGEMENT LLC420,000 GOLDMAN SACHS GROUP INC 407,464 PARKMAN HEALTHCARE PARTNERS LLC 325,000 RENAISSANCE TECHNOLOGIES LLC 258,467 AFFINITY ASSET ADVISORS, LLC 200,000 MYDA ADVISORS LLC 200,000 CAAS CAPITAL MANAGEMENT LP 150,000 BOOTHBAY FUND MANAGEMENT, LLC 130,920 BARCLAYS PLC 128,586 ¦Xp ¬ù27,000,000 , 38.5%(27,000/70,000) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/13 ¤W¤È 09:54:49²Ä 5785 ½g¦^À³
|
¥V©u²§½§µo§@¡u§O§ì¤F¡v¡I ¥Ö½§¬ìÂå®v±Ð¤T©Û¤£¦A¯}¥Ö¬yÁw ³¯ ¶v³Í 2022¦~12¤ë11¤é ¶g¤é ¤U¤È2:00 ¶×¬y·s»Dºô°OªÌ³¯¶v³Í¡þ¥x¥_³ø¾É ÄoÄo¡A§O¦A§ì¤F¡I³o¬O¥V©u¥Ö½§¬ì¶E¶¡³Ì±`Å¥¨ìªº¹ï¸Ü¡AÂù©MÂå°|¥Ö½§¬ìÂå®v¬I©É½åªñ´Á´N¦¬ªv¤@¦W5·³¨kµ£¦]²§¦ì©Ê¥Ö½§ª¢µo§@¡A¾ã±ß¤£°±§ìÄo¡AµLªk¤J¯v¡A¤£¥u§ì¨ì¯}¥Ö¬y¦å¡A¬Æ¦Ü¥X²{¶Ë¤fµoª¢¡B¬yÁwµ¥²Óµß·P¬Vªº±¡ªp¡A¥þ¨¥¬º¡·s¶ˤf¡CÂå®v´£¿ô¡A¥®É¥i¥H¥[±j«O·Ã¡BÁקK¨ë¿E¡B»·Â÷¹L±Ó쬰·ÓÅ@ì«h¡C ²§¦ì©Ê¥Ö½§ª¢¤W¨¡A°ê¤ºªù¶EÆ[¹î¡A¤£¤Ö¤pªB¤Í±`¦]·kÄoÃø@¡AµLªkÀò±o¥R¨¬ºÎ¯v¡Aºë¯«¤£ÀÙªº±¡ªp¤U¡A¶i¦Ó¼vÅT¨ì¥Õ¤Ñªº¶¼¹¡B¾Ç²ßµ¥¬¡°Ê¡A¥t¥~¡A®aªø¤]±`·P¨ü¨ìº¡º¡ªº¯h ¬I©É½å¡A²§¦ì©Ê¥Ö½§ª¢¬O¥xÆW±`¨£ªº¥Ö½§¯e¯f¡A¬O¤@ºØ¦h°ò¦]¿ò¶Çªºµoª¢¯e¯f¡A¥Dn¬O¥Ñ¥ý¤Ñ©Ê§K¬Ì½Õ¸`²§±`¤Îªí¥Ö¤º¦b½Õ±±¥¢½Õ©Ò¤Þ°_¡C®Ú¾Ú²Îp¡A¥xÆW¦³¶W¹L200¸U¦W±wªÌ¡A«Ü¦h¤H±qÀ¦¥®¨à®É´Á´N¶}©lµo¯f¡A°£¤FÄY«·kÄo±a¨Óªº¤£¾A¤§¥~¡A¬õ´³¡B¥C¯l¤Î¤ÏÂеo§@³y¦¨ªº¥Ö½§aÄö¤Æ¡A¤]¶¡±µ¼vÅT¨ì±wªÌ¦Û«H¡BªÀ¥æ¤Î¤H»ÚÃö«Yµo®i¡A©ö´_µoªº¯S©Ê¤£¶ÈÅý¯f¤Í¹ïªvÀø¥¢¥h´Á«Ý¡A¬Æ¦Ü²£¥ÍÀ£¤O»Pt±±¡ºü¡C ªù¶E¤¤´N´¿¦³±wªÌ¦]¤â³¡¦³¤j¤ù¯f¨_¦Ó¤£´±»P¤H´¤¤â¡Aªø¤[¤U¨ÓºtÅܬ°ªÀ¥æ»Ùê¡A¥[¤W¨ä®ø·¥ºA«×¡A¦b¨D¾Ç¤Î¨D¾¹Lµ{¤¤ÀWÀW¸I¾À¡C ¬I©É½å«ü¥X¡A²§¦ì©Ê¥Ö½§ª¢ªº§Î¦¨©M¨â¤j¦]¯À¦³Ãö¡Aº¥ý¬O¡uªí¥Ö«Ì»Ù¯Ê³´¡v¹³¬O¡AÅÖ»E³J¥Õ¯Ê³´¡B¯«¸gñQÓi¤£¨¬µ¥µ¥¡F¨ä¦¸¬O¡u§K¬Ì²ÓM¹L«×¤ÏÀ³¡v¡A·í¯S©w§K¬Ì²ÓM¥H¤Î¢â²ÓM¹L«×¬¡¤Æ¡A´N·|³y¦¨¥Ö½§µoª¢¡A§Î¦¨ªx¬õ¡BµoÄo¡B²æ®hµ¥Á{§Éªí²{¡C ȱoª`·Nªº¬O¡A¬I©É½å»¡¡A²§¦ì©Ê¥Ö½§ª¢ªº¯f¨_¤À¥¬·|ÀHµÛ¦~ÄÖ¦Ó¦³©Ò¤£¦P¡A¦bÀ¦¨à¤Î¥®µ£®É´Á¡A¯f¨_¥Dn¤À¥¬¦bÁy¡B¤â¨y¤Î½¥»\¡F¦~¬ö¸û¤jªº¤p«Ä¡A«h¦b¥|ªÏÅs¦±³B¥X²{ºC©ÊaÅ~¤Æ¯f¨_¡F¨ì¤F«C¤Ö¦~©Î¦¨¤H¡A¤Ö³¡¤À¯f±w¥i¯à·|¦nÂण¦A´_µo¡A¦ý¤j¦h·|«ù¥©Î§ïÅÜ«¬ºA¡A¬Æ¦ÜÅܦ¨ÄY«ªº§½³¡¯f¨_©Î¥þ¨©Ê»´«×¯f¨_¡C ¬I©É½å«Øij¡A¥®µ£°£©w´Á´NÂå±µ¨üªvÀø¡Aµo¯f®É¥t¥i¥ý±q°·Å¡B³q·¶}©l¡A¨Ã§Q¥Î¨ä¥L¨Æª«Âಾª`·N¤O¥H§K§ì¶Ë¡A¥±`«hª`·N«O·Ã¡BÁקK¨ë¿E¤Î»·Â÷¹L±Óìµ¥·ÓÅ@ì«h¡F¦Ü©ó¨àµ£©Î«C¤Ö¦~¡A¦b¤ß²z¤ä«ùªº³¡¤À±o¯S§Oª`·N¡A¹³¬O«C¬K´ÁªºµJ¼{¡A©Î¬O¨D¾Ç¡B·Ç³Æ¦Ò¸Õ¹Lµ{¤¤ªºÀ£¤O³£¦³¥i¯àIJµo¡A°£¥HÃĪ«±±¨î¡B§ïµ½¯fªp¥~¡A¥²n®É¤]¥i´M¨D¤ß²z¿Ô°Ó¨ó§U¡A©Î¬O§ä¨ì¾A¦X¤è¦¡§çµo¤º¤ßÀ£¤O¡A¹³¬O¾A«×¹B°Ê¡B³W¹º¨ã³Ð³y©Êªº¥ð¶¢¬¡°Ê©Î¥[¤J¦P¾«¹ÎÅé¤À¨É¤ß±¡µ¥¡C ·Ó¤ù¨Ó·½¡GÂù©MÂå°| ¤Ñ§N ¡i¤å³¹Âà¸ü½Ðµù©ú¥X³B¡j -~B/aD0yMDA7dz02NzA7YXBwaWQ9eXRhY2h5b24-/s.yimg.com/os/creatr-uploaded-images/2022-12/3dbc4bf0-76d7-11ed-bbfc-88e626aa2a99 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/12 ¤U¤È 04:10:35²Ä 5784 ½g¦^À³
|
Lebrikizumab ¤G½u(¦³Dupilumab¨Ï¥Î¸gÅç)¤¤-««×AD ¤T´ÁÁ{§É120¤H,§Y±N¶}©l.¹wp12Ӥ맹¦¨. ¤w¤½§G16Ó¬ü°ê¦¬®×¤¤¤ß: ASLAN004 ¤G½u(¦³Dupilumab¨Ï¥Î¸gÅç)¤¤-««×AD ,¤G´Á, ¹wp12¤ë©³§¹¦¨²Ä¤@Ó©Û¶Ò. ¥H¤W¤GÓÁ{§É´X¥G¦P®É©l --------------------------------------- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/10 ¤W¤È 07:53:50²Ä 5783 ½g¦^À³
|
³¯¤j¡B whalewisdom.com/stock/asln «ùªÑ1000¤dªÑªº¤jªÑªFªk¤H¦³7Ó¤½¥q¡D ¥L̪º¸g²z¤H·|©MASLN¤½¥q°µ¹Hªkªº ¤º½u¥æ©ö? ¤£·|¨º»ò儍! ¦D¨Æ/¥Á¨Æ½ßÀv¦b¬ü½ß¤j¤F¡D ¦óªp¥¼¸Ñª¼¹ê¦bµL¥¿½T¼Æ¾Ú¥i¨Ñ¤º½u! |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/9 ¤U¤È 11:44:01²Ä 5782 ½g¦^À³
|
³o®a¤½¥q¨C¦¸°Ñ¥[°ê»Ú·|ij«á¡A ©ÎªÌ¤½¥¬¸Ñª¼°T®§¡A±q¨S¦n¨Æµo¥Í¹L¡AªÑ»ù±q¥¼¥¿±¤ÏÀ³¡A³£¬O«æ¶^©Î¬O½w¶^«ùÄò¶^¡A·Pı¬OÓªÅÀY¤½¥q¡ACEO ´N¬O¥Ö¥]²Õ¶RªÅ½æªÅªº¡A 004 2bªì¨Bªº´Á¤¤¼Æ¾Ú¦pªG¤£¿ù¡A ì©l¤jªÑªF¤@©w·|¥ýª¾¹D¡AªÑ»ù¤S¦b¾ú¥vªº§CÀÉ¡A¤jªÑªF̲@µL§@¬°¡AµL¥ô¦óÅ@½L°Ê§@¡A´N¬O¹ï¤½¥q²@µL«H¤ß¡A §Ú¹ï¤½¥q¤]¤£©ê§Æ±æ¡A´N·í¶R¼Ö³z¡A¥á¨ì¯ä¤ô·¾¸Ì¡A |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/8 ¤W¤È 06:48:13²Ä 5781 ½g¦^À³
|
Aslan004 2b ²q´ú¤Î´Á±æ¡G¨Ì¾ÚDupilumab¤ÎLebrikizumab 2b,ASLAN004 1b 1.400mg/Q2W EASI75 69% IGA0,1 53% 2.400mg/Q4W EASI75=69%*93%=64% IGA0,1=53%*75%=40% IGA0,1Àø®Ä²q´ú 400mg/Q2w//53%>300mg/Q2W//49%> 600mg/Q4W//47%>400mg/Q4W//40%> ¹ï·Ó组15% ,¥¼¸Ñª¼¥H¤W¥§¡40%. |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/12/6 ¤U¤È 04:47:29²Ä 5780 ½g¦^À³
|
¤½¥q¦U¤½§i¦¨¥ß¦¬®×¤¤¤ß®É¶¡ÂI¡A©¹«á±À¦ô¤½§i¸Ñª¼¼Æ¾Ú®É¶¡¡G 1.05/06¤½§i¦¨¥ß36Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A111/12/06¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C 2.06/28¤½§i¦¨¥ß39Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/01/28¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C 3.07/13¤½§i¦¨¥ß42Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/02/13¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C 4.07/15¤½§i¦¨¥ß43Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/02/15¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C 5.08/01¤½§i¦¨¥ß45Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/03/01¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C 6.08/23¤½§i¦¨¥ß65Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/03/23¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C (¨Ñ°Ñ) |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/12/6 ¤U¤È 12:44:01²Ä 5779 ½g¦^À³
|
´£¿ô¡G ¤µ¦~5¤ë6¤é¡A¤½¥q¤½§i¤w¶}¹F36Ó©Û¶Ò¤¤¤ß(¶W¹L´Á¤¤´¦ÅS©Ò»Ý±ø¥ó)¡A °²³]¥Î2Ó¤ë¨Ó©Û¶Ò(¿z¿ï)¡A§Y7¤ë6¤é¶}©lªvÀø¡C ¦A¥Î4Ó¤ëªvÀø¡A«h11¤ë6¤éªº16¶gªvÀø§¹¦¨¡C ¦A1Ó¤ë¸ê®Æ¾ã²z¡A¤]´N¬O¤µ¤Ñ(12¤ë6¤é)¥H«á¥i¥H´¦ÅS´Á¤¤¼Æ¾Ú¡C (ºÞ²z¶¥¼h¤w´x´¤ª¼¼Æ¾Ú) ¦U¦ì¥i¥H¶}©lÆ[¹îªÑ»ùªºªí²{¤F¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/6 ¤W¤È 11:59:43²Ä 5778 ½g¦^À³
|
¤@¡BLebrikizumab 2b ¤¤-«¯gAD x16¶gªvÀø www.clinicaltrials.gov/ct2/show/results/NCT03443024 125mg-Q4W//250mg-Q4W//250mg-Q2W//¹ï·Ó²Õ 1.EASI 75¡]%¡^ 43.3//56.1//60.6//24.3 2.IGA0,1¡]%¡^ 26.6//33.7//44.6//15.3 ¨C¥|¶g¤@°w¤@250mg vs ¨C2¶g¤@°w250mg 1.EASI75 56.1/60.6=93% 2.IGA0,1 33.7/44.6=76% Lebrikizumab 2b ªº¥|¶g¤@°w¦bEASI75ªºÀø®Ä¬°¤G¶g¤@°w93%¡]«e16¶gªvÀø¡^ Lebrikizumab 2b ªº¥|¶g¤@°w¦bIGA0,1ªºÀø®Ä¥u¦³¤G¶g¤@°wªº75%¡C¡]«e16¶gªvÀø¡^ ¤@¤@¤@Lebrikizumab ph3 17¡ã52¶gªvÀø.¦b4¶g¤Î2¶gEASI75&IGA0,1Àø®Ä®t¤£¦h¡C ¤G¡BDupilumab 2b ¥|¶g¤@°w vs ¤G¶g¤@°w www.clinicaltrials.gov/ct2/show/results/NCT01859988 300mg-Q4W//300mgQ-2W//¤ñ²v 1.EASI75 49.2%//53.1%//93% 2.IGA0,1 21.5%///29.7%//74% ¤T¡AASLAN004 2b ¥|¶g¤@°w vs ¤G¶g¤@°w ªºÀø®Ä®t²§¡H¡H¡H ¤]³\±µªñ¤WzLebrikizumab 2b¤ÎDupilumab 2b ¥|¶gVs ¤G¶gÀø®Ä®t²§ ¦bEASI75 ®t²§93% IGA0,1 ®t²§75% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/3 ¤W¤È 08:05:13²Ä 5777 ½g¦^À³
|
¥Ö½§¬ìÂå®v¨Ï¥Î¤@ºØ«ÈÆ[ªºµû¦ô¤è¦¡¡GEASIµû¤À¡A¥Î¥Hpºâ²§¦ì¥Ö½§ª¢ªºÄY««×¡FEASI¤À¼Æ¶V°ª¶VÄY«¡CEASI-50¥NªíÄY««×§ïµ½¤@¥b¡BEASI-75¥NªíÄY««×§ïµ½¤C¦¨¤¡A¥H¦¹Ãþ±À¡C ¥H§Ú̪ºÁ{§É¸gÅç¡A 1.¹F¨ìEASI-50(ÄY««×°§C¤@¥b)¡A±wªÌ¸ò®aÄÝ´Nı±o®ÄªG«Ü¦n¡A³q±`º¡·N«×´N«Ü°ª¡F 2.¦ÓEASI-75(§ïµ½¤C¦¨¤)·|ı±o®ÄªG«D±`¦n¡Aı±o§ä¹ïÂå¥Í¤F¡A·P¿E®÷¹s¡F 3.EASI-90(§ïµ½¤E¦¨)·|ı±o´X¥G¦n¤F¡A§Ö§âÂå¥Í·í¯«¦b«ô¡CY±NªvÀø®ÄªG¶q¤Æ¡G www.dr-skin.com.tw/health/view/240 ²§¦ì©Ê¥Ö½§ª¢¼Ð¹vÃĪ«¡u§ùÁת¢¡v¡GÀø®Ä¡B°Æ§@¥Î¡B¨Ï¥Î¤è¦¡¡B¶O¥Î¸ÑªR |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/12/2 ¤U¤È 08:34:16²Ä 5776 ½g¦^À³
|
³¯¤j¡A§Ú¤]»{¬°¤w¦³50%¥H¤Wªº16¶g¸ÕÅç¤w§¹¦¨¡A¦ý¥HªÑ»ùªºªí²{¨Ó¬Ý¡AÁ٬ݤ£¥Xª¼¼Æ¾Ú¦³¦n¨ìn¤jº¦ªº¸ñ¶H~Ó¤H§PÂ_¡A¤£·íªÑ²¼¶i¥Xªº°Ñ¦Ò~~~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/2 ¤U¤È 12:11:35²Ä 5775 ½g¦^À³
|
³¯¤j¡A ASLN ¤½¥qÀ³¸Ó¥u¦³¥¼¸Ñª¼ªº¼Æ¾Ú¡C ¦p¸ó±i¤j©Ò¦ô¡A¦Ü¤Ö¦³¬ù50%§¹¦¨16¶gªvÀø¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/12/2 ¤W¤È 10:57:19²Ä 5774 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/2 ¤W¤È 06:32:10 ¬Q±ß¶È¨Ñ¿ýµÀÉ¡D¥i¤Wºô¤U¸ü¡D¨ä¥L¦p11¤ë²³ø¤º®e¡D¥D«ù¤H°Ý¨ìASLAN004¤T´Á·Ç³Æ¡Bµª¡G±N¬O400¤HªºÁ{§É ´£¿ô¡G 1.¤]´N¬O2b Á{§É´Á¤¤¼Æ¾Ú¸g¤½¥q¤º³¡½T»{¬O¥¿¦VµL»~¡A¤~·|³Q°Ý¨ìASLAN004n°µ¤T´Á·Ç³Æ¡C 2.¤µ¦~5¤ë6¤é¡A¤½¥q¤½§i¤w¶}¹F36Ó©Û¶Ò¤¤¤ß¡A°²³]¥Î2Ó¤ë¨Ó©Û¶Ò(¿z¿ï)¡A§Y7¤ë6¤é¶}©lªvÀø¡C¦A¥Î4Ó¤ëªvÀø¡A«h11¤ë6¤éªº16¶gªvÀø§¹¦¨¡C¦A1Ó¤ë¸ê®Æ¾ã²z¡A 12¤ë6¤é¥H«á¥i¥H´¦ÅS´Á¤¤¼Æ¾Ú¡C(¦ý¡A¬Ý¨Ó¡A´Á¤¤³ø§i¼Æ¾Ú´£«e1¬P´Á¥X¨Ó¤F) (ºÞ²z¶¥¼h¤wª¾¹D´Á¤¤¼Æ¾Ú¤º®e¡A¥D«ù¤H¤~·|°Ý¤T´Á·Ç³Æ°ÝÃD) ¦U¦ì¥i¥H¶}©lÆ[¹îªÑ»ùªºªí²{¤F¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/12/2 ¤W¤È 10:56:55²Ä 5773 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d004¤T´Á¡A¬°400¤HÁ{§É°µ·Ç³Æ ¬O§_¥Nªí2´ÁÁ{§É¤wµL°ÝÃD¶Ü ¥i¯à·|¦³2´Á´Á¤¤³ø§i¶Ü¡A¸Ñ¨MªÑ»ùªø´Á§C©ó1¬ü¤¸¦M¾÷ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/2 ¤W¤È 06:32:10²Ä 5772 ½g¦^À³
|
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference ¬Q±ß¶È¨Ñ¿ýµÀÉ¡D¥i¤Wºô¤U¸ü¡D ¨ä¥L¦p11¤ë²³ø¤º®e¡D ¥D®u¤H°Ý¨ìASLAN004¤T´Á·Ç³Æ¡B µª¡G±N¬O400¤HªºÁ{§É (Ó¤H¸É¥R¡G¤@¯ë¬O2Ó¤T´ÁÁ{§É¡B¥B¥[52¶gªº©µªø¹êÅç¡B¥t¥i¯à°l¥[¤QTCS¥~¥ÎÃÄ»I¤@Ãþ©T¾J¤T´ÁÁ{§É¡B¥H¦¹¥Ó½Ð¬ü°êªºÃĵý) |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2022/11/22 ¤U¤È 06:09:40²Ä 5771 ½g¦^À³
|
CBO ¥¿¶}©l¦£,¨SªÅ¥h¡H |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/11/22 ¤U¤È 03:42:05²Ä 5770 ½g¦^À³
|
¤½¥q©ó5¤ë6¤é¤½¥¬²Ö¿n36Ó¦¬®×¤¤¤ß¦¨¥ß(¶W¹L´Á¤¤³ø§i´¦ÅS©Ò»Ýn¥ó)¡A °²Y©ó6¤ë20¤é¦¬º¡¸ÕÅçªÌ¨Ã¶}©lªvÀø¡A ¸g4Ó¤ëªvÀø«á§Y¬O10¤ë20¤é¡A ¦A1Ó¤ë¸ê®Æ¾ã²z§Y¬O11¤ë20¤é¡C ¬Q¤Ñ(11/21)¤½¥q¤½§i±N¦b¯Ã¬ù°Ñ¥[ÂåÀø«O°··|ij(11/29~12/1)¡C (¤£n´Á«Ý¤Ó²`¡A¦]¥u¦³CEO¥h) |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/11/22 ¤W¤È 09:04:23²Ä 5769 ½g¦^À³
|
±aÓ004´Á¤¤¼Æ¾Ú¡A©Î¬Oª¼¼Æ¾Ú¤]¦n¡AÅý¥«³õ¤ÀªR®v±M®aÀ°§A»{ÃÒ¡A¦Ñ·à¤~¦³¾÷·|¥XÀY¤Ñ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/21 ¤U¤È 08:54:59²Ä 5768 ½g¦^À³
|
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY. A replay of the fireside chat will be made available on the Investor Relations section of ASLAN¡¦s website and can be accessed directly at this link. Management will be available for one-on-one meetings with investors throughout the conference. Please contact your representative at Piper Sandler to schedule a meeting. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/20 ¤W¤È 10:27:49²Ä 5767 ½g¦^À³
|
ASLAN 2b¼ÒÀÀ(¸É¥R) ²Ä0¤Ñ EASI28 ²Ä21¤Ñ ¹êÅç组¥§¡EASI=14¤À(°50%¡^ ¹ï·Ó组¥§¡EASI=25¤À(°12%) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/18 ¤U¤È 03:20:15²Ä 5766 ½g¦^À³
|
Æ[¹î¤G¡C www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab 2Ó¤T´ÁÁ{§É¡A¹Ï¤G¡A¦U¶gEASI¤U°Àø®ÄÁͶչϡC ¹ï·Ó²Õ¥u¥´¦w衞¾¯ªº±wªÌ¡C ¦b²Ä¤T¶gªºÀø®Ä¬ù12¡ã15%¡A¤§«á«ùÄò¤U°¦Ü12¶g33%¡C¡]¥´¦w¥þ衞¾¯ªÌ¥ç¦³AD¦Û¡¯à¤O¡A¦¹´Á¶¡°20%¡ã18%¡^ ¦Ó¥´Dupilumabªº²Õ¤£ºÞ¨C¶g¤@°w©Î¤G°w¡A¦b²Ä¤T¶gÀø®Ä¤w¤U°¦Ü45¡ã50%EASI ²Ä¤Q¤G¶g¨£©³ÂI¥§¡¬ù°¦Ü70%¡C¡]¦¹´Á¶¡¶È°70%¤@45¡ã50%=25%~20%) ¦b²Ä¤T¶g®É¥´Dupilumab¬Û¹ï©ó¥´¦w衞¾¯²Õ¯f±¡§ó»´¬ù35%±j¡A©Ò¥H¦Û¡¯à¤O²zÀ³¤j©ó¦w衞¾¯²Õ¡C ASLAN004 2b«e¤T¾¯¥i§¹¥þ§í¨îIL/IL4¨ì²Ä21¤é¡A¤§«á¦³22¡ã27¤é¥i¯àµL§¹¥þ§í¨îª¬ªp¡A¦ý¤´°ª©ó¦w衞¾¯²Õªº¦Û¡¯à¤O¥i¯à¡C µ¥²Ä28¤é¥´²Ä¥|°w´N°¨¤W§Î¦¨§¹¥þ§í¨î¤F¡C Æ[¹î¤T¡C ¦pASLN004ªº´Á¥ZµoªílbX8¶gªvÀø ¥Íª««ü¼Ð¦b²Ä¤T¶gTRAC¤x°¦Ü¬Û¹ï§C¤ô·Ç¡C TRAC¹ï©ó©MEASI¤U°ÁͶլO¥¿¬ÛÃöªº»â¥ý«ü¼Ð¡C ªñ²Ä¤K¶g¤§¤ô凖¡A²Ä7¡ã11¶g¥¼¥´°w¡A¤´«O¦³§C¤ô¥ªºTRAC¡C ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c P¡A26 ¥H¤W¬OÆ[¹î¤Î±À²z¦Ó¨Ó¡C¹ê»Ú¤´«Ý2b¸Ñª¼¤èª¾¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/17 ¤U¤È 03:40:24²Ä 5765 ½g¦^À³
|
www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@¡ADupilumab ¦´Á EASI50 75mg vs 150mg vs300mg vs¹ï·Ó²Õ x¨C¶g¤@°wx4¶g ¥Ñ¹Ï¤@¥iÆ[¹î¨ì¡A²Ä30¤ÑªºÀø®Ä 300mg >150mg>75mg>¹ï·Ó²Õ ¨ä¤¤300mg/150mg ¦b²Ä15¤éªºpÈ´N¤p©ó0¡P05 ²Îp¤Wªº©úÅã®t²§¡C 75mg/150mg ¨C¶gÀø®Ä¦H©ó300mgªí¥Ü¡A¾¯¶q¤£¨¬¡AµLªk§¹¥þ«ÊªýI4/IL13¸ê°T¶Ç»¼¡C ¦¹®É¥u¬OÀø®Ä·|»¼©µ¡A¥un°÷ªø®É¶¡ªvÀø¡A§C¾¯¶q²Õ¥i¯à²×±N°l¤W°ª¾¯¶q²Õ¡C Lebrikizumab ¤]¦³Ãþ¦üª¬ªp¡A©µªøªv¡¨ì52¶g¡BIGA0¡A1·|¦A¼W¥[4%¡ã5%¡C ASLAN004 0/7/14¤é¦U¤@°w.¥i§¹¥þ§í¨î¨ì21¤é¡AEASI50 ¥i¹F¨ì55%¡A ³o¨Ç¤w¦³¤ÏÀ³ªÌ¦b0¡ã7¤Ñªº¥i¯à¤£¨¬¾¯¶q´Á¶¡¡AÄ~Äò´î±Ó©Îú£½w´î±Ó¡A¤Ï¼u¾÷·|¤£¤j¡C ²Ä4°w¦b28¤é¥´°w«á¡A´î±Ó³t«×´NÀ³¸Ó«ì´_¡C ©Ò¥H004 2b ¥Î16¶gX9°wx2¶g¤@°wÀø®Ä¡A¦ôp>=1b ªºmITT 8¶gÀø®ÄÀ³¸Ó¬O¦X²z±À´ú¡C ¤@¤@.¤@.¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@ 2b ¹w´ÁÀø®Ä¡]°ò缐EASI27.5, IGA=3 65%)¡A¼ÒÀÀ EASI 75=73%~81% vs 24% (©M¹ï·Ó²Õ®t²§ 49%¡ã57%¡^vs Dupilumab 2b 61% IGA0,1=57%~61%. Vs 15%¡]¡G®t²§ 42%¡ã46%¡^vs Dupilumab 2b 43% ¦©°£¹ï·Ó²Õ®t²§¡A¤´¦³Àu©óDupilumab 2b 30%¥H¤Wªº¾÷·|¡AÀø®Äª½¤ñ¤fªAÃĪ«¡]JAK§í¨î¾¯¤G缐ÃĪ«¡^ªº¥i¯à©Ê¤j¡C ¥H¤WÓ¤H¼ÒÀÀ¡C ¥t¥~Q2 ¬ü°ê¹ïú}°òª÷«ù¦³ASLN ´î¤Ö¬ù1400¤dªÑADR ³Ì¤jªÑªFTang ¸ê¥»§ë¸ê¤½¥q¤´¤p¥[½X100¤dªÑADR ·s¥[©Y²H°¨¿ü«ùªÑ¤£ÅÜ¡C whalewisdom.com/stock/asln |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/12 ¤U¤È 07:52:46²Ä 5764 ½g¦^À³
|
Lebrikizumab 2b ¦PÀø®Äªº¹F¦¨³t«×§C©óDupilumab 2a ,¦ý²Ä16¶g¦³¬ÛªñªºÀø®Ä¡C ASLAN004 ¨C¶g¤@°w¡A«e8¶gEASI¤U°Àø®Ä³t«×©MDupilumab¬Ûªñ¡C ¤@¤@¤@¤@ Dupilumab 2a N=110 QWx12¶g Vs Lebrikizumab 2b Q2Wx16¶gN¡×75:52 1¡AEASI50 Dupilumab.//Lebrikizumab ²Ä¤T¶g 55%// ²Ä¥|¶g 65%//52% ²Ä¤¶g 85%¡]¨£°ªÂI¡^// ²Ä¤»¶g 85%// ²Ä¤K¶g 85%//70% ²Ä¤Q¤G¶g85%//81%¡]¨£°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//81% Dupilumab ¥i¦P®Éªý¾×Âù¼Ð¹vIL4/IL13¡A©Ò¥H¦b²Ä¤¶gEASI50´N¹F°ªÂI85%¦ÓLebrikizumab¥u¯àªýÀÉIL13¤Î³¡¤ÀlL4©Ò¥Hª½¨ì²Ä¤Q¤G¶g¤~¹F81%°ªÂI¡C ¤G¡AEASI75 Dupilumab.//Lebrikizumab ²Ä¥|¶g 35%//30% ²Ä¤K¶g ¡X//42% ²Ä¤Q¤G¶g62%//62%¡]°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//61% ¤T¡BIGA 0,1 Dupilumab.//Lebrikizumab ²Ä¥|¶g 18%//18% ²Ä¤K¶g ¤@¤@//30% ²Ä¤Q¤G¶g40%//41% ²Ä¤Q¤»¶g¡X¡X//43%¡]°ªÂI¡^ Lebrikizumab ªý¾×°T®§¯à¤O®Ä¯à¸û®t¡A¦ý®É¶¡©Ôªø¨ì16¶g¡A¤´¥i¸É¨¬IGA0,1ªºÀø®Ä¡C www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@ Dupilumab www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg ¹Ï¤G¡þªí¤G Lebrikizumab ¤T¡BDupilumab ¤T´Á vs ASLAN004 1b mITT 600mg ¦U¶g¥§¡EASI¤U°´T«×«e8¶g¬Ûªñ¡C¡]¥Nªí¦³¬Û·í¦P®Éªý¾×IL4//IL13¸ê°Tªº®Ä²v) www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab ¹Ï¤G¡C ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c p¡A21 |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/11/11 ¤U¤È 06:24:28²Ä 5763 ½g¦^À³
|
§Ú»{¬° ©Û¶Ò¯f¤Hªº²{ªp¶i«× ¤Î¬O§_¤w©Û¶Ò§¹¦¨ ¨´¤µ¬ÒµL®ø®§ 2b¥¿±´Á¤¤¼Æ¾Ú¤£´±«ü±æ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/11/11 ¤U¤È 02:35:58²Ä 5762 ½g¦^À³
|
§Ö¨ÓÓ¥¿¦Vªº´Á¤¤¼Æ¾Ú¡A¶^¯}¤j®aªº²´Ãè¡AÅý¾÷ºcªk¤H¨Ó¤£¤Î¤ÏÀ³ ! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/10 ¤W¤È 08:39:57²Ä 5761 ½g¦^À³
|
²¤¶¡X§¨Ó¤½¥q¦V FDA ´£¥æ BLA ¥Î©óªvÀø¯SÀ³©Ê¥Öª¢ÃĪ« 02-11-2022 ¥´¦L §ó¦hÃö©ó³oÓ¬G¨Æ EMA ±µ¨ü Almirall ªº lebrikizumab ¶ñ¥Rª«ªvÀø¯SÀ³©Ê¥Öª¢ 28-10-2022 ¬ü°ê»sÃÄ¥¨ÀY§¨Ó (Eli Lilly) ¤w¦V¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) ´£¥æ¤F lebrikizumab ªº¥Íª«»s«~³\¥i¥Ó½Ð (BLA)¡Alebrikizumab ¬O¤@ºØ¥Î©óªvÀø¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ (AD) ªº¬ã¨s©Ê¥Õ²ÓM¤¶¯À (IL)-13 §í»s¾¯. AD ¬O¤@ºØ IL-13 ¥D¾É¯e¯f¡A¨ä¤¤ IL-13 ¾ÉP¥Ö½§«Ì»Ù¥\¯à»Ùê¡Bæ±Äo¡B¥Ö½§¼W«p©M·P¬V©ö·P©Ê¡C Lebrikizumab ¦®¦b¥H°ª¿Ë©M¤O¡BºC¸ÑÂ÷³t²v©M°ª®Ä¤Oµ²¦X IL-13¡A¥H§í¨î IL-13 ªº¥Íª«¾Ç®ÄÀ³¡C ¸Ó´£¥æ±o¨ì¤F ADvocate 1 ©M ADvocate 2 16 ©P©M 52 ¶gµ²ªG¥H¤Î ADhere 16 ¶gµ²ªGªº¤ä«ù¡A³o¨Çµ²ªG¬OÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¥¦æ²Õ¡B¥þ²y¡BIII ´Áµû¦ô lebrikizumab §@¬°³æ¤@Àøªk¨Ã»P¼Ð·ÇÅ@²z¥~¥Î¥Ö½èÃþ©T¾JÁp¦X¥Î©ó«C¤Ö¦~©M¦¨¤H¡]12 ·³©Î¥H¤W¡^ªºÀø®Ä©M¦w¥þ©Êªº¬ã¨s¡C ®Ú¾Ú GlobalData ªº¼Æ¾Ú¡A¯SÀ³©Ê¥Öª¢ (AD) ¥«³õªº»ùȹwp±N±q 2020 ¦~ªº 64 »õ¬ü¤¸¼Wªø¨ì 2030 ¦~ªº 7 Ó¥Dn¥«³õªº 168 »õ¬ü¤¸¡A½Æ¦X¦~¼Wªø²v (CAGR) ¬° 10.1%¡C BRIEF¡XLilly submits BLA to FDA for atopic dermatitis med 02-11-2022 Print MORE ON THIS STORY EMA accepts Almirall¡¦s filling for lebrikizumab in atopic dermatitis 28-10-2022 Lilly and Almirall¡¦s lebrikizumab impresses a year in to eczema trial 07-06-2022 Lebrikizumab has significant impact on atopic dermatitis severity 12-04-2022 OTHER STORIES OF INTEREST Under geopolitics and market rout, Chinese biotechs center on data quality and survival 09-11-2022 AI firm Insilico could pocket $1.2 billion in Sanofi tie-up 09-11-2022 Broader label to support greater US growth for Libtayo 09-11-2022 RELATED COMPANIES Eli LillyArteaus TherapeuticsLilly RELATED DRUGS lebrikizumab US pharma major Eli Lilly has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lebrikizumab, an investigational interleukin (IL)-13 inhibitor for the treatment of moderate-to-severe atopic dermatitis (AD). AD is an IL-13 dominant disease in which IL-13 drives skin barrier dysfunction, itch, skin thickening and susceptibility to infection. Lebrikizumab is designed to bind IL-13 with high affinity, slow disassociation rate and high potency to inhibit the biological effects of IL-13. The submission is supported by the ADvocate 1 and ADvocate 2 16-week and 52-week results, as well as the ADhere 16-week results, which are randomized, double-blind, placebo-controlled, parallel-group, global, Phase III studies that evaluated the efficacy and safety of lebrikizumab as a monotherapy and in combination with standard-of-care topical corticosteroids in adolescents and adults (12 years of age or older). The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData. |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/11/9 ¤U¤È 07:01:11²Ä 5760 ½g¦^À³
|
´¼Àº¤@½u¯Ø¸¢ÀùÁ{§É¼Æ¾Ú¹F¼Ð ©ú¦~ªì¥Ó½Ð¬üÃÄÃÒ ¹d¦ëºô¥x¥_2022/11/09 ´¼Àº (4162-TW) ¤µ (19) ¤é¤½§i¡AºX¤U¯Ø¸¢Àù·sÃĦw¯à±o (ONIVYDE) ªº²Õ¦XÀøªk¡AªvÀø¤@½u¯Ø¸¢Àùªº¥þ²y¼Ï¯Ã©ÊÁ{§É¸ÕÅç¡A¥Dn»P¦¸nµû¦ô«ü¼Ð§¡¹F¨ìÅãµÛÁ{§É·N¸q¡A«áÄò±N¶i¤@¨B¾ã²z¼Æ¾Ú¡A³Ì§Ö©ú¦~ªì¦V¬ü°ê FDA ´£¥XÃÄÃҥӽСC ´¼Àºªí¥Ü¡A¸ÓÁ{§É¸ÕÅç¬O¥Ñ±ÂÅv¦X§@¥ë¦ñ IPSEN ¨Ó°õ¦æ¡A±N¦w¯à±o·f°t¤ÆÀøÃÄ«~ Oxaliplatin (OX)¡B¸~½F¥ÎÃÄ 5 Fluorouracil (5-FU)¡B¸Ñ¬r¾¯ Leucovorin(LV) ªº²Õ¦XÀøªk¡A¨Ã¥H¥Ø«e¤@½u¯Ø¸¢Àù¼Ð·Ç²Õ¦XÀøªk§@¬°¸ÕÅç¹ï·Ó²Õ¡A¦¬®×¹ï¶H¬°Âಾ©Ê¯Ø¸¢¾ÉºÞ¸¢Àù±wªÌ¡A¦@ 770 ¤H¡C ®Ú¾Ú¸ÕÅçµ²ªGÅã¥Ü¡A¥Dnµû¦ô«ü¼ÐªºÁ`¦s¬¡´Á (OS)¡A¦w¯à±o²Õ¦XÀøªkÅãµÛÀu©ó¼Ð·Ç²Õ¦XÀøªk¡B¦¸nµû¦ô«ü¼Ð¤¤ªºµL´c¤Æ¦s¬¡®É¶¡¤]¦³ÅãµÛªº§ïµ½¡F¦w¥þ©Ê¤è±»P¹L¥hÁ{§É¤@ / ¤G´Á¼Æ¾Ú¹p¦P¡C ´¼Àºªí¥Ü¡A¦X§@¹Ù¦ñ IPSEN ±N·|§â¦¹¦¸¸ÕÅçµ²ªG¡A·f°t¹L¥h¤wÀò±oªº§Ö³t¼f¬d¸ê®æ¡A¦V¬ü°ê FDA »¼¥æ¾AÀ³¯g©µ¦ùªº¥Ó½Ð¡A³Ì§Ö©ú¦~ªì§¹¦¨¡A¥¼¨Ó¦A³°Äò¦V¼Ú¬w¡B¤é¥»¡B¥xÆWµ¥¦a°Ï´£¥X¤å¥ó¡A«Ý¨ú±oÃÄÃÒ«á±N·|Àò±o¨½µ{¸Oª÷¡C ¾Ú²Îp¡A¥þ²y¨C¦~¶EÂ_¥X 50 ¸U¦W¯Ø¸¢¾ÉºÞ¸¢Àù±wªÌ¡A¬ü°ê¨C¦~«h¦³ 6 ¸U¤H¡A¥Ñ©ó¦´Á¶¥¬q¨S¦³¯S©w¯gª¬¡A³q±`¯e¯fÂX´²¨ì¨Åé¨ä¥L³¡¦ì«á¤~·|³Qµo²{¡A¥Ø«e¦³¶EÂ_¥Xªº±wªÌ¤¤¡A¤£¨ì 2 ¦¨ªº¤H¦s¬¡´Á¶W¹L¤@¦~¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/11/9 ¤U¤È 12:29:25²Ä 5759 ½g¦^À³
|
§Ú¤]ı±o¶}ÂåÀø«O°··|ij, ¬°¤°»òn±aCBO¥h???ì¨Ó¬O...... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/9 ¤W¤È 10:35:26²Ä 5758 ½g¦^À³
|
Mr Stephen Doyle, CBO CBO¶}©l¦£±ÂÅv¡B¨ÖÁʤF!¡B |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/8 ¤U¤È 10:18:13²Ä 5757 ½g¦^À³
|
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference ASLAN PHARMACEUTICALS LIMITED Tue, November 8, 2022 at 8:00 PM¡P1 min read ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London. Please contact your Jefferies representative to request a one-on-one meeting with management. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/5 ¤U¤È 09:43:38²Ä 5756 ½g¦^À³
|
2022¦~Q3°]³ø¥XÄl investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2022-financial-and-operating ¤µ¦~«e¤T©uÀ禬¤w¶W¹L2021¥þ¦~¡A¤µ¦~¾P°â¦ôªñ87»õ¬ü¤¸¡C©ú¦~¦ô110»õ¬ü¤¸¡C Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp 2022 Q1 1,325.6//484.8//1,810.4 Q2 1,582.1//509.7//2,091,8 Q3 1,824.0//506.1//2,330.1 Q4 ¦Xp4731//1500//623 2021 Q1 961.5 //301.4//1262.9 Q2 1140//352//1492 Q3 1256.7//406.2//1662.9 Q4 1348//426//1774 ¦Xp 4712.8//1486//6198.8 2020 Q1 679.0 174.2 853.2 Q2 770.4 176.6 947.0 Q3 851.2 221.4 1072.6 Q4 925.6 246.4 1172.0 ¤pp3226.2 818.6 4044.8 2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6 2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0 2017 Q1 ******* Q2 ******* Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥« |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤U¤È 03:45:42²Ä 5755 ½g¦^À³
|
MOA www.taiwan-pharma.org.tw/weekly/2166/2166-5-3.htm Janus Kinases¡]JAKs¡^ÄݲÓM¤º»Ã¯À¡A¨Ã±N²ÓM½¤¤Wªº°T®§¶Ç¥X¡A¦b¶Ç»¼¸ô®|¤¤¡AJAKs·|«P¨Ï°T®§¶Ç¾É»PÂà¿ý¬¡¤Æ¦]¤l(STATs)ÁC»Ä¤Æ¤Î¬¡¤Æ¡A½Õ¸`²ÓM¤ºªº¾÷¯à¡A¥]¬A°ò¦]ªí²{¡A¼vÅT³y¦å²ÓM¹BÂà»P§K¬Ì²ÓM¥\¯à¡CJAK§í¨î¾¯¬°¼Ð¹v¦X¦¨§Ü·Àã¯fÃĪ«¡]targeted synthetic DMARDs, tsDMARDs¡^¬Oªñ¦~¨Ó·sµo®iªºÃĪ«Ãþ§O¡A¸g¥ÑJAKs½Õ¸`²ÓM°T®§¶Ç»¼¸ô®|¡Aªý¤îSTATsÁC»Ä¤Æ»P¬¡¤Æ¡A¶i¦Ó§í¨îµoª¢¤ÏÀ³¡A¬°²{¦³ÃĪ«µLªk¹F¨ìªvÀø¥Ø¼Ðªº¯f¤HªvÀø±a¨Ó·s¿ï¾Ü¡C¬Û¸û©ó¥Íª«»s¾¯¬ÒÄÝ°w¾¯¡A¦¹ÃþÃÄ«~ªº¯S¦â¬°¤fªA§ë¤©¡A¯f¤H¨Ï¥Î§ó«K§Q¡C«ØijªvÀø®É¾÷»PboDMARDs¬Û¦ü¡A¥Î©ócsDMARDs¦X¨ÖªvÀø«á¤´¤£¨£§ïµ½®É¡A¦ý¥Ø«e«ü¤Þ¤´Àu¥ý«Øij¨Ï¥ÎboDMARDs¡A¥¼¹FªvÀø¥Ø¼Ð¤~¦Ò¼{¨Ï¥ÎtsDMARDs¡C¥Ø«eªvÀø«ü¤Þ¤¤¦¬¿ýªº¬°JAK§í¨î¾¯tofacitinib¡Bbaricitinib¬Ò«D¿ï¾Ü©Ê§í¨îJAK-1¡A¨ä¤¤¦P®É§í¨îJAK-2¡B3·|¾ÉP³y¦å·F²ÓM¡]hematopoietic cell)¡B¬õ¦å²y¥Í¦¨¯À¡]erythropoietin¡^µ¥«n¥Í²z¾÷Â઺°T®§¶Ç»¼³QªýÂ_¡A¶i¤@¨B³y¦¨¬ÛÃö°Æ§@¥Î¡C ¿ï¾Ü©ÊJAK-1§í¨î¾¯³z¹L±M¤@©Ê§í¨î¡A´Á±æ¯à´î§C¦]§í¨îJAK-2¡B3©Ò±a¨Óªº°Æ§@¥Î¡A¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^©ó2019¦~8¤ë16¤é¨Ì¾ÚFleischmann µ¥¤Hµoªíªº¸ÕÅçµ²ªG¡A®Öã¿ï¾Ü©ÊJAK-1§í¨î¾¯ upadacitinib¡]UPA¡^¥Î©óªvÀø¤¤««×¦¨¦~RA¯f¤H¡C¦¹ÀH¾÷¸ó°ê²Ä¤T´Á¦w¼¢¾¯¹ï·Ó¸ÕÅ笰´Á26¶g¡A¦@¦¬¯Ç449¦ì¨ü¸ÕªÌ¡A¬Ò±w¦³¬¡°Ê©ÊRA¥B¨Ï¥ÎMTXéwªvÀø¦Ü¤Ö¤TÓ¤ë¥H¤W¡A¥¼´¿¨Ï¥Î¹L¨ä¥LboDMARDs©ÎtsDMRADs¶W¹L¤TÓ¤ë¡A¥B¦bªvÀø«á¤´ºû«ù¯e¯f¬¡©Ê¡C¨ü¸ÕªÌ¸gÀH¾÷¤À¬£¬°¤T²Õ¡G¨C¤é¤fªAUPA 15 mg¡B¨C¨â¶g¥Ö¤Uª`®gadalimumab¡]ADA¡^40 mg¥H¤Î¦w¼¢¾¯²Õ¡A¦U²Õ¬ÒÄ~Äò¨Ï¥Îì³B¤è¤§Ã©w¾¯¶qMTX¡C¸ÕÅçµ²ªGÅã¥Ü¡A¦b²Ä 12 ¶gªºµû¦ô¡A»P¦w¼¢¾¯²Õ¤ñ¸û¡A¹F¨ì¸~µÈ¤ÎIJµhÃö¸`¼Æ§ïµ½¹FACR20¡]American College of Rheumatology 20% improvement criteria¡^ªº¯f¤H¤ñ²v¡A±µ¨üUPA 15 mg»P¦w¼¢¾¯²Õ¤À§O¬°71% »P 36%¡]p¡Ø0.001)¡A¥B¦b26¶g¤´ºû«ù¸û¦w¼¢¾¯²Õ¨Îªºªí²{¡F»P ADA ²Õ¤ñ¸û¡A¦b²Ä26¶g¹F¨ì¸~µÈ¤ÎIJµhÃö¸`¼Æ§ïµ½¹F50%¡]ACR50¡^ªº¯f¤H¤ñ²v¡A±µ¨üUPA 15 mg»P ADA ²Õ¤À§O¬°54% »P 42%¡]p¡Ø0.001)¡A¬Ò¹F²Îp¤WÅãµÛ®t²§¡C¦w¥þ©Ê¤è±¡A©ó²Ä26¶g²Îp¥ô¦ó¤£¨}¨Æ¥ó¡]AE¡^ªºµo¥Í¤ñ¨Ò¡A¦b UPA 15 ²@§J¡B¨C¨â¶g¥Ö¤Uª`®gADA 40 mg»P¦w¼¢¾¯²Õ¤À§O¬°64.2%¡B60.2% »P 53.2%¡A«e¨â²Õµo¥Íªº¤ñ¨Ò¬Û·í¡CUPA©ó¸ÕÅ礤¥X²{ªº¤£¨}¤ÏÀ³¥H·P¬V¡]¦p¡G±aª¬疱¯l)¡B¦Ù»Ä¿E»Ã¯À¡]creatine phosphokinase, CPK¡^¤W¤É¡BÀR¯ß¦å®ê®ê¶ë¡]venous thromboembolic event, VTE¡^¬°¥D¡C¦Ó¥t¤@Ó¿ï¾Ü©ÊJAK-1§í¨î¾¯ filgotinib ¤]¦b²Ä¤T´ÁÁ{§É¸ÕÅ礤¬°Ãøªv«¬ªº¤¤««×¦¨¦~RA¯f¤H±a¨ÓÅãµÛªºÁ{§É§ïµ½¡A¨Ã©ó2019¦~12¤ë16¤é´£¥X·sÃĥӽСC |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤U¤È 02:25:46²Ä 5754 ½g¦^À³
|
Upadacitinib¤T´Á¡]¤fªAÃĪ«¡^JAK§í¨î¾¯ MOA IL4+IL4Ra+IL13Ra1 ²£¥Í«¬II½Æ¦X¨üÅé¡A¦A¨Ó´N²£¥ÍJAK1/2,IgE¤U´åªº¤ÏÀ³¤À¤l¡C IL13+IL13Ra1+IL4Ra²£¥Í«¬II½Æ¦X¨üÅé¡A¦A¨Ó´N²£¥ÍJAK1/2,IgE¤U´åªº¤ÏÀ³¤À¤l¡C ¥H¤W2Ó³~®|¤À§O¥Ñ¤W´åªºIL4¡BIL13¶}©l¡C §í¨îJAK²£¥Í¸û¨ÎÀø®Ä¡A¥u¯à¤Ï±ÀDupilumab «Ê¦íIL4Ra ªº°T®§¶Ç»¼¤´¦³º|¬}¡C ¦ÓASLAN004Àø®Ä¥i±µªñ¤fªAÃĪ«¡A«ÊÂêIL4¤ÎIL13°T®§¶Ç»¼§ó±j¡C ¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^ IGA0,1 15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤U¤È 01:49:22²Ä 5753 ½g¦^À³
|
¨ä¹ê¨C¶g¤@°w8¶g´N¥i¼ÒÀÀ¥X IGA0,1 mITT 7/16=44% (7+6)/(16+6-1)=61% ì¦]¦P¤U¡D EASI75=81% ¦A¥[9-16¶g¡B¨C¶g¤@°w¡B¥DnªvÀø°ò½uEASI>41 ªº±Ú¸s¡D «D¶Ç统AD±wªÌ¥²¶·³Q±Æ°£¡D ............ 004-1b mITT*8¶g¼ÒÀÀ EASI75 11/16=69%... mITT (11+6)/(16+6-1)=81% ¥t¥[6Ó°ò½u=EASI19»´¯gªÌ¡B¦ý°ªTRAc/°ªIgE «h6/6Àø®Äªñ100% ¥t¥~3¤H¤¤Â_¡B°²³]´î¤Ö¬°2¤H¡B ¥Ø¼ÐEASI75=81% IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1ªºÀø®Ä¡D) ......16 ¶gªvÀø ¯uªº¦³¾÷·|¡B¦p¤½¥q©Ò¨¥³ô¤ñ¤fªAÃÄ®Ä |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 10:46:32²Ä 5752 ½g¦^À³
|
¦UÃĦy®p¾P°â¤@2==004 ¼ÒÀÀ¤G 1¡ALebrikizumab ¨âÓAD¤T´ÁÁ{§ÉÀø®Ä¥Dn«ü¼ÐIGA0,1 ¦©°£¹ï·Ó²Õ¡]16¶g¡^¡ã¦ô¦y®p¾P°â45»õ¬ü¤¸(¬ü°ê¤ÀªR®vªñ´Á¤ÀªR) AD¤@l 30%¡]43%-13%¡^//52¶g©Ô°ª¨ì¹êÅç²Õ46% AD¤@2 22% (33%-11%)//52¶g©Ô¨ì¹êÅç²Õ39% 2¡ADupilumab ¨âÓAD3´Á¡ã¦©°£¹ï·Ó²Õ¡A¦ôAD¦y®p¾P°â80»õ¬ü¤¸(¤½¥q¥»¨¦ôl40»õ¦yûß¾P°âx55%=80»õ¬ü¤¸¬°AD.) Solo1 28%(38%-10%)//52¶g°¨ì¹êÅç²Õ¬ù36% Solo2 28%(36%-8%)//52¶g°¨ì¹êÅç²Õ¬ù34% 3¡AASLAN004 2b Á{§É16¶gx¨C¶g¤@°w80%Àu©óDupilumab¡]¦©°£¹ï·Ó²Õ¡^ 28%x180=52%¡K73»õ¬ü¤¸¾P°â ASLAN004 2b 16¶gx¨C¶g¤@°w¡AÀø®Ä³ô¤ñ¤fªAÃĤG½u ´Á±æÈ64%¡ã15%=49%¡]¤é«á¤T´Á¹ï·Ó²Õ·|°¨ì8¡ã10%¡A¹êÅç²Õ¤@¹ï·Ó²Õ®t²§©Ô°ª¨ì52%¥ª¥k¡^ ¦Xp¦ôASLAN004 ¦y®p¾P°â 73¤Q17¡×90»õ¬ü¤¸ ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ 4¡AUpadacitinib¤T´Á¡]¤fªAÃĪ«¡^¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^ IGA0,1 15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^ ........ 004¥[¤W¨ä¥L¾AÀ³¯gµ´¹ï°_¹L100»õ¬ü¤¸¦yºÝ¾P°â ©Ò¥H©ú¦~©³ªº¤G½u¸Ñª¼¤ñQ2ªº¸Ñª¼¨Óªº§ó«n¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 09:26:14²Ä 5751 ½g¦^À³
|
³¯¤j¡B 2018/2019¨âÓ¤å¥óªº«O±K©µªø¨ì2027¦~. |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/11/4 ¤W¤È 09:03:02²Ä 5750 ½g¦^À³
|
¤Ñ©R¤j ¤U¦C2«Ê«H¡A¦³¤°»ò¯S®í·N¸q¶Ü ¬ü°ê ÃÒ¨é¥æ©ö©eû·| 2022 ¦~ 11 ¤ë 3 ¤é ±Â¤©¾÷±KªvÀøªº©R¥O ®Ú¾Ú 1934 ¦~ÃÒ¨é¥æ©öªk ªü´µÄõ»sÃĦ³¤½¥q ¤å¥ó¸¹ 1-38475 - CF#37122 _____________________ ASLAN Pharmaceuticals Limited ®Ú¾Ú³W«h 24b-2 ´£¥æ¥Ó½Ð ½Ð¨D©µªø¥ý«e±Â¤©ªº¹ï¨ä«H®§ªº«O±K³B²z ±Æ°£¦b 2019 ¦~ 1 ¤ë 9 ¤é´£¥æªº 6-K ªí®æªºªþ¥ó¤§¥~¡C ®Ú¾Ú ASLAN Pharmaceuticals Limited ªº³¯z¡A¥» «H®§²Å¦X«O±K°Ó·~©Î°]°È«H®§ªº±ø¥ó «H®§¦Û¥Ñªk¡A5 U.S.C. 552(b)(4)¡A¤½¥q°]°È³¡¦³ ¨M©w¤£¤½¶}¡C ¦]¦¹¡A±q ¥H¤U®i«~¦b«ü©wªº®É¶¡¬q¤º¤£·|¦V¤½²³µo¥¬¡G ¹Ïªí 10.1 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹ï©ó©eû·|¡A¥Ñ¤½¥q°]°È³¡®Ú¾Ú ±ÂÅv ¬ü°ê ÃÒ¨é¥æ©ö©eû·| 2022 ¦~ 11 ¤ë 3 ¤é ±Â¤©¾÷±KªvÀøªº©R¥O ®Ú¾Ú 1933 ¦~ÃÒ¨éªk ªü´µÄõ»sÃĦ³¤½¥q ¤å¥ó¸¹ 333-223920 - CF#35819 _____________________ ASLAN Pharmaceuticals Limited ®Ú¾Ú³W«h 406 ´£¥æ¥Ó½Ð ½Ð¨D©µªø¥ý«e±Â¤©ªº¹ï¨ä«H®§ªº«O±K³B²z ±q 2018 ¦~ 3 ¤ë 26 ¤é´£¥æªº F-1 ªí®æµn°OÁn©úªºªþ¥ó¤¤±Æ°£¡A ¸g×¥¿¡C ®Ú¾Ú ASLAN Pharmaceuticals Limited ªº³¯z¡A¥» «H®§²Å¦X«O±K°Ó·~©Î°]°È«H®§ªº±ø¥ó «H®§¦Û¥Ñªk¡A5 U.S.C. 552(b)(4)¡A¤½¥q°]°È³¡¦³ ¨M©w¤£¤½¶}¡C¦]¦¹¡A±q ¥H¤U®i«~¦b«ü©wªº®É¶¡¬q¤º¤£·|¦V¤½²³µo¥¬¡G ¹Ïªí 10.5 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹Ïªí 10.6 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹Ïªí 10.7 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹ï©ó©eû·|¡A¥Ñ¤½¥q°]°È³¡®Ú¾Ú ±ÂÅv¡G ¹F®R«¢¯ý ª¾ÃѺ޲z¿ì¤½«Ç¥D¥ô |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 08:54:09²Ä 5749 ½g¦^À³
|
°²³]¤G½uÀø®Ä¹F¼Ð ¥¼¨Ó¤T´Á¤@½u¥²·|¥[¤J¨C¶g¤@°w¡D Y¦p预´Á80%Àu©óDupilumab «h¤@½uÃĪº¦yºÝ¾P°â73»õ¬ü¤¸´N«Ü¦X²z. 预´ÁASLAN004ªº3´ÁÁ{§É¨C¶g¤@°wÀø®Ä °ò½uEASI31//IGA3=51% EASI75=78% vs 15%(®t²§63%) IGA0.1=62% vs 10%(®t²§52%) ©Ò¥H¤½¥q°õ¦æ¤G½uÁ{§É¬O¹ïªº¡D ¤@½u16¶gx¨C¶g¤@°w75¤H¥i¥H¤£¥Î°µ¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 05:27:11²Ä 5748 ½g¦^À³
|
¦b³\¦h¾AÀ³¯g¤W ¦b®a¥´SC(¥Ö¤Uª`®g) ¨C¶g¤@°w¥ý±À¥X¡B¦A±À¨C¤G¶g¤@°w(Àø®Ä¬Û¦P) ±wªÌ¤j³£ÁÙ¬O°¾¦n¨C¶g¤@°w¡D ¨C¶g¤@°w¦n°O¡B¦P¼Ë»ù®æ¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 04:59:09²Ä 5747 ½g¦^À³
|
¨Ì004-1b mITT*8¶g¼ÒÀÀ EASI75 11/16=69%... mITT (11+6)/(16+6-1)=81% ¥t¥[6Ó°ò½u=EASI19»´¯gªÌ¡B¦ý°ªTRAc/°ªIgE «h6/6Àø®Äªñ100% ¥t¥~3¤H¤¤Â_¡B°²³]´î¤Ö¬°2¤H¡B ¥Ø¼ÐEASI75=81% IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1ªºÀø®Ä¡D) ......16 ¶gªvÀø ¯uªº¦³¾÷·|¡B¦p¤½¥q©Ò¨¥³ô¤ñ¤fªAÃĮġD |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 04:37:01²Ä 5746 ½g¦^À³
|
½Ð¦U¦ì¤j¤j ¼g«Hµ¹ ASLN ¤½¥q n¨D¼W¤@Ó75¤Hªº¤@½ux¨C¶g¤@°wªºAD Á{§É¡D ÅçÃÒÀø®Ä³ô¤ñ¤fªAÃĪ« IGA0,1=64%-15%=49% EASI75=80-24%=56% AD ¦y®p¾P°â¤W¬Ý70»õ¬ü¤¸ ¥[¨ä¥L¾AÀ³¯g>100»õ¬ü¤¸¤¸ Àø®Ä¤j©ó¤@¤Á! (¦b¦w¥þ¦Pµ¥ªºª¬ªp¤U) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 04:16:49²Ä 5745 ½g¦^À³
|
×¥¿¤@l Dupilumab ¹s°â»ù3300¬ü¤¸/600mg¡B¤½¥q¥X¼t»ùx80%=2660¬ü¤¸/600mgªºÀ禬 »s³y¦¨¥»=2660*10%=266/600mg 0.45 ¬ü¤¸/mg °²³]ASLAN004 16¶gx¨C¶g¤@°w·í¤@½uÃÄ Àø®Ä³ô¤ñ¤fªAÃÄ IGA0,1=62%-10%(¹ï·Ó组)=52% vs Dupilumab ªºÀø®Ä38%-10%=28% 52%/28%=186% °²³]¨C¤ëq»ù¬Û¦P3300¬ü¤¸/4°w ASLAN004¤@ ½uÃĪ«¥i¾P80»õ¬ü¤¸¥i´Á ¦¨¥»400mg*4=1600mg...ASLAN004 ¤ñDupilumab 600mg¦h1000 mg ¦¨¥»¦h¥X1000*0.45=450¬ü¤¸/¨C¤ë 16 ¶g¦¨¥»¤ñDupilumab¦h¥X1800¬ü¤¸ 1800/24000(¦~¥§¡ÃĶO)=7.5%(17-52¶g¥i«ì´_¥Î¤G¶g¤@°w/¥|¶g¤@°w¡D 80»õx(60%-7.5%)=52»õ¬ü¤¸²b§Q ©Î¬Û·í80*92.5%=73»õ¬ü¤¸ªºDupilumab 销°â(60%²b§Q) µ²½×¡G«Øij ASLN004 ¨C¶g¤@°wx16¶gªº¤@½uÃĪ«¥i¨Ï¦y®p销°â¥Ñ26»õªº¤G¶g¤@°w¡B´£¤É¨ì73»õ¬ü¤¸ ¤G½uÃıN«D±`¤Ö¡D(¦]ASLAN004. ¬O¤@½u¥D¤O) ¬GASLN ¤½¥qÀ³±N75¤Hªº¤GÃĪ«¼È½w¡B §ï¬°¤@½u75¤H¡B¨ú±o³ô¤ñ¤fªAÃĪ«ªvÀøªºÀø®Äµ²ªG¡D ¤T´Á¼W¥[¨C¶g¤@°wªºÁ{§É(¦Pdupilumab) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/4 ¤W¤È 04:03:22²Ä 5744 ½g¦^À³
|
Dupilumab ¹s°â»ù3300¬ü¤¸/600mg¡B¤½¥q¥X¼t»ùx80%=2660¬ü¤¸/600mgªºÀ禬 »s³y¦¨¥»=2660*10%=266/600mg 0.45 ¬ü¤¸/mg °²³]ASLAN004 16¶gx¨C¶g¤@°w·í¤@½uÃÄ Àø®Ä³ô¤ñ¤fªAÃÄ IGA0,1=62%-10%(¹ï·Ó组)=52% vs Dupilumab ªºÀø®Ä38%-10%=28% 52%/28%=186% °²³]¨C¤ëq»ù¬Û¦P3300¬ü¤¸/4°w ASLAN004¤@ ½uÃĪ«¥i¾P80»õ¬ü¤¸¥i´Á ¦¨¥»400mg*4=1600mg...ASLAN004 ¤ñDupilumab 600mg¦h1000 mg ¦¨¥»¦h¥X1000*0.45=450¬ü¤¸/¨C¤ë 16 ¶g¦¨¥»¤ñDupilumab¦h¥X1800¬ü¤¸ 1800/24000(¦~¥§¡ÃĶO)=7.5% 80»õx(40%-7.5%)=26»õ¬ü¤¸²b§Q ©Î¬Û·í80*92.5%=73»õ¬ü¤¸ªºDupilumab 销°â(40%²b§Q) µ²½×¡G«Øij ASLN004 ¨C¶g¤@°wx16¶gªº¤@½uÃĪ«¥i¨Ï¦y®p销°â¥Ñ26»õªº¤G¶g¤@°w¡B´£¤É¨ì73»õ¬ü¤¸ ¤G½uÃıN«D±`¤Ö¡D ¬GASLN ¤½¥qÀ³±N75¤Hªº¤GÃĪ«¼È½w¡B §ï¬°¤@½u75¤H¡B¨ú±o³ô¤ñ¤fªAÃĪ«ªvÀøªºÀø®Äµ²ªG¡D ¤T´Á¼W¥[¨C¶g¤@°wªºÁ{§É(¦Pdupilumab) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/3 ¤U¤È 09:09:27²Ä 5743 ½g¦^À³
|
¦UÃĦy®p¾P°â 1¡ALebrikizumab ¨âÓAD¤T´ÁÁ{§ÉÀø®Ä¥Dn«ü¼ÐIGA0,1 ¦©°£¹ï·Ó²Õ¡]16¶g¡^¡ã¦ô¦y®p¾P°â45»õ¬ü¤¸ AD¤@l 30%¡]43%-13%¡^//52¶g©Ô°ª¨ì¹êÅç²Õ46% AD¤@2 22% (33%-11%)//52¶g©Ô¨ì¹êÅç²Õ39% 2¡ADupilumab ¨âÓAD3´Á¡ã¦©°£¹ï·Ó²Õ¡A¦ôAD¦y®p¾P°â80»õ¬ü¤¸ Solo1 28%(38%-10%)//52¶g°¨ì¹êÅç²Õ¬ù36% Solo2 28%(36%-8%)//52¶g°¨ì¹êÅç²Õ¬ù34% 3¡AASLAN004 2b Á{§É16¶g¤G¶g¤@°w¤½¥q¦ô8%Àu©óDupilumab¡]¦©°£¹ï·Ó²Õ¡^ 28%x108%=30.3% ASLAN004 2b 16¶gx¨C¶g¤@°w¡AÀø®Ä³ô¤ñ¤fªAÃĤG½u ´Á±æÈ64%¡ã15%=49%¡]¤é«á¤T´Á¹ï·Ó²Õ·|°¨ì8¡ã10%¡A¹êÅç²Õ¤@¹ï·Ó²Õ®t²§©Ô°ª¨ì52%¥ª¥k¡^ ¦Xp¦ôASLAN004 ¦y®p¾P°â 26¤Q17¡×43»õ¬ü¤¸ ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ 4¡AUpadacitinib¤T´Á¡]¤fªAÃĪ«¡^¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^ IGA0,1 15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^ |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/11/3 ¤U¤È 05:40:43²Ä 5742 ½g¦^À³
|
to©t¨à¤j §Ú¤]¬O´Á«Ý©_ÂÝ°Ú ¥u¬O¥Ø«e´N¬O°µ¦n³ÌÃa¥´ºâ¡A¥áµÛ¤£ºÞ ³o¼Ë¤£·|¼vÅT¦Û¤v¤ß±¡ ©Î³\þ¤Ñ¬ðµM¦¨¥\¤F´N¹³µo¤@µ§¾î°] ¤]¤£¿ù°Õ |
|
|
·|û¡G·RµL10148552 µoªí®É¶¡:2022/11/3 ¤W¤È 11:05:28²Ä 5741 ½g¦^À³
|
ªÑ²¼¯u¬O¤@Ó¯«©_ªº°Ó«~! º¦®É¬Ý¦n! ¶^®É¬ÝÃa! 1¦~«e¡A6¤¸ªº®ÉÔ»¡·Ç³Æ¼Q¤F°Õ¡A¸Ñª¼¤@©w¦¨¥\¡C 1¦~«á¡A0.35¤¸ªº®ÉÔ»¡¤½¥q¤@©w´£¦¬Ý¨ì¼Æ¾Ú¡A¸Ñª¼¤j¾÷²v¥¢±Ñ¡C ¦ý¡A¸Ñª¼µ²ªG¨Ã¥¼¥X¨Ó¡A³Ót¥¼¤À¡C 6¤¸¨g¶R¡A0.35¨g½æ¡A¤£Åܪº¬O¤H©Ê-°l°ª±þ§C¡C«¢~~~~~~~~~~~ |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/11/3 ¤W¤È 09:41:38²Ä 5740 ½g¦^À³
|
¬Q±ß9ÂI51¤À¶R¶i70¸UªÑ¡AªÑ»ù0.365¤¸¬üª÷¡A¬ù26¸U¬üª÷¡A¥x¹ô830¸U â±á3ÂI40¤À¶R¶i148¸UªÑ¡AªÑ»ù0.3405¤¸¬üª÷¡A¬ù50¸U¬üª÷¡A¥x¹ô1600¸U ³o¨âµ§³£¬O³æµ§©w»ù©w®É¥æ©ö¡An¶Rªº¤Hn§ä¨ì½æ®a(n½æªº¤Hn§ä¨ì¶R®a)¡A¨ÃÁ¿¦n¥æ©ö®É¶¡©M»ù®æ¡A ²{¦b¬OªÑ»ùµ´¹ï§CÂI¡A©Ò¥H¤£À³¸Ó¬O¦³¤H·Q½æ¡C¦Ó¬O¦³¤H·Q¶R¡C(ÅÞ¿è) ¦ý¤]¦³¥i¯à¬O¥ª¤â½æµ¹¥k¤â¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/3 ¤W¤È 06:10:54²Ä 5739 ½g¦^À³
|
¯È¤j, ¤½¥qªº¥«½Õ¦p¦¹°²³]Àø®Ä¤è®×¡B¥L̬O¦³¼Æ¾Ú¦b¤âªº±M®a¡B§Ú¥u¬O¼ÒÀÀ¸Õºâ¦Ó¤w¡B ¤]§Æ±æ¦³©_ÂÝ¡B¥´§¹²Ä¤T°w«á¦p¦P¥´§¹²Ä¤K°w¦³4-6¶g´Á¶¡¤£¥´°w¦Ó¥Íª««ü¼Ð¬Oéwªº¤£·|¤Ï¼u¡B³o¼Ë«á±ªº4¤@9°wªºÀø®Ä¯à©ñ¤j¨ì¤fªAÃĪ«ªºÀø®Ä¼ç¤O¡B¦¹®É¤~¯à¦b²Ä¤@½uÃĪ«¤¤¤j´T»â¥ýDupilumab, ¤è¯à¦³¦Ê»õ¡B¬ü¤¸ªº¾P°â¼ç¤O¡D ¤£¹L¬Ý¤FASLAN004±À¥X16¶gx¨C¶g¤@°wªºÁ{§É³]p´N±o¨Ì¤½¥q°²»¡¨Ó¼ÒÀÀ¡D |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2022/11/3 ¤W¤È 12:21:28²Ä 5738 ½g¦^À³
|
A+B=26+17 =43»õ¬ü¤¸¤§³Ì°ª¾P°â 2023³Q¦~©³¨ÖÁÊ¥«È¦ô¬ù20-25»õ¬ü¤¸ ¨CªÑ20-25¬ü¤¸´Á±æÈ¡D ------------------------------ ¦L¶H¤¤À³¸Ó¬O¤Ñ©R¥S¦ô¹L³Ì§Cªº¤@¦¸ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/11/2 ¤U¤È 11:26:49²Ä 5737 ½g¦^À³
|
¦³¤H§Û©³嘞 9ÂI51¤À¶R¶i70¸UªÑ¡AªÑ»ù0.37¤¸¬üª÷¡A¬ù26¸U¬üª÷¡A¥x¹ô830¸U ¬ù¶R¶i¨È·à±d ¦Ê¤À1ªÑ¥÷ ¡Ä |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/11/2 ¤U¤È 02:42:46²Ä 5736 ½g¦^À³
|
ì¥ý¹w´Á¦~©³À³¦³´Á¤¤¼Æ¾Ú¡A¥H²{¤µªºªÑ»ù¨Ó¬Ý¡A¥Ø«eªºª¼¼Æ¾Ú¥i¯àÁÙ¤W¤£¤FÂi±;¦Ñ·à¤Ín¦hÂI@¤ß¤F¡AÁöµM¦p¦P«Ó°¶¤j©Ò»¡±o¤@¼Ë¡A¦³Ãz±¼ªº¥´ºâ¡A¦ýÁÙ¬O´Á«Ý¦³©_ÂÝ¡A¦Ü©ó·s·à¤Í´N¦Û¦æ§PÂ_¤F¡A¦]³o»ò§C»ù¡A·ÀI¦Ût~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/2 ¤U¤È 02:20:29²Ä 5735 ½g¦^À³
|
¤G缐75¤HADÁ{§É¸Ñª¼¤½¥q©ã¦b2023¦~¡A¥¿±`¦b¦~©³¡C ©Ò¥H295¤H¡AQ2¸Ñª¼³ø§i¡A¤£·|¦³¤G缐ªvÀø¸ê®Æ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/2 ¤U¤È 01:02:33²Ä 5734 ½g¦^À³
|
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 11¤ë¥÷¤½¥q³Ì·s²³ø¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/2 ¤W¤È 10:34:34²Ä 5733 ½g¦^À³
|
Ó¤H¦ô ¤@¡B _________________________ ASLAN004 2B 16¶g´Á±æÈ (¨C¤G¶g¤@°w) 295¤H °ò½u¦ô(EASI26~28) EASI75 69% VS 24% IGA0.1 46% VS 15% ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3% µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤@½uÃÄÀø®Ä(¨C¤G¶g¤@°w) ¥i8% °ªDupilumab °w¨b¾¯¾÷·|¤j. ¤G¡BASLAN004 2B 16¶g´Á±æÈ (¨C¶g¤@°w) 75¤H °ò½u¦ô(EASI26~28) EASI75 73%~80% VS 24% IGA0.1 57%~64%% VS 15% ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3% µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤G½uÃÄÀø®Ä(¨C¶g¤@°w) ¥i¤ñ¤fªAUpadacitinib ¾÷·|¤j. . ¤T¡B¥«³õ¹w´Á ¤@½uÃĪ«47%¬Û¹ï©óDupilumab°¾¦n, ¥Ñ©ó¤G½uÃĪ«Àu²§ªí²{¡A¥¼¨Ó52¶gÀø®Ä¦³¼ç¤O¦A©Ô°ª¡B¥[¤W¨ä¥LÃĪ«¦Ò¶q¡B¥«¦û¦ô¬ùDupilumab1/3=80*1/3=26»õ¬ü¤¸¡KA ¤G½uÃĪ« 46% °¾¦n¬Û¹ï©ó¤fªAÃĪ«¡D ¨Ì¦~ªì½÷·ç¦Û¦ôAD ¤fªAÃÄ¥i¾P35»õ¬ü¤¸¡B ¦ô¬ù¦³ªñ½÷·ç1/2¥«¦û¬ù17»õ¬ü¤¸¥i´Á...B A+B=26+17 =43»õ¬ü¤¸¤§³Ì°ª¾P°â 2023³Q¦~©³¨ÖÁÊ¥«È¦ô¬ù20-25»õ¬ü¤¸ ¨CªÑ20-25¬ü¤¸´Á±æÈ¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/2 ¤W¤È 08:54:08²Ä 5732 ½g¦^À³
|
Upadacitinib AD ¤T´ÁÁ{§Éµ²ªG: 1. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) °ò½u EASI29(15mg)//EASI30(30mg)//EASI28(¹ï·Ó²Õ) °ò½u IGA=4 46%(15mg)//47%(30mg)//45%(¹ï·Ó²Õ) clinicaltrials.gov/ct2/show/results/NCT03569293?term=NCT03569293&draw=2&rank=1 2.16¶g Àø®Ä (1).EASI75 ¹êÅç²Õvs¹ï·Ó²Õ 15mg 69.6% vs 16.3% 30mg 79.7% vs 16.3% (2).IGA0,1 15mg 48.1% vs 8.4% 30mg 62% vs 8.4% _________________________ Ó¤H¦ô ASLAN004 2B 16¶g´Á±æÈ (¨C¶g¤@°w) 75¤H °ò½u¦ô(EASI26~28) EASI75 73%~80% VS 24% IGA0.1 57%~64%% VS 15% ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3% µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤G½uÃÄÀø®Ä(¨C¶g¤@°w) ¥i¤ñ¤fªAUpadacitinib ¾÷·|¤j. ----------------------- 3.AD-2/AD-3 没¤½¶}Á{§Éµ²ªG¸ê®Æ A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) clinicaltrials.gov/ct2/show/NCT03607422?term=NCT03607422&draw=2&rank=1 A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) clinicaltrials.gov/ct2/show/NCT03568318?term=NCT03568318&draw=2&rank=1 --------------------------------------------------------------------------------------- |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/1 ¤U¤È 05:59:47²Ä 5731 ½g¦^À³
|
www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s004lbl.pdf RINVOQ® (upadacitinib) FDA ¼ÐÅÒÀÉ Äµ§i¡GÄY«·P¬V¡B¦º¤`²v¡B ´c©Ê¸~½F¡A¥Dn¤£¨}¤ß¦åºÞ ¨Æ¥ó¡]MACE¡^©M¦å®ê§Î¦¨ ¦³Ãö§¹¾ãªº¶Â®Øĵ§i¡A½Ð°Ñ¾\§¹¾ãªº³B¤è«H®§¡C • ÄY«²Óµß¡B¯uµß¡B¯f¬r©M·P¬Vªº·ÀI¼W¥[ ¾÷·|©Ê·P¬V¾ÉP¦í°|©Î¦º¤`¡A ¥]¬AªÍµ²®Ö¡]TB¡^¡C¨Ï¥Î RINVOQ ¶i¦æ¤¤Â_³B²z ¦pªGµo¥ÍÄY«·P¬V¡Aª½¨ì·P¬V±o¨ì±±¨î¡C´ú¸Õ ªvÀø«e©MªvÀø´Á¶¡ªº¼ç¥ñ©Êµ²®Ö¯f¡FªvÀø¼ç¥ñ©Êµ²®Ö¯f §Q¥Î¡C¦bªvÀø´Á¶¡ºÊ´ú©Ò¦³±wªÌªº¬¡°Ê©Êµ²®Ö¯f¡A¬Æ¦Ü ªì©l³±©Ê¡B¼ç¥ñ©Êµ²®Ö¯f¸ÕÅ窺±wªÌ¡C (5.1) • §ó°ªªº¥þ¦]¦º¤`²v¡A¥]¬AÖ`¦º ¥t¤@ºØ Janus ¿E酶 (JAK) §í»s¾¯¾ÉP¤ß¦åºÞ¦º¤` »PÃþ·Àã©ÊÃö¸`ª¢¤¤ªº¸~½FÃa¦º¦]¤l (TNF) ªýº¢¾¯¤ñ¸û (RA) ±wªÌ¡C (5.2) • ±µ¨ü RINVOQ ªvÀøªº±wªÌµo¥Í¤F´c©Ê¸~½F¡C ¥t¤@ºØ JAK ªº²O¤Ú½F©MªÍÀùµo¯f²v§ó°ª RA ±wªÌ¤¤§í»s¾¯»P TNF ªýº¢¾¯ªº¤ñ¸û¡C (5.3) • ¸û°ªªº MACE µo¥Í²v¡]©w¸q¬°¤ß¦åºÞ¦º¤`¡B ¤ß¦Ù±ð¶ë©M¤¤·¡^»P¥t¤@ºØ JAK §í»s¾¯ »P RA ±wªÌ¤¤ªº TNF ªýº¢¾¯¬Û¤ñ¡C (5.4) • ±µ¨ü RINVOQ ªvÀøªº±wªÌµo¥Í¦å®ê§Î¦¨¡C ªÍ®ê¶ë¡BÀR¯ß©M°Ê¯ß®ê¶ëªºµo¥Í²v¼W¥[ ¥t¤@ºØ JAK §í»s¾¯»P TNF ªýº¢¾¯ªº¦å®ê§Î¦¨¡C (5.5) WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS See full prescribing information for complete boxed warning. • Increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with RINVOQ if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1) • Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK) inhibitor vs. tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients. (5.2) • Malignancies have occurred in patients treated with RINVOQ. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3) • Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4) • Thrombosis has occurred in patients treated with RINVOQ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5) ¯SÀ³©Ê¥Öª¢ • 12 ·³¤Î¥H¤WÅé«¦Ü¤Ö 40 ¤½¤ç©M 65 ·³¥H¤Uªº¦¨¦~¤H¡G¶}©l¤fªA 15 mg ªvÀø ¨C¤Ñ¤@¦¸¡C ¦pªG¨S¦³Àò±o¨¬°÷ªºÅTÀ³¡A½Ð¦Ò¼{¼W¥[ ¾¯¶q¬° 30 mg¡A¤fªA¡A¨C¤é¤@¦¸¡C (2.5) • 65 ·³¤Î¥H¤Wªº¦¨¤H¡G±ÀÂ˾¯¶q¬° 15 ²@§J¤@¦¸ Atopic Dermatitis • Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg and Adults Less Than 65 Years of Age: Initiate treatment with 15 mg orally once daily. If an adequate response is not achieved, consider increasing the dosage to 30 mg orally once daily. (2.5) • Adults 65 Years of Age and Older: Recommended dosage is 15 mg once Table 13: Efficacy Results of Monotherapy Trials at Week 16 in Patients with Moderate to Severe AD 16¥«¶g¤T´ÁÀø®Ä(°ò½u¥§¡EASI29//IGA0,1=449%)---¥¼¥Î¹L¥Íª«¨î¾¯ªº¤¤-««×AD±wªÌ 1.IGA0,1 ¹êÅç²ÕVS ¹ï·Ó²Õ Trial AD-1 15mg 48% vs 8% 30mg 62% vs 8% Trial AD-2 15mg 39% vs 5% 30mg 52% vs 5% Trial AD-3( RINVOQ+TCS VS TCS) 15mg 40% vs 11% 30mg 59% vs 11% 2.EASI75 ¹êÅç²ÕVS ¹ï·Ó²Õ Trial AD-1 15mg 70% vs 16% 30mg 80% vs 16% Trial AD-2 15mg 60% vs 13% 30mg 73% vs 13% Trial AD-3( RINVOQ+TCS VS TCS) 15mg 65% vs 26% 30mg 77% vs 26% ¤fªAÀø®Ä¬O¤£¿ù,¥i±¤°Æ§@¥Î¤Ó«. ASLN ¤½¥q 9/15°²³]ASLAN004 ¨C¶g¤@°wÀø®Ä¥i»P RINVOQ® (upadacitinib)¤ñ¸û. RINVOQ®¤T´Á¬O-¥¼¥Î¹L¥Íª«¨î¾¯ªº¤¤-««×AD±wªÌ Trial AD-3 ¹ï RINVOQ+TCS ,®Ä¯q¤£¤j. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/1 ¤W¤È 10:29:43²Ä 5730 ½g¦^À³
|
9/15 R&D DAY ir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f P.38 ASLN004 ¬Û¹ï©óRinvoq (upadacitinib)¤fªAÃÄ--(¦³«¤j°Æ§@¥Î ·ÀI-) ¨Ï¥Î°¾¦n¹ï¤ñ: 2B 75¤H ,¥i¯à¤è®×c: TREK-AD QW(¨C¶g¤@°w) 47%---¤G½uÃĪ« Rinvoq (upadacitinib) ¥«»ù5600¬ü¤¸/¤ë, °ª©óDupilumab 3300¬ü¤¸/¤ë ¬ù5600/3300=1.7¿ ASLAN004 ¤G½u, ¨C¶g¤@°w*16¶gÀøµ{¶O¥Î©MRinvoq (upadacitinib)¤ñ¥ÎÃĦ¨¥»¥i¦³¬Û·íªºÄvª§¤O. www.goodrx.com/rinvoq |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/31 ¤U¤È 09:40:12²Ä 5729 ½g¦^À³
|
aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf 1A °·±d¤H¥´¤@°w SC(¥Ö¤Uª`®g) 300mg/600mg ²Õ§¹¥þ§í¨î¥u¦³7¤Ñ. ²Ä14¤Ñ¦³30%/10%ªº¤Ï¼u °·±d¤H¥´¤@°w IV(ÀR¯ßª`®g) 10mg/KG(60¤½¤ç600mg) ²Õ§¹¥þ§í¨î30¤Ñ ASLAN004 SC¥Í¦¨²v(¥´¦bªí¥Ö ¶i¤JÀR¯ßÃĶq¤ñ²v)¥i¯à¤£¨ì50%. DUPILUMAB SC¥Í¦¨²v53%. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/31 ¤U¤È 09:26:42²Ä 5728 ½g¦^À³
|
aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf 1A °·¼o±d¤H¥´¤@°w SC 300mg/600mg ²Õ§¹¥þ§í¨î¥u¦³7¤Ñ. ²Ä14¤Ñ¦³30%/10%ªº¤Ï¼u 1b SC 400mg/600mg ¥´§¹°w«á,¨Ì¾ÚTRAC/IgE ¥Íª««ü¼Ð¥i«O4~6¶g©³ÀÉ,¥B±q²Ä¤T¶g¶}©l´N¹F¬Û¹ï§CÂI. 2b SC 300mg/400mg Q2w/0/1/2¶g¦U¥´¤@°w«á±q²Ä4¶g°_¨C¤G¶g¤@°w¨ì²Ä14¶g.¥Íª««ü¼Ðºû«ù¦b©³Àɦ³¾÷·|,¦ý4¶g«án¦A©³¥i¯à¤£·|¤Ó¦h. ¬GÀø®Ä¥i¯à©M8¶g/1-°wªº1b¬Ûªñ. ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c p.24//p.25 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/31 ¤U¤È 09:11:31²Ä 5727 ½g¦^À³
|
Ó¤H²q°¼: 2b clinicaltrials.gov/ct2/show/NCT05158023 295¤H Àø®Ä´N¤j¬ùµ¥©ó 1bmITT EASI75 69% VS24% (¹ï·Ó²Õ)---®t²§55% IGA0,1 45.5% VS 15% (¹ï·Ó²Õ) ---®t²§30.5%(30.5%/28% DUPILUMAB=109%) ¦]¬°2B °w¼Æ9°w ªñ1B 8°w. Àø®ÄÀ³¬Û·í. ˬO¤G½uÃÄ16¶g16°w, ¤~¦³¾÷·| EASI75 73%//IGA0,1 57%. ¦h7°w¦³¨äÀø®Ä. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/31 ¤U¤È 08:48:25²Ä 5726 ½g¦^À³
|
9/15 R&D DAY ir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f P.38 ASLN004 ¬Û¹ï©ódupilumab ¨Ï¥Î°¾¦n: 2B 295¤H .¥i¯à TREK-DX Q4W(°w/4¶g)57% /Q2W(°w/2¶g)47%----¤@½uÃĪ« 2B 75¤H ,¥i¯à¤è®×c: TREK-AD QW(¨C¶g¤@°w) 47%---¤G½uÃĪ« 47%*65%(dupilumab ¤¤Â_²v)=30.55%------¤G½uÃĪ« ¦ô¤»¤ë©³¸Ñª¼¥i¼W¥[¤G½uÃĪ«30.55% +¤@½uÃĪ«47%~57% = 78%~88% ---- --------------------------------------------------- ¤½¥qªºì·N¦p¤W,¨Ì¦¹¨Ó¼W¥[³Q¨ÖÁÊ»ùÈ. ¦ý2023/3¤ë16~26¤é, ¦p¦ó©Ô¹L1¬ü¤¸?§_«hn´î¸ê~ ·|¤£·|3¤ëªì¥ý¸Ñª¼«á,¥ý§ä¨p¶Ò°òª÷¬ü¤¸7*80%*88%=4.92¬ü¤¸/ªÑ,6¤ë¤½§G¼Æ¾Ú¥]¾P7*80%=5.6¬ü¤¸/ªÑ ---------------------- ¦p2021¦~2¤ë24¤é¥ý¨p¶Ò3.52¬ü¤¸/ªÑ,1800¸U¬ü¤¸ (3.52/4=88%) ir.aslanpharma.com/static-files/8e211cfa-512e-4f27-b382-dea0efcc2e14 2021/3¤ë1¤éªì¤½§G´Á¤¤¸Ñª¼ 2021/3¤ë4¤é«á¥]¾P4¬ü¤¸/ªÑ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/31 ¤U¤È 08:07:47²Ä 5725 ½g¦^À³
|
9/15·s»Dº` ASLAN Pharmaceuticals ±Ò°ÊÁ{§Ép¹º¥H¬ã¨s Eblasakimab ¦b Dupilumab ¸g¾úªº¯SÀ³©Ê¥Öª¢±wªÌ¤¤ªº§@¥Î ASLAN p¹º©ó 2022 ¦~²Ä¥|©u«×¶}©l TREK-DX¡]EblasaKimab ¦b Dupilumab eXperienced AD ±wªÌ¤¤ªº¸ÕÅç¡^¡A¥Hµû¦ô eblasakimab §@¬°´À¥N¥Íª«»s¾¯¹ï¤w°±¤î¨Ï¥Î dupilumab ªvÀøªº¯SÀ³©Ê¥Öª¢ (AD) ±wªÌªºÀø®Ä©M¦w¥þ©Ê TREK-DX ±N¬ã¨s eblasakimab ¦b±µ¨ü¹L dupilumab ªvÀøªº±wªÌ¤¤ªº¼ç¦b¥Î³~¡A¥H¸É¥R¥¿¦b¶i¦æªº TREK-AD ¸ÕÅç¦b¥Íª«¤Ñ¯uªº±wªÌ¤¤¶i¦æ ¨â¶µ¬ã¨sªºµ²ªG¥i±N¨Ì¥¬©Ô¦è³æ§Ü©w¦ì¬°ªvÀø¤¤«×¦Ü««× AD ªºº¿ï¥Íª«»s¾¯ ------------------------------ (TREK-DX²Ä¤@¦ì¹wp¦~©³©Û¶Ò//¥þ¬°(¥_¬ü±wªÌ2:1,¦ô³Ì¦h25©Û¶ÒÓ¤¤¤ß) --¦ô2023¦~6¤ë©³TREK-DX 75¤H ¸Ñª¼//¦P®É¤½§GTREK-AD 2B 295¤H,¸Ñª¼³ø§i) ------------------------------ ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab, complementing the ongoing TREK-AD trial in biologic naïve patients Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD TREK-DX program is part of the Company¡¦s existing operating plan and has no impact on previously-reported cash runway Further discussion of TREK-DX will take place during the Company-hosted R&D Day on September 15, 2022 California and Singapore, September 14, 2022 ¡V ASLAN Pharmaceuticals (¡§ASLAN¡¨, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of eblasakimab for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile. ASLAN expects to enroll the first patient in the trial in the fourth quarter of 2022. ¡§In contrast to our Phase 2b trial in biologic naïve patients, TREK-DX will allow us to evaluate eblasakimab¡¦s unique mechanism of action in a new patient population,¡¨ said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. ¡§We believe that many patients previously treated with dupilumab can benefit from eblasakimab, and this data could support the use of eblasakimab in both the biologic naïve and experienced patient populations.¡¨ The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe AD previously treated with dupilumab. The trial will enroll patients who have discontinued dupilumab treatment for any reason, including inadequate control of AD, loss of access or an adverse event. The program is part of the Company¡¦s existing operating plan and has no impact on its previously-reported cash runway. The trial will consist of a 16-week treatment period and a 12-week safety follow-up period. The primary efficacy endpoint is percentage change in Eczema Area Severity Index (EASI) score from baseline to week 16. Key secondary efficacy endpoints include the proportion of patients achieving Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear), proportion of patients with a 75% or greater reduction in EASI (EASI-75), proportion of patients achieving EASI-50 and EASI-90, and changes in peak pruritus. ¡§Dupilumab has played an important role in demonstrating the benefits of targeting the IL4/IL-13 signaling pathway in AD. However, some patients do not demonstrate an optimal or sustained response to dupilumab, or develop adverse events such as conjunctivitis, and thus seek an alternative treatment option that could offer an improved safety and efficacy profile,¡¨ said Dr Alex Kaoukhov, CMO, ASLAN Pharmaceuticals. ¡§As we have seen in other indications, such as psoriasis, targeting different molecular components of the same signaling pathway can lead to different clinical outcomes and we believe that eblasakimab¡¦s unique approach to blocking the Type 2 receptor may offer an effective treatment for dupilumab-experienced patients.¡¨ ASLAN is also conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data from this trial is expected in the first half of 2023. ASLAN¡¦s management is hosting a Research and Development (R&D) Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York. To attend the event in person or virtually, please click here for registration. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical¡¦s website at ir.aslanpharma.com/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/31 ¤U¤È 07:49:37²Ä 5724 ½g¦^À³
|
¬ü°ê¤G¤jú³°Ó³Ì·sºû«ùASLN ºû«ù¶R¶iµûµ¥ ¥Ø¼Ð»ù 7~4 ¬ü¤¸. 1.H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals (ASLN ¡V Research Report) today and set a price target of $7.00. The company¡¦s shares closed last Friday at $0.40. H.C. Wainwright Sticks to Their Buy Rating for Aslan Pharmaceuticals (ASLN) Oct 31, 2022, 06:15 PM www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aslan-pharmaceuticals-asln?mod=mw_quote_news 2. ASLN 12:29 10/28/22 Aslan Pharmaceuticals ended Q3 with $69M in cash, says Piper Sandler Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $4 price target on Aslan Pharmaceuticals shares. Aslan is conducting the Phase IIb TREK-AD study of eblasakimab in ~300 moderate-to-severe atopic dermatitis with top-line data expected in 2Q23, and the company ended Q3 with cash of $69M, Tenthoff tells investors in a research note. Aslan is also planning a Phase II study of DHODH inhibitor farudodsta in skin autoimmune disease that will commence in 1H23, the analyst adds. Read more at: thefly.com/n.php?id=3605306 |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/28 ¤U¤È 11:32:53²Ä 5723 ½g¦^À³
|
¤Ñ©R¤j¡A ¦pªG¨ì©ú¦~3¤ë26¤é«e¡A004 2b¹êÅç¼Æ¾Ú¦nÃa¡A¾ã²z²Îp¸ê®Æ®É¡AÀ³¸Ó¦´N¤ß²z¦³¼Æ YªÑ»ù¤´¥¼¯à³sÄò¯¸¤W1¬ü¤¸¡A¥Nªí¤jªÑªF¤Îªk¤H¤w¤£»{¦P¸Ó¤½¥q¡A¤£Ä@¦A¼W¸ê¡C §Ú»{¬°¦Ñ·à°_¦º¦^¥Íªº¾÷·|¤w·L¥G¨ä·L¡A©¡®É¥u¯à©ñ±ó»{¿é ¦Û¤vªº¤½¥q¦Û¤w¤£±Ï½Ö·|±Ï¡A¤j®a¥u¯à©ñ±ó©ñ¥Í |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/28 ¤U¤È 10:18:06²Ä 5722 ½g¦^À³
|
³¯¤j¡A ½Ðª`·N¡A©ú¦~3¤ë26¤é«eYªÑ»ù¥¼³sÄò¯¸¤W1¬ü¤¸¡C ¥Bn«ùÄò¤W¥«¡C ASLN ¤½¥q¤èªk 1¡A´î资 2.¼W¥[ìªÑ¹ï´«ADR¤ñ²v¡C ¥Ø«e¤½¥q¡A2bªº¸Ñª¼资®Æ¤½§G¤é´Á¦ô¦b2023¦~²Ä¤G©u¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥i¯à¤]µL´Á¤¤³ø§i¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/28 ¤U¤È 09:40:11²Ä 5721 ½g¦^À³
|
¬ü°êªF³¡®É¶¡ 2022 ¦~ 10 ¤ë 28 ¤é 07:00 | ¸ê®Æ¨Ó·½¡G ¨È´µÄõÃÄ·~¦³¤½¥q ... ºI¦Ü 2022 ¦~ 9 ¤ë 30 ¤é¡A¤½¥q¥H 6,890 ¸U¬ü¤¸ªº²{ª÷¡B²{ª÷µ¥»ùª«©Mµu´Á§ë¸êºû«ù°·±dªº¸gÀ窬ªp¡F¹wp¨ì 2023 ¦~©³ªº¶]¹D ¬ã¨s eblasakimab ¦bdupilumab¤¤ªº¼ç¤Oªº·s TREK-DX Á{§Ép¹º¸g¾ú¤F¯SÀ³©Ê¥Öª¢ (AD) ±wªÌ¡A¦³±æ¦b 2022 ¦~©³«e©Û¶Ò²Ä¤@¦ì±wªÌ eblasakimab¦b¥Íª«¥®¸X¤¤«×¦Ü««× AD ±wªÌ¤¤ªº 2b ´Á TREK-AD ¸ÕÅ祿¦b¶i¦æ¤¤¡A¹wp±N¦b 2023 ¦~²Ä¤G©u«×²£¥Í¤@½u¼Æ¾Ú ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2022 ¦~ 10 ¤ë 28 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬°]°ÈºI¦Ü 2022 ¦~ 9 ¤ë 30 ¤éªº²Ä¤T©u«×·~ÁZ¡A¨Ã´£¨Ñ¤F³Ìªñ¤½¥q¬¡°Êªº³Ì·s±¡ªp¡C ¡§¦b²Ä¤T©u«×¡A§ÚÌ´Neblasakimab¦b¯«¸g¤¸æ±Äo©Mª¢¯g³q¸ô¤¤ªº¤£¦P§@¥Î¾÷¨î´£¥X¤F³\¦h·sªº«n¨£¸Ñ¡A¥H¤Î»Pæ±Äo©MºÎ¯v³à¥¢¬ÛÃöªº AD ±wªÌªº¼ç¦b§ïµ½¡A³o³q±`¬O³o¨Ç±wªÌ¡A¡¨ ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h¤À¨É¹D¡C¡§§ÚÌ´Á«Ý 2b ´Á¼Æ¾Ú¦b 2023 ¦~²Ä 2 ©u«×¦b¥Íª«¤Ñ¯u¤¤«×¦Ü««× AD ±wªÌ¤¤µû¦ôeblasakimabªº¥Dn¼Æ¾Ú¡C¦b§Ú̱N±q TREK-AD ©M TREK-DX ¥Í¦¨ªº·s¼Æ¾Ú¤§«e¡A§ÚÌ¥¿¦b±q¥¿¦b¶i¦æªº¬ã¨s¦X§@¤¤«Ø¥ß¤@®M±j¦³¤Oªº¨£¸Ñ¡A³o¨Ç¦X§@±N©ó©ú¦~ªì®i¥Ü¡A¥H¤ä«ùeblasakimab¨ã¦³§@¬°¤¤««× AD ªº®t²§¤ÆªvÀøªº¼ç¤O¡A¦b 2 «¬ÅX°Êªºª¢¯g©Ê¯e¯f¤¤¨ã¦³¼sªxªºªvÀø¼ç¤O¡C¡¨ 2022 ¦~²Ä¤T©u«×¤Îªñ´Á·~°È«GÂI ¨Ì¥¬©Ô»ô³æ§Ü 8 ¤ë¡A¤½¥q»P Belle.ai ñ¸p¤F¤@¶µ³\¥i¨óij¡A¥Î©ó¦b¥þ²y¦hÓ¯¸ÂI¨Ï¥Î belleStudy ™¼Æ¦r¹Ï¹³®·Àò³n¥ó¡A¥Î©ó AD ¤¤¥¿¦b¶i¦æªºeblasakimabªº TREK-AD ¬ã¨s¡C©ö©ó¨Ï¥Îªº¸Ñ¨M¤è®×¥i¥H³q¹L¹Ï¹³®·Àò¼Ð·Ç¤Æ°O¿ý AD ¯e¯fÄY«µ{«×µû¤À¡A¸Ó§Þ³N±N¨Ï ASLAN ¯à°÷¶i¤@¨B¥[±j¨ä¦b TREK-AD ¬ã¨s¤¤ªº½è¶q±±»sµ{§Ç¡C 9 ¤ë¡A¦b²Ä 31©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·| (EADV) ¦~«×¤j·|¤W®i¥Ü¤F¤T±i®ü³ø¡A¨ä¤¤¥]§t¥ý«e³ø§iªºeblasakimab 1b ´Á·§©ÀÅçÃÒ¸ÕÅ窺¥Íª«¼Ð»xª«¡BÀø®Ä´ú¶q©M±wªÌ³ø§iªºµ²ªG´ú¶qªº·s¼Æ¾Ú¡C¼Æ¾ÚÅã¥Üeblasakimab§í¨î AD ªº¤U´åª¢¯g¥Íª«¼Ð»xª«¡A¨Ã¥B³oºØ§@¥Î¦b³Ì«á¤@¦¸µ¹ÃÄ«á«ùÄò 4 ¨ì 6 ¶g¡C±µ¨üeblasakimabªvÀøªº±wªÌ¦bºÎ¯v½è¶q´ú¶q©MeblasakimabªvÀø¤è±ªí²{¥XÅãµÛ§ïµ½»P¦w¼¢¾¯¬Û¤ñ¡AP-NRS¡]Äo¡^µû¤À°§C¡A¦b©Ò¦³¾¯¶q²Õªº¤K©PªvÀø¹Lµ{¤¤³£¦³§ïµ½¡C®ü³ø¥i¦b¤½¥qºô¯¸ªº·s»D©M¥Xª©ª«³¡¤À§ä¨ì¡C 9 ¤ë¡A¤½¥q¶}©l¤F TREK-DX¡]EblasaKimab ¦b Dupilumab eXperienced AD ±wªÌ¤¤ªº¸ÕÅç¡^¡A³o¬O¤@¶µ¬ã¨seblasakimab¦bdupilumab¤¤«×¦Ü««× AD ±wªÌ¤¤ªº·sÁ{§É¸ÕÅç¡C¸Ó¸ÕÅç¥]¬A 16 ¶gªºªvÀø´Á©M 12 ¶gªº¦w¥þÀH³X´Á¡C¥DnÀø®Ä²×ÂI¬OÀã¯l±¿nÄY««×«ü¼Æ (EASI) µû¤À±q°ò½u¨ì²Ä 16 ¶gªº¦Ê¤À¤ñÅܤơCµ²¦X TREK-AD ¸ÕÅ礤¥Íª«ªì©l AD ±wªÌªº¼Æ¾Ú¡A§Ú̬۫H TREK-DX ¬ã¨sªºµ²ªG¦b¦³¥Íª«¾Ç¸gÅ窺¤H¸s¥i¥H±Neblasakimab©w¦ì¬°¤¤«×¦Ü««× AD ªºº¿ïº¿ïªvÀø¤èªk¡C ¤½¥q©ó 9 ¤ëÁ|¿ì¤F¬ãµo¤é¬¡°Ê¡AºÞ²z¼h¦b·|¤W¥þ±§ó·s¤Feblasakimab¶}µop¹º¡C¦è¥_¤j¾Ç Feinberg Âå¾Ç°|ªº Peter A Lio ³Õ¤h©M¬ù¿«ÀN´¶ª÷´µ¤j¾Çªº Shawn Kwatra ³Õ¤h°Q½×¤F AD ©M 2 «¬ÅX°Ê¯e¯f¤¤·s¥X²{ªº¥¼º¡¨¬»Ý¨D¡BªvÀø«e´º©M¼ç¦bªº¤À¤l¾÷¨î¡C¥i¥H¦b¤½¥qºô¯¸ªº§ë¸êªÌÃö«Y³¡¤À§ä¨ì¬¡°Ê©Mºt¥Ü§÷®Æªº«¼½¡C 9 ¤ë¡A¤½¥q¦b¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¨ó·| (ESDR) ¦~·|ªº³Ì·s·|ij¤W®i¥Ü¤Feblasakimabªº·sÂà¤Æ¼Æ¾Ú¡C»P Shawn Kwatra ³Õ¤h©M Madan Kwatra ³Õ¤h¥¿¦b¶i¦æ¦X§@ªº²Ä¤@§å¼Æ¾ÚÅã¥Ü¡AAD ±wªÌ¥Ö½§¼Ë¥»¤¤ªÎ¤j²ÓM©M¶Ý»Ä©Ê²É²ÓMªº IL-13R£\1 ªí¹F¼W¥[¡A±q¦Ó¥[±j¤F IL-13R£\1 ¦b AD ¤¤ªº®Ö¤ß§@¥Î¡C¦b¤HÃþ¯«¸g¤¸¼Ò«¬¤¤¡A¨Ì¥¬©Ô°ò³æ§Ü ÅãµÛ°§C¤F¥Ñ¤£¦Pªº IL-4 ©M IL-13 æ±Äo³~®|¤Þ°_ªº¯«¸g¤¸æ±Äo±Ó·P©Ê¡A¨Ã¥BÁÙ½T©w¤F IL-13R£\1 «H¸¹¶Ç¾É¦b¤¶¾É AD ¤§¥~ªº¯«¸g¤¸¿³¾Ä©Ê©M±Ó·P©Ê¤¤ªº·s§@¥Î¡C ªk¾|¹F (ASLAN003) ¥Ö½§¦Û¨§K¬Ì©Ê¯e¯fªºÁ{§É¶}µop¹º¥¿¦b³Ì«áºV©w¡A¹wp 2023 ¦~¤W¥b¦~¶}©l¶i¦æ 2 ´Á¸ÕÅç¡C ¹wp§Y±N¨ì¨Óªº¨½µ{¸O ¨ì 2022 ¦~©³¡A²Ä¤@¦ì±wªÌ°Ñ¥[¤F TREK-DX ¸ÕÅç¡C ¬ð¥Xeblasakimab§@¥Î¾÷¨î¿W¯S§@¥Îªº·sÂà¤Æ¼Æ¾Ú±N©ó 2023 ¦~ªì¤½§G¡C eblasakimab 2b ´Á TREK-AD ¸ÕÅ窺¤@½u¼Æ¾Ú¹wp±N©ó 2023 ¦~²Ä¤G©u«×µo¥¬¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/28 ¤U¤È 07:50:24²Ä 5720 ½g¦^À³
|
ASLAN Q3°]³ø¤Î资°T§ó·s¡C finance.yahoo.com/news/aslan-pharmaceuticals-reports-third-quarter-110000300.html ¦Ü 2022 ¦~ 9 ¤ë 30 ¤é¡A¤½¥q¥H 6,890 ¸U¬ü¤¸ªº²{ª÷¡B²{ª÷µ¥»ùª«©Mµu´Á§ë¸êºû«ù°·±dªº¸gÀ窬ªp¡F ¹wp¨ì 2023 ¦~©³ªº¶]¹D ¬ã¨s eblasakimab ¦b dupilumab ¤¤ªº¼ç¤Oªº·s TREK-DX Á{§Ép¹º¸g¾ú¤F¯SÀ³©Ê¥Öª¢ (AD) ±wªÌ¡A¦³±æ¦b 2022 ¦~©³«e©Û¶Ò²Ä¤@¦ì±wªÌ eblasakimab ¦b¥¼¸g¥Íª«ªv¾¯¹Lªº¤¤«×¦Ü««× AD ±wªÌ¤¤ªº 2b ´Á TREK-AD ¸ÕÅ祿¦b¶i¦æ¤¤¡A¹wp±N¦b 2023 ¦~²Ä¤G©u«×²£¥Í¤@½u¼Æ¾Ú¡C Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023 New TREK-DX clinical program studying eblasakimab¡¦s potential in dupilumab experienced atopic dermatitis (AD) patients on track to enroll first patient by the end of 2022 The Phase 2b TREK-AD trial for eblasakimab in biologic naïve moderate-to-severe AD patients is on track and anticipated to generate topline data in Q2 2023 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/28 ¤W¤È 06:59:40²Ä 5719 ½g¦^À³
|
³¯¤j¡A ¦]ªG¤£¬N¡A 随缘¤£ÅÜ¡A ¤£ÅÜ随缘¡C 11¤ë¤¤¦¯¡A¤½¥¬Q3°]³ø¡A¦ôp·|«Å¥¬2b ¦¬®×§¹¦¨¡C ¦ô©ú¦~2¤ë¤¤¦¯-3¤ë¤W¦¯¸Ñª¼¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/28 ¤W¤È 12:03:09²Ä 5718 ½g¦^À³
|
¤Ñ©R¤j ¦p²Ä2°¦¸}¤£¯}«e§C¡A¤S¥X¤j¶q¡A§Û©³¥i¦æ¶Ü¡A ·Pı°÷«K©y¤F¡A¦n¹³¾À¯È¤@¯ë ·Q¤F¸Ñ±zªº¬Ýªk |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/27 ¤U¤È 11:49:18²Ä 5717 ½g¦^À³
|
¾ú¥v³Ì§C»ù0.3555§Ö¨ì¤F |
|
|
·|û¡GDHL10147526 µoªí®É¶¡:2022/10/27 ¤U¤È 07:43:41²Ä 5716 ½g¦^À³
|
³q±`¥¢±Ñ¹Lªº¤½¥q¡A«ÜÃø¯¸±o°_¨Ó ¦ý¯¸±o°_¨Óªº¤½¥q¡A³q±`¦n¹B¨ì¤F ¥[ªo¡I¨È·àÅܶ¯·à¡I |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/10/27 ¤U¤È 06:13:00²Ä 5715 ½g¦^À³
|
ªÑ»ù¤w¸g®z¶Õ¨ì¹³³Q©ñ±ó¤@¼Ë §Ú¤w¸g¤£´Á«Ý¸Ñª¼¦³¤°»ò¥i¯à¤F ´N¥áµÛ·í¼Ö³z¡A¤[¤[¨Óª©¤W¬Ý¤@¤U |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/27 ¤U¤È 04:52:53²Ä 5714 ½g¦^À³
|
³¯¤j¡A °²³] ªñ¦ü Lebrikizumab 2b Àø®Ä clinicaltrials.gov/ct2/show/results/NCT03443024 1.IGA0,1 ¹ï·Ó²Õ=15.3% 4¶g¤@°w 125mg =22.6% p=0.1917(pÈ>0¡P05¡^ 4¶g¤@°w 250mg=33.7% p=0.0392(¤T´Á°µ¬°18¡ã52¶g©µªøªvÀø¤§¤@¡A¨ÃµL1¡ã16¶gªvÀø³]p¡^ 2¶g¤@°w 250mg=44.6% p=0.0023 2¡PEASI75 ¹ï·Ó²Õ=24.3% 4¶g¤@°w 125mg =43.3% p=0.0610(pÈ>0¡P05¡^ 4¶g¤@°w 250mg=56.1% p=0.002)¤T´Á°µ¬°18¡ã52¶g©µªøªvÀø¤§¤@¡A¨ÃµL1¡ã16¶gªvÀø³]p¡^ 2¶g¤@°w 250mg=60.2% p=0.0005 280¤H¤@4²Õ¡A58Ó¤¤¤ß¡A¥§¡4.82¤H¡þ¤¤¤ß ¥H¤W³]p¡A§Y¨Ï¦³¨CÓ¤Hªº¨C¤G¶g¸ê®Æ¡A¦pªGµL¸Ñª¼¡A¬Ý¤£¥X¨C²ÕªºÀø®Ä¡C ASLAN004 2b ¡A§ó¦h²Õ¦@5²Õ¡A°²³]295¤H¡þ65¤¤¤ß¡×4¡P5¤H/¤¤¤ß⋯⋯ ¥¼¸g¸Ñª¼¹ê¬Ý¤£¥X¡A¦U²ÕªºÀu¦H¡C ¸Ñª¼¤è¯àª¾±x¡A¦U²ÕpÈ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/27 ¤U¤È 12:14:49²Ä 5713 ½g¦^À³
|
ir.aslanpharma.com/static-files/60a95013-835e-4341-9b3b-270ce73b9b1d 2022/Q2 ASLN °]³ø¡A¦p¤W ²bÈ3200¸U¬ü¤¸ ·l¯q-1300¤d¸U¬ü¤¸¤@Q2 ²{ª÷7800¸U¬ü¤¸ ¨ì2022/Q4. ²bȦô³Ñ600¸U¬ü¤¸ ²{ª÷¦ô³Ñ5200¸U¬ü¤¸¡C¡]¨C©u·l¥¢1300¸U¬ü¤¸¡^ finance.yahoo.com/quote/ASLN/?p=ASLN ASLN ¦¬½L¥«È3080¸U¬ü¤¸¡C ¤@¤@¤@¤@ ASLN¤½¥qªÑ»ù¡A¥Ø«e¥H¥]¾P¨é°Óªº¦ôȳ̷ǽT¡C 2b ¸Ñª¼¼Æ¾Ú¡AY¦p¹w´Á¡]¦p 1bmITT EASI 69%/IGA 44%),¥Ø¼Ð»ù7¬ü¤¸¡A¤U¦¸¥]¾P»ù5¡D6¬ü¤¸¡þªÑ¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/10/27 ¤W¤È 11:58:04²Ä 5712 ½g¦^À³
|
Á`ı±o¥Ø«e¦Ñ·àªºªÑ»ù¡A¤£¹³¬O¸Ñª¼ªºµ²ªGn¶W¶V§ù¥²ª¢¤ÎLebrikizumabªº¼ËºA¡A§Y¨Ï¸Ñª¼¸õ¤W5¿¡A¤]¥u¦³2.25¡A¥u¬O¤£´î¸ê¦Ó¤w¡A«ÂI¬OCEOn§V¤O¤@ÂI¡A¦h«µøªÑ»ù¡A¤£µM´«ð¾÷ºc¨Ó¸gÀç¤]¤£¿ù¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/27 ¤W¤È 11:57:57²Ä 5711 ½g¦^À³
|
³¯¤j¡A ¥H¤UÓ¤HÆ[¹î¡C ¬ü°ê¤p«¬·sÃĪѪºªÑ»ùªº¥«È±`¦b¥¼¨úÃĵý®É±µªñªÑ²¼²bÈ¡C ¨ú±oÃĵý«á3Ӥ몺¥«È¬ù©Ô°ª¨ì¡C¥«³õ»{¥i¦y®p¾P°âÃBx3¿¡C ³Q¨ÖÁÊ»ùÈ=¨C¦~Àç·~²bȪº§é²{È ¡]¦pLebrikizumab 2019¦~©³¦©°£¼Ú¬w°Ï¾P°â¡A¤W¥«²Ä5¦~³Ì°ª¾P°â15»õ¬ü¤¸¡A¨CÀç·~§Q¯q§é²{11»õ¬ü¤¸¡^¡A³Ì«á11»õ¬ü¤¸³Q¨ÖÁÊ¡C ¨ÖÁʤ½¥q¥i¦b²bȪº°ò¦¤WÀò¤T¿¥H¤WªÑ»ù³ø¹S¡C ¤½¥q¥DºÞ¥Dn¦¬¤J¡A¬Ò¾aªÑ²¼¤À¬õ¡A¬ü°ê¤½¥q¤ÀªÑ§Q½Òµ|«¡A©Ò¥H¦hªº¸êª÷¬Ò¶R¤½¥q®wÂêѡC |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/27 ¤W¤È 10:07:10²Ä 5710 ½g¦^À³
|
CNTB¤½¥qCBP201 AD 2b ¸Ñª¼¤ê(²q2021/07/28)¡A ªÑ»ù¦b°ªÀÉ23-28¬ü¤¸¡A11¤ë19¤é¤½¥¬¸Ñª¼¼Æ¾Ú¡A·í¤é³Ñ4¬ü¤¸¦h¡C DERM¤½¥q Lebrikizumab AD 2b ¸Ñª¼/·í¤é(2019/02/07)¤½¥¬¡C ªÑ»ù¦b§CÀÉ6¶ô¦h¬ü¤¸¡A¸Ñª¼·í¤é¤jº¦约¤@¿¨ì12¬ü¤¸¥ª¥k¡C 2019¦~10¤ë¶}©l¤T´ÁADÁ{§É¡AªÑ»ù¦^¨ì©³ÂI6¬ü¤¸¥ª¥k¡C 2019¦~12¤ë 18¬ü¤¸¦h/ªÑ¡A³Q§¨Ó¤½¥q«Å¥¬¨ÖÁÊ¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/27 ¤W¤È 10:05:17²Ä 5709 ½g¦^À³
|
¤Ñ©R¤j ·PÁ±zªº¦^´_ ¥i¯à¬O¥xªÑ¤º½u¥æ©ö¤ÓÄY« Á`»{¬°ªÑ²¼¤H¬°¾Þ±±ªº¦]¯À·¥¤j ªÑ»ù¨«¶Õ·|¥ý¤Ï¬M¤½¥q¥¼¨Ó¡A¦]¬°¦³¤H¤w¥ýª¾¹D ©Ò¦³»{¬°004 2b¼Æ¾Ú¥i¯à¤£¨Î ±z»¡ªº¨º®a¤½¥qªÑ»ù³Ì§C¨ì6.6¤¸ ±q¥¼ªø´Á§C©ó1¤¸¡A¦³¤U¥«¦M¾÷ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/27 ¤W¤È 09:42:18²Ä 5708 ½g¦^À³
|
³¯¤j¡A www.clinicaltrials.gov/ct2/show/NCT04444752?term=NCT04444752&draw=2&rank=1 CBP 201 AD, 2b 2021/7/28 ¥Dn资®Æ(16¶gªº«ü¼Ð)¡C ¥LªºªÑ»ù¡A¦³³s°Ê²{¶H¡C finance.yahoo.com/quote/CNTB/ 2021/08/10 ³Ì°ª©Ô¤W28¬ü¤¸¡C (2021/7/28 ¥i¯à¤w¸Ñª¼¡H¡H¡H) 2021/11/19 ¤½§G¼Æ¾Ú ·í¤é³Ñ4¶ô¦h¬ü¤¸¡C ¿éŦb¸Ñª¼¤é¤§«á¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/27 ¤W¤È 09:16:58²Ä 5707 ½g¦^À³
|
004 2b¸ÕÅç ±q8¤ë26¤é«á¡A §YµL¥ô¦ó¶i«×§ó·s¸ê®Æ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/27 ¤W¤È 09:12:50²Ä 5706 ½g¦^À³
|
³¯¤j¡A DERM (Lebrikizumab ) 2019/02/07 AD2b ¸Ñª¼ 2019/02/12 ¼Ú¬w°Ï±ÂÅv DERM ªÑ»ù¨«¶Õ¡A¦p¤U www.netcials.com/stock-price-chart-history-nasdaq/DERM-Dermira-Inc/ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/27 ¤W¤È 08:59:42²Ä 5705 ½g¦^À³
|
¤Ñ©R¤j ³Ìªñ¦³¤°»ò§QªÅ ¬°¦óªÑ»ù¤´«ùÄò¨«§C ²@µL¤î¶^¸ñ¶H ¬O§_¥i¯à¬O004 2b¼Æ¾Ú¤w¦³¤H¥ýª¾¹D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/22 ¤U¤È 12:27:00²Ä 5704 ½g¦^À³
|
×¥¿-1 ASLAN004 1b mITT¡]8¶gªvÀø¡^ vs 2b ITT´Á±æÈ ¡]16¶gªvÀø¡^//¹ï·Ó²Õ´Á±æÈ¡]16¶g¡^//(¦©°£¹ï·Ó²Õ«áPk¡^ EASI75 =69% vs 73%// ¹ï·Ó²Õ24%//(®t²§ 45% vs 49%)---×¥¿-1(¤¤Â_²v3/16,¥i¯à¤Uרì1/16.¨ì®É¥i¯à¦A©Ô¤ÉEAS75 ¨ì80%¥H¤W¾÷²v¤£¤p) IGA0¡A1 =44% vs 57%//¹ï·Ó²Õ15%//¡]®t²§ 29% vs 42%) ¤@¤@¤@¤@¤@¸g16¶gªvÀø«áIGA0,1 ·|¦A´£°ª¡A¦pLebrikizumab 2b/ph3 EASI75 ©MIGA0,1®t¶Z16%¡]16¶g¡^ Lebrikizumab 2b//ph3 ¦P¼Ë¼vÅTIL13a1,Àø®Ä§ó¦³°Ñ¦Ò»ùÈ¡A¥u¬OASLAN004 ®Ä²v§ó§Ö¡C ¤@¤@¤@¤@16¶gªº¹ï·Ó²ÕÀø®Ä°Ñ¦ÒLebrikizumab 2b¸ê®Æ¡A¦ôp°ò缐EASI¦b25.5~27.5¤ô·Ç¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/22 ¤W¤È 11:59:53²Ä 5703 ½g¦^À³
|
¨È·à±dªºì©lªÑ¥»500¡A000¤dªÑ//ADR100¡A000¤dªÑ¡C Y¤£©Ô°ªªÑ»ù¨ì18.5¬ü¤¸¥H¤W¡A¦ôp¤£¨¬¶Ò¨ì3´ÁÁ{§É4»õ¬ü¤¸ªº¸êª÷¡C »Ý¦A¥l¶}ªÑªF·|ÂX¼W¸ê¥»ÃB¡C¦ôp¦Ü¤Ö¼W¥[¨ì50%¡A¼W¥[¨ìADR150¡A000¤dªÑ 75¡A000¤dªÑx7¤¸x80%x97%=¬ù4»õ¬ü¤¸¡]·í®ÉDERM AD2b¸Ñª¼«áªº¸êª÷¦s¶q¡^ ¤@¤@¤@¤@ ¥t¤@¤è¦¡´N¬O©Ô°ªªÑ»ù¨ì18.4¬ü¤¸¥H¤W 18.4x80%X97%=14.28¬ü¤¸ 4»õ¬ü¤¸/14.28=28,000¤dªÑADR¡]¤£¥Î¦AÂX¥RªÑ¥»¡^ ¥«È©Ô¤É¦Ü15~18.5»õ¬ü¤¸¥H¤W¡A¦p¦¹³Q¨ÖÁÊ»ù¦A¤@¿40»õ¬ü¤¸§ó¦n½Í¡C ¤½¥qn¥[ªo³á¡ILebrikizumab AD ³Ì°ª¾P°â¤w«O¦u¦ô¨ì45»õ¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/22 ¤W¤È 11:27:51²Ä 5702 ½g¦^À³
|
¤½¥qªº´XÓ1bªº´Á¥Z¸ê®Æ¨¬¥H°µ¬°±ÂÅv«eªº¸ê®Æ°Ñ¦Ò¡G aslanpharma.com/news/?cat=publications ¦p±ÂÅv½Í§P¡A±N¨Ì¾Ú¸Ñª¼¼Æ¾Ú¨Ó©w»ùÈ¡C ¤è®×¥i¥ý°²³] A¡DÀø®Ä¦P1b mITT ®Éªº¥«Ô·»ùÈ¡H¡]¼ç¦b¦y®p¾P°â¡þ²{ª÷§é²{È¡^ B¡BÀø®Ä°ª©ó 1b mITT®Éªº¥«³õ»ùÈ¡H¡]¡§¡^ µ¥¸Ñª¼¦A·L½Õ»ùÈ¡C Æ¿¤@¤@¤@¤@ ASLAN004 1b mITT¡]8¶gªvÀø¡^ vs 2b ITT´Á±æÈ ¡]16¶gªvÀø¡^//¹ï·Ó²Õ´Á±æÈ¡]16¶g¡^//(¦©°£¹ï·Ó²Õ«áPk¡^ EASI75 =69% vs 73%// ¹ï·Ó²Õ24%//(®t²§ 45% vs 59%) IGA0¡A1 =44% vs 57%//¹ï·Ó²Õ15%//¡]®t²§ 29% vs 42%) ¤@¤@¤@¤@¤@¸g16¶gªvÀø«áIGA0,1 ·|¦A´£°ª¡A¦pLebrikizumab 2b/ph3 EASI75 ©MIGA0,1®t¶Z16%¡]16¶g¡^ Lebrikizumab 2b//ph3 ¦P¼Ë¼vÅTIL13a1,Àø®Ä§ó¦³°Ñ¦Ò»ùÈ¡A¥u¬OASLAN004 ®Ä²v§ó§Ö¡C ¤@¤@¤@¤@16¶gªº¹ï·Ó²ÕÀø®Ä°Ñ¦ÒLebrikizumab 2b¸ê®Æ¡A¦ôp°ò缐EASI¦b25.5~27.5¤ô·Ç¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/22 ¤W¤È 09:38:00²Ä 5701 ½g¦^À³
|
°²³] ¨Ì¾ÚDERM ¤½¥qLebrikizumab AD 2b,2019/02/07¸Ñª¼,02/12¼Ú¬w°Ï°Ó·~¤ÆÅv¤O±ÂÅv. ASLAN004 2022¦~10¤ë15¤éASLAN004 2¤ë, ¤w¦¬§¹³Ì«á¤@¤H¥B¥´²Ä¤@°w. 2023¦~2¤ë15¤é¸Ñª¼ 2023¦~2¤ë16¤é¶Ò¸ê(¨p¶Ò/¥]¾P)3~5»õ¬ü¤¸,·Ç³Æ°µ¤T´Á. 2023¦~2¤ë22¤é¼Ú¬w°Ï°Ó·~¤ÆÅv¤O±ÂÅv. ²{¦b¤½¥qÀ³¸Ó¦b°µ¦ó¨Æ? À³¸Ó«Ü¦£!!! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/19 ¤W¤È 08:06:35²Ä 5700 ½g¦^À³
|
Pk 1.Lebrikizumab 2b clinicaltrials.gov/ct2/show/results/NCT03443024 Àø®ÄPK(°ò½uEASI25.5) ¹êÅç²Õ vs ¹ï·Ó组 EASI75 61% vs 24%(®t²§37%) IGA0,1 45% vs 15%(®t²§30%) 2.Lebrikizumab ph3 16¶g Àø®ÄPK(°ò½uEASI???) ¹êÅç²Õ vs ¹ï·Ó组 (1)AD1 clinicaltrials.gov/ct2/show/results/NCT04146363 EASI75 59% vs 16%(®t²§43%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组¥§¡47% IGA0,1 43% vs 13%(®t²§30%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组47%~45%//¥§¡46% (2)AD2 clinicaltrials.gov/ct2/show/results/NCT04178967 EASI75 51% vs 18%(®t²§33%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组¥§¡41% IGA0,1 33% vs 10%(®t²§22%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç²Õ 41%~33%//¥§¡37% (3)Lebrikizumab¤QTCS Lebrikizumab ¤QTCS¡Ñ16¶g ¤T´Á¡A¦©°£¹ï·Ó组 @% IGA. 41-22=19 EASI75 70-42=28 3.ASLAN004 2b ´Á±æÈ °ò½u°²³]EASI25.5(¦PLeb. 2b) Àø®ÄPK ¹êÅç组vs ¹ï·Ó²Õ EASI75 73% vs 24%(®t²§49%) IGA0,1 57% vs 15%(®t²§42%) 4.Dupilumab ph3 www.nejm.org/doi/full/10.1 16¶g °ò½uEASI32.5 (1)SOLO1 EASI75 51%vs 15%(®t²§36%) IGA0,1 38%vs 10%(®t²§28%) (2)SOLO2 EASI75 44%vs 12%(®t²§32%) IGA0,1 36%vs 8%(®t²§28%) (3)Dupilumab +TCS 16¶gvs 52¶g clinicaltrials.gov/ct2/show/results/NCT02260986 A.EASI75 QW//Q2W//¹ï·Ó²Õ--% 16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6 B.IGA0,1 QW//Q2W//¹ï·Ó²Õ--% 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------(2017/10 ¤½§G) 5¡BLebrikizumab ¦y®p¾P°â预¦ô¥«³õ¤À§é®v45-150»õ¬ü¤¸¡C §¨Ó¤½¥q»{¬°¥i¬° ¤¤-««×AD²Ä¤@½uÃĪ«¡C (Ó¤H»{¬°Lebrikizumab 45»õ¬ü¤¸¦³¾÷·|//YµLASLSN004¤W¥«) Dupilumab ªºREGN ¤½¥q¦ô¦y®p¾P°â130»õ¼Ú¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/18 ¤U¤È 09:28:11²Ä 5699 ½g¦^À³
|
³¯¤j¡A ¥H¤U¨PÄÝÓ¤H¦ôºâ¡A ASLAN004 2b Á{§É clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3 °²³]65Ó¤¤¤ß¦b2022/08/30¶}¨S¬°³Ì«á ASLAN004 2b Á{§É¡A¹w¦ô¸Ñª¼¤é´Á¡G2023/02/15 ¹w¦ô³Ì«á¤@¦ì§¹¦¨²Ä¤@°wª`®g¤ê´Á¡G2022/1015 ⋯⋯⋯¨Ì¾ÚLebrikizumab 2bÁ{§Éªº®Éµ{¸gÅç¡C ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/7 ¤W¤È 08:44:19²Ä 5683 ½g¦^À³ clinicaltrials.gov/ct2/show/NCT03443024 Lebrikizumab 2b Á{§É°O¿ý 2018/8/23 ³Ì«á©Û¶Ò¤¤¤ß资®Æ§ó·s 2018/10/6¡]±À¦ô³Ì«á¤@¦ì±wªÌ¥´²Ä¤@针¤é´Á¡^ 2018/11/06 °±¤î©Û¶Ò¸ê®Æ§ó·s 2019/02/07 ¸Ñª¼ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/18 ¤U¤È 09:17:07²Ä 5698 ½g¦^À³
|
³¯¤j¡A ¦¬®×§¹¦¨¯ÂÄݨ̾ÚLebrikizumab 2bÁ{§É±À¦ô¡A °²³]8¤ë30¤é65Ó¤¤¤ß¬°³Ì«á¦¬®×¤¤¤ß¶}³]¡A¸g45¤Ñªº¿zÀË©Ò°ï¦ô¡]¦PLebrikizumab) ¤@¤Á¨Ì¤½¥q¤½¥¬¬°·Ç¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/18 ¤U¤È 08:13:18²Ä 5697 ½g¦^À³
|
¤Ñ©R¤j ASLAN004 2b¤w§¹¦¨³Ì«á¤@¦ì¦¬®×¡A¬O§_¦³¦@¦¬®×´X¤Hªº¸ê°T¶Ü |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/18 ¤U¤È 05:48:26²Ä 5696 ½g¦^À³
|
¨Ì¾ÚLebrikizumab 2b ùµ{¸gÅç¡C ¦ô ASLAN004 2b 2023¦~2¤ë15¤é¸Ñª¼¡C ³Ì«á¤@¦ì¤w¦¬®×§¹¦¨²Ä¤@°w¡C¦b2022¦~10¤ë15¤é |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/18 ¤U¤È 05:32:07²Ä 5695 ½g¦^À³
|
www.aad.org/member/meetings-education/am23/faculty/abstracts AAD 2023 ³Ì·s¬ã¨s½×¤å¸`¿ý ³Ì«á¦¬¥ó¤é¡G2023/01/13 |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/10/18 ¤U¤È 03:26:20²Ä 5694 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j: °²Y004©ó112¦~2¤ë¤¤¸Ñª¼¥¿¦V¡A½Ð°Ý¨Ó±o¤Î°Ñ¥[·í¦~«×¬ü°ê¥Ö½§¾Ç·|(¨q¸ê®Æ)¶Ü? (¤µ(111)¦~¬ü°ê¥Ö½§¾Ç·|¬O¦b3¤ë25¤éÁ|¦æ). |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/16 ¤U¤È 03:35:04²Ä 5693 ½g¦^À³
|
§¨Ó¤½¥q¦b9¤ë8¤éµoªí Lebrikizumb ¤T´Á52¶gÁ{§É³ø§i ¤½¥q¬Û«H ¥¼¨ÓLebrikizumab Y³Q®Öã¤W¥«¡A ¥i³Q¥Î©óªvÀø¤¤-««×ADªº²Ä¤@½uÃĪ«¡C °ò©ó§Ú̦b¯SÀ³©Ê¥Öª¢Á{§É¸ÕÅ綵¥Ø¤¤Àò±oªºÃ°·¥B¨ã¦³Á{§É·N¸qªºµ²ªG¡A§Ú̬۫H¡A¦pªGÀò±o§åã¡Alebrikizumab ¥i¯à¦¨¬°¥Ö½§¬ìÂå¥Í¤Î¨ä³\¦h±w¦³¨Ï¤H°I®z¯gª¬ªº¤¤«×¦Ü««×¯e¯f±wªÌªº¤@½uªvÀøÃĪ«¨Ã´M¨D·sªºªvÀø¿ï¾Ü¡A¨Ã§ó³ßÅw¤£¨º»òÀWÁcªºµ¹ÃÄ¡A¡¨Â§¨Ó¤½¥q¥þ²y§K¬Ì¾Ç¶}µo©MÂå¾Ç¨Æ°È°ÆÁ`µô Lotus Mallbris Âå¾Ç³Õ¤h»¡ Based on the robust and clinically meaningful results from our clinical trial program in atopic dermatitis, we believe lebrikizumab, if approved, could become a first-line treatment for dermatologists and many of their patients with moderate-to-severe disease who suffer from debilitating symptoms and seek new treatment options and prefer less frequent dosing, said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly. finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/15 ¤U¤È 02:24:50²Ä 5692 ½g¦^À³
|
¨Ì¾ÚLebrikizumab ADªº«O¦u¾P°â¦ôºâ45»õ¬ü¤¸¡C 004 2b ¸Ñª¼¦p预´Á EASI 75 73% vs Leb. 2b 61% vs ¹ï·Ó组24% IGA0,1 57% vs Leb. 2b 45% vs ¹ï·Ó组15% °²³] °ò½uEASI 26-EASI 28 «h³æ¦bAD ³QASLAN004 ¨ÖÁʪ÷ÃB 约¬°2020¦~Leb.³Q¨Öª÷ÃB 11»õ¬ü¤¸x3¿=33»õ¬ü¤¸°_¸õ¡C(·í®É¦ô15»õ¬ü¤¸ªº¦y®p¾P°â¡K¡K¦©°£欧¬w区) ¨ä¥L¾AÀ³¯g=33/0.55-33=27»õ¬ü¤¸(2´Á§¹¦¨) ¥´Ó¹ï§éÁÙ¦³13.5»õ¬ü¤¸¡C 33+13.5=46.5»õ¬ü¤¸ ¦ôp³Q¨ÖÁÊ»ù¦b45-50»õ¬ü¤¸¤§¶¡¡C °²³]1000,000¤dªÑADR ªÑ¥» ¨CªÑ45-50¬ü¤¸¤§¶¡¡C ¶W¹L¤]¤£·N¥~¡C ¥H¤WÓ¤H¦ôºâ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/13 ¤U¤È 07:24:14²Ä 5691 ½g¦^À³
|
ASLAN004 µ´¹ïÀu©óLebrikizumab ,¦]MOAÃö«Y¡AÀø®ÄµLªkéw¡A®É¦n®ÉÃa¡C Lebrikizumab ¤x¦bý³Ý¡þCOPD ¤T´ÁÁ{§É¥¢±Ñ¡A¤x°±¤îÁ{§É¸ÕÅç¡C Lebrikizumab ¶È¦bAD¥«¾P°â´N³Qµû¦ô45¡X150»õ¬ü¤¸ªº¦y®p¾P°â¡C ¤@¤@¤@¤@¤@ 1¡ALebrikizumab ¤T´ÁÁ{§É vs¹ï·Ó²Õ AD1. IGA. 43% vs 13%¦©°£¹ï·Ó²Õ ®t²§30%¡^ EASI75 59% vs 16%¡]¦©°£¹ï·Ó²Õ®t²§43%¡^ AD2 IGA 33%. Vs 11%(®t²§22%¡^ EASI75 51% vs 18%(®t²§33%¡^ ¤@¤@¤@¤@¤@ 2¡ADupilumab ¤T´Á Solo1 IGA 38% vs 10%¡]®t²§28%¡^ EASI 75 51% vs 15%¡]®t²§36%¡^ Solo2 IGA 36% vs 8%(®t²§28%¡^ EASI75 44% vs 12%(®t²§32%¡^ ¤@¤@¤@¤@ 3¡AASLAN004 2b ¥Ø¼ÐÀø®Ä IGA 53% vs 15%(®t²§38%¡^ EASI75 73% vs 24%(®t²§49%¡^ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/13 ¤U¤È 06:57:57²Ä 5690 ½g¦^À³
|
Lebrikizumab ¦y®p¾P°â45»õ¬ü¤¸¤@¤@¤@¬ü°ê¤ÀªR®vEdmund Ingham¦ô ³Ì°ª¹w´ú½æ150»õ¬ü¤¸¡C 2022/09/28 ¤å³¹¦p¤U I am more optimistic on sales of 2 newcomers however in Lebrikizumab and Mirikizumab. Lebrikizumab has been compared to Sanofi¡¦s Dupixent, itself forecast to achieve peak sales of ~$15bn by some optimistic analysts, and has even outperformed Dupixent in some studies, so perhaps I am being too conservative forecasting peak sales of just $4.5bn. Lebrikizumab ©M Mirikizumab ªº 2 ¦W·sÃĪº¾P°â§ó¬°¼ÖÆ[¡C Lebrikizumab »PÁɿյ᪺ Dupixent ¶i¦æ¤F¤ñ¸û¡A¤@¨Ç¼ÖÆ[ªº¤ÀªR®v¹wp¨ä¾P°âÃB®pȱN¹F¨ì¬ù 150 »õ¬ü¤¸¡A¦b¤@¨Ç¬ã¨s¤¤¬Æ¦Ü¶W¹L¤F Dupixent¡A©Ò¥H¤]³\§Ú¹L©ó«O¦u¦a¹w´ú®pȾP°âÃB¶È¬° 45 »õ¬ü¤¸¡C Eli Lilly: Valuation Feels Impossibly High - Don¡¦t Board This Hype Train Sep. 28, 2022 12:26 PM ETEli Lilly and Company (LLY)9 Comments 1 Like Edmund Ingham seekingalpha.com/article/4543610-eli-lilly-valuation-feels-high-dont-board-the-hype-train |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/13 ¤U¤È 03:19:34²Ä 5689 ½g¦^À³
|
©MDupilumab ¦³¥i¯à±M§Q°ÝÃD¡AÃø¦b2037¦~«e¬ü°ê¤W¥«¡C ¤¤°ê¥Ó½Ð´X¦~«á¤W¥«¦³¥i¯à¡A ¤¤°ê2´Á ¥Dn«ü¼ÐIGA 0,1 ¶È30.3%°¾§C. ¬Q¤ÑCNTBªÑ»ù¤S§C©ó1¬ü¤¸¡A¦¬0.95¬ü¤¸¡AÃø¦b¨Ìp¹º¦b¬ü°ê¥«³õ¶Ò¶°3»õ¬ü¤¸°µ¤T´ÁADÁ{§É¡C CNTB 2023/10/04 ¤½§G CBP201 ¤¤°ê2 ´Á¤¤¤@««×ADÁ{§É¸Ñª¼³ø§i October 4, 2022 ¤@¤@¤@ CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China finance.yahoo.com/news/correcting-replacing-connect-biopharma-reports-125600879.html All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the IL-4R£\ pathway Data support advancing the regulatory discussions with the CDE for submitting an NDA in China ¹êÅç²Õ vs. ¹ï·Ó²Õ ¥Dn«ü¼ÐIGA0¡A1 30.3% vs 7.5%(¦©°£¹ï·Ó²Õ«á22.8%//Dupilumab¤T´Á¬°28%¡]38%vs 10%¡^¡^ ¦¸n«ü¼Ð EASI75 62.9% vs 23.4%¡]¦©°£¹ï·Ó²Õ«á 39.5%//dupilumab ¤T´Á¬°36%¡]51%-15%) ) EASI50 83.1%vs 43.1% EASI90 35.8% vs 6.3% The primary endpoint of IGA of 0 or 1 (¡§clear¡¨ or ¡§almost clear¡¨) with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p < 0.001). CBP-201 also met key secondary endpoints, including 83.1%, 62.9% and 35.8% of patients achieving a 50%, 75%, 90% reduction in the Eczema Area and Severity Index score (EASI-50, EASI-75, EASI-90) from baseline compared to 41.1%, 23.4% and 6.3% for the placebo group (p < 0.001), respectively. Significant improvement in pruritus with 35.0% of patients experiencing a reduction of 4 or greater on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% for placebo (p < 0.001). A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China clinicaltrials.gov/ct2/show/NCT05017480?term=Cbp201&draw=2&rank=2 |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/13 ¤W¤È 08:51:20²Ä 5688 ½g¦^À³
|
Tang Capital Management LLC ³Ìªñ«Å¥¬¦¬ÁÊ ASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^ªº·sªÑ¥÷¡C¾÷ºc§ë¸êªÌ³q¹LÁʶR227¸UªÑ¡A±N¨ä¦bÂåÀø«O°·¤½¥qªºªÑÅv¼W¥[69.04%¦Ü555¸UªÑ¡C³o¶µ·s§ë¸ê²{¦b¨Ï¨ä«ùªÑ¤ñ¨Ò¹F¨ì 7.97%¡A¥Ø«e¦ôȬ° 344 ¸U¬ü¤¸¡C¦¹¥~¡AMillennium Management LLC ¼W«ù 43949.0 ªÑ¦Ü 161 ¸UªÑ¡CRenaissance Technologies LLC ¤w±N¨äÀY¤o¼W¥[ 574.07% ©Î 41 ¸UªÑ¡A¦Ü 48 ¸UªÑ¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/10/12 ¤W¤È 10:43:02²Ä 5687 ½g¦^À³
|
§Æ±æÁÙ¬O·|¦³¥¿¦V´Á¤¤¼Æ¾Ú¡A³o¼Ë¹ï¦Ñ·à¤Í¤ñ¸û¦n~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/11 ¤W¤È 10:33:26²Ä 5686 ½g¦^À³
|
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 10¤ë7¤é³Ì·sªº¤½¥q²³ø |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/11 ¤W¤È 10:28:02²Ä 5685 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3 ASLAN004 2b Á{§É¡A¹w¦ô¸Ñª¼¤é´Á¡G2023/02/15 ⋯⋯⋯¨Ì¾ÚLebrikizumab 2bÁ{§Éªº®Éµ{¸gÅç¡C ¦A¨Ó11¤ë¤¤¦¯·|«Å¥¬¡A¤w§¹¦¨³Ì«á¤@¦ì©Û¶Ò¡A¦Ó°±¤î©Û¶Ò¡C ¦p¦¹ªº³W¹º¡AÀ³¸Ó¤£·|¦³´Á¤¤³ø§i¡C ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/7 ¤W¤È 08:44:19²Ä 5683 ½g¦^À³ clinicaltrials.gov/ct2/show/NCT03443024 Lebrikizumab 2b Á{§É°O¿ý 2018/8/23 ³Ì«á©Û¶Ò¤¤¤ß资®Æ§ó·s 2018/11/06 °±¤î©Û¶Ò 2019/02/07 ¸Ñª¼ |
|
|
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 µoªí®É¶¡:2022/10/10 ¤W¤È 12:02:33²Ä 5684 ½g¦^À³
|
www.nature.com/articles/s41573-021-00266-6.pdf ¤µ¦~ªì¦³¤H¾ã²zªº¤å³¹ ¸Ì±¦³´£¨ìASLN004ªº³¡¤À ASLAN004 is a fully humanized antibody directed against IL-13R£\1, thereby blocking the binding of IL-4 and IL-13 on the type II receptor (IL-4R£\/IL-13R£\1). Owing to the more selective binding compared with dupilumab, ASLAN004 may provide the option of a low-dose regimen and a better safety profile. An interim data analysis from a phase Ib study showed that the com- pound is well tolerated and provided promising efficacy data, with 67% of the patients achieving EASI75 versus 0% in the placebo group |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/7 ¤W¤È 08:44:19²Ä 5683 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT03443024 Lebrikizumab 2b Á{§É°O¿ý 2018/8/23 ³Ì«á©Û¶Ò¤¤¤ß资®Æ§ó·s 2018/11/06 °±¤î©Û¶Ò 2019/02/07 ¸Ñª¼ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/6 ¤W¤È 07:22:54²Ä 5682 ½g¦^À³
|
600mg组16¤H¡K¡KmITT,¤¤Â_3¤H (65%¡Ñ16-27%¡Ñ2)/14=70%¡P¡P¡P¡P¤¤断²v½Õ¾ã¬°1¤H¡A1/14=7.1%¡K ¡K¡K¡K²Ä8¶g¤§¥§¡Àø®Ä¡C Pk Dupilumab ¥§¡8¶gêq®Ä ¬°65% 70%/65%=108%¡K¡K¡K¡KASLAN004¦b²Ä8¶g¥§¡Àø®Ä¦³8%Àu©ódupikumabªºÁͶաC |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/6 ¤W¤È 05:41:06²Ä 5681 ½g¦^À³
|
1¡B www.nejm.org/doi/full/10.1056/nejmoa1610020 ¹Ï¤G¡C Dupilumab 2Ó¤T´ÁÁ{§É EASI ¤U°¦U¶gÁͶժí¡C ...16¶g 2.ASLAN004 1b mITT ¦U¶gEASI¤U°ÁͶժí¡C ¡K¡K8¶g¡A ¦p¹Ï¤@¡C ASLN ´Á¥Zºô¯¸ aslanpharma.com/news/?cat=publications EADV(2022) ²Ä¤GÓ´Á¥Z Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study 3.PK ASLAN004 EASI ¤U°´T«×/³t«×¤ñDupilumab ¤T´ÁÀu¡C ¤U°EASI50 ASLAN004 ¦b²Ä¤T¶g¹F¨ì¡ADupilumab ¦b²Ä¥|¶g¤~¨ì¹F¡C ¤U°¦ÜEASI60 :ASLAN004¦b²Ä¥|¶g¡ADupilumab ¦b²Ä5¶g ¡K¡KDupilumab ¤T´Á¤¤断²v7¡P5%¡C(°ò½uEASI32.5) A.°ò½uEASI25.5/§CTRAC ¡A¥§¡°´TEASI 77% B.°ò½uEASI31/¤¤TRAC ¡A¥§¡°´TEASI 67% C.°ò½uEASI42/°ªTRAC,¥§¡°´TEASI66% Á`¥§¡°ò½u32.5¡A¥§¡°´TEASI 70% ....¥H¤W¦U组¤H¼Æ¬Ûªñ¡C ¡K¡KASLAN004 1b mITT (°ò½uEASI 31.2) ¤¤断²v3/16=18.8%¡K¡K600mg |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/10/5 ¤U¤È 10:55:51²Ä 5680 ½g¦^À³
|
¤ô©¤°]´I¤½¥q¦b´£¥æµ¹¬ü°êÃÒ¨é¥æ©ö©eû·|ªº³Ì·sForm 13F¤å¥ó¤¤ºÙ¡A¸Ó¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĦ³¤½¥q(¯Ç´µ¹F§J¥N½X¡GASLN-GETµû¯Å)ªº«ùܤW½Õ¤F7.3%¡C¸Ó¾÷ºc§ë¸êªÌ¦b¥»©u«×ÃB¥~ÁʶR¤F2.4¸UªÑ«á¡A«ù¦³35.3¸UªÑ¸Ó¤½¥qªÑ²¼¡CºI¦Ü³Ìªñ¤@Ó©u«×¥½¡A¤ô©¤°]´I¤½¥q¾Ö¦³ªü´µÄõ»sÃĤ½¥q¬ù0.51%ªºªÑ¥÷¡A»ùÈ17.5¸U¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/5 ¤W¤È 06:52:09²Ä 5679 ½g¦^À³
|
004 1b mITT TRAC/IgE ªº20¶g¤¤¦ì¼Æ¦U¶gÁͶչϡC ¦b¤½¥qEADV2022 ´Á¥Z¡C TRAC«ü¼Ð¦b²Ä3¶g´N´X¥G°¨ì³Ì§C¡C IgE ¦b²Ä12¶g~14¶g°¨ì³Ì§C¡C (²Ä7¶g³Ì«á¤@°w) 600mg 16¦ì¡AmITT¤¤¦³3¦ì¤¤断±wªÌ¡C Y¦©°£¤ÏÀ³¤ñ²v·|³Ì°ª¡C ¥Íª««ü¼Ð¦b²Ä8-11¶g¬Ò维«ù¦b§CÀÉ¡C ¤½¥qªº2bÁ{§Éªº¥´°w³]p«Ü¤j³¡¥÷¨Ó¦Û¥»³ø§i¡C ÁٰѦҡAPK¡A¦¨¥»¡A¥«Ô·Ävª§¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/4 ¤U¤È 11:16:51²Ä 5678 ½g¦^À³
|
¹ï¤â´N¬ODupilumab ASLN ¥u´±°²³]赢8%¡C ¦n¦n¬ã¨sDupilumab¤ñ¹ïASLAN004 1b mITT. µ´¹ï§Uº¦«H¤ß¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Dupilumab ¦U´ÁÁ{§É¼Æ¾Ú¡C 1. Dupilumab ¦´Á¥|Ó AD Á{§É 4¶g/12¶g , 2014/07/10 Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis www.nejm.org/doi/10.1056/NEJMoa1314768 2. Dupilumab 2a/2b Á{§É ,2018/SEP journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx 3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15 Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/4 ¤U¤È 08:47:15²Ä 5677 ½g¦^À³
|
ASLAN004 2bªº¥´°wÁ{§É³]p 0,1,2 ¦U¤@°w¡A²Ä21¤Ñ®É¶¡¡A 200mg/400mg/600mg(¨Ìlb mITT),¥§¡Àø®Ä¥i°EASI50, °²³]³Ì«á¤ÏÀ³¥§¡¹FEASI75 , 3°w´N¥i¹F66%ªº³Ì终µ²ªG¡C(50%/75%) ¨ä¥Lªº¥|¶g¤@°w¬Ý³y¤Æ¤F¡A¦pªG¹F¼Ð´N¦hÁȽu40%ªº°¾¦n«×¡C(¬Û¹ï©ódupilumab ,¥i¹F54%.) 2¶g¤@°w4/6/8/12/14¶g¦U¥´¤@针300mg/400mg, ¥Ø¼Ð±NEASI75¤ÎIGA0,1 ©Ô¨ì73% / 57%,¦¨¥\²v¥²¶·°ª¡C ¤è¯à®ü©ñdupilumab,赢8%§_«h¥u¯à¥¤À¥«³õ¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Lebrikizumab 2b 4¶g¤@针¦bIGA,0,1¥¼¹FÅãµÛ®t²§¡A©Ò¥H¤T´ÁÁ{§É©ñ¦b18-52¶gªººû«ù©ÊÁ{§É¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/4 ¤U¤È 08:27:19²Ä 5676 ½g¦^À³
|
Time is our best friend ! ®É¶¡¬O§Ú̳̦nªºªB¤Í¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/4 ¤U¤È 04:55:38²Ä 5675 ½g¦^À³
|
³¯¤j¡A Ó¤H§PÂ_¡C ¥Ø«eDupilumab ¼Ú¬w¾P°â¦û¤ñ12%¡A lebrikizumab 2b 58¤¤¤ß¥þ¦b¬ü°ê¡A¼Ú¬w¬°¹s¡C Yn¶}¼Ú¬w¤¤¤ßÀ³¸Ó9¤ë´Nn¤½§i¡C ¥H¤WÓ¤H²q´úªºì¦]¡C ½Ð¨Ì¤½¥q¤½§i¬°¥D¡C Y¯uªº¥u¶}65Ó¡A¦A¨Ó11¤ë¤¤¡þ¤U¦¯À³¸Ó¤½§i¦¬§¹³Ì«á¤@Ó¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/10/4 ¤U¤È 03:54:54²Ä 5674 ½g¦^À³
|
¤Ñ©R¤j ¦¬®×¤¤¤ß¬O§_¶È°±¯d¦b65³B ¤£¦A·s¼W¡AÀ³¥Ñ¤½¥q»¡©ú¨ä¥¼¨Ó¾Þ§@¤º®e¡A ©ÎªÌ¬O§A¦³¸ß°Ý¹L¤½¥q ·PÁ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/4 ¤W¤È 10:37:04²Ä 5673 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023 004 2b clients. ²§°Ê¤é´Á: ÁÙ¬O°±¦b8¤ë30 ¤é. Ó¤H²q65 Ó¤¤¤ß¬°³Ì«áªº©Û¶Ò¤¤¤ß¼Æ. ¼Ú¬w±wªÌ¤T´Á¦A¨Ó°µ´N¦æ¤F. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤U¤È 08:42:29²Ä 5672 ½g¦^À³
|
©t¤j¡A ¬Oªº¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/30 ¤U¤È 08:01:42²Ä 5671 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¥H¤U¨â¤p®É¤º¨â«h±z©Ò´£±o¬O¦P¤@¥ó¨Æ¶Ü ? Y¬O¡A´N¬O±z¤]»{¦P¦~©³¦³´Á¤¤¼Æ¾Ú¡A¥u¬O¥¿¦V»P§_¶Ü? ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 09:52:19²Ä 5668 ½g¦^À³ ¦pªG65Ó¤¤¤ß¬°³Ì终¼Æ¶q¡C ¤£·|¦³´Á¤¤³ø§i¡C ©ú¦~3¤ëªì¸Ñª¼295¤Hªº¾÷²v°ª¡C Y须100Ó¤¤¤ß©Û¶Ò¡A´Á¤¤¤ÀªR´N¥i¯à¬°¥²n¡C ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 11:22:32²Ä 5670 ½g¦^À³ ¸Ø±i¤j¡A ¥u¶}65Ó¤¤¤ß¡A12¤ëªì´Á¤¤¸Ñª¼+¨p¶Ò¡A¬O¬Û¹ï¦X²z¡B¦w¥þªº¤è®×¡C ¤]¬O2023¦~3¤ëªì¡C ¥H¤WÓ¤H²q´ú¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 11:22:32²Ä 5670 ½g¦^À³
|
¸Ø±i¤j¡A ¥u¶}65Ó¤¤¤ß¡A12¤ëªì´Á¤¤¸Ñª¼+¨p¶Ò¡A¬O¬Û¹ï¦X²z¡B¦w¥þªº¤è®×¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/9/30 ¤W¤È 11:05:20²Ä 5669 ½g¦^À³
|
ªÑ»ù¤w¸g¤£¬OÅý¨È·à±d¤U¥«ªº°ÝÃD¤F¡A´Nºâ112¦~3¤ë27¤éªÑ»ùÁÙ§C©ó1¬ü¤¸¡A ¤½¥qÁÙ¬O¯à§Q¥Î´î¸êµ¥¨ä¥L¤è¦¡(¤½¥q¦b¤½§i¤¤¦³´£¨ì)Åý¨È·à±d¤@ª½¯d¦b¨º´µ¹F§J¸ê¥»¥«³õ¡C ¦¬®×¤¤¤ß¥Ø«e¦³65³B¡A¬O§_¦A¼W¥[? «O¦u¤@ÂI¡A§ÚÌÆ[¹î¨ì10¤ë©³¡A©¡®ÉYµL¦¬®×¤¤¤ß¼W¥[(Y10¤ë©³«e¦A§ó·s¡A©ú¦~ªÖ©w¨Ó¤£¤Î¸Ñª¼)¡A ´N½T©w¬O65³B¦¬®×¤¤¤ßµL»~¤F¡C °²³]65³B¦¬®×¤¤¤ß¬O³Ì²×µ²ªG ¦b111¦~5¤ë6¤é®É¡A¤½¥q·í®É´N¤w¤½§i¦¨¥ß36Ó¦¬®×¤¤¤ß(¦¬ªv¶W¹L¤@¥b¸ÕÅç¤Hû)¡A ¹F¤½§i´Á¤¤³ø§i¦¬ªv¤Hû³Ì§CªùÂe 5¤ë6¤é+2Ó¤ë©Û¶Ò+4Ó¤ëªvÀø+1Ó¤ë¸ê®Æ¾ã²z=111¦~12¤ë6¤é«á¥i¥H¤½§i´Á¤¤³ø§i(¥H«K¶i¦æ¨p¶Ò)¡C 111¦~11¤ë6¤é«á¤½¥q¤â¤W¤w¸g¦³¤@¥b¦¬ªv¤Hû¥¼¸Ñª¼¼Æ¾Ú¡A¨p¶Ò»ù¬O§_¶}©l³s°Ê¡K¡K ¤½¥q¤â¤W½Í§PÄw½X(¥¼¸Ñª¼¼Æ¾Ú)¡A¤w¸g°÷¹F¨ì112¦~4¤ë¸Ñª¼«áñ¸p¼Ú¬w°Ï¦X¬ù±ÂÅvª÷¦aªO»ù¡C 112¦~4¤ë¸Ñª¼«á¡A±ÂÅvª÷¦aªO»ùª½±µ©¹¤W¸õ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 09:52:19²Ä 5668 ½g¦^À³
|
¦pªG65Ó¤¤¤ß¬°³Ì终¼Æ¶q¡C ¤£·|¦³´Á¤¤³ø§i¡C ©ú¦~3¤ëªì¸Ñª¼295¤Hªº¾÷²v°ª¡C Y须100Ó¤¤¤ß©Û¶Ò¡A´Á¤¤¤ÀªR´N¥i¯à¬°¥²n¡C ¤]¬O2023¦~3¤ëªì¡C ¥H¤WÓ¤H²q´ú¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/30 ¤W¤È 09:00:40²Ä 5667 ½g¦^À³
|
65*5=325 «D±`¨¬°÷ªº©Û¶Ò¹w´Á¤H¼Æ¡A»°§Ö»{¯u¥J²Ó¦¬®×¡A¤½¥¬´Á¤¤¥¿¦V¼Æ¾Ú¡AÅý¥«³õ»{¦P¦Ñ·àªº¸gÀç¤è¦V¡C¥[ªo!¦Ñ·à |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 07:03:36²Ä 5666 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT03443024 Lebrikizumab 2b AD Á{§É 4组/280¤H¡C¶}58Ó¦¬®×¤¤¤ß¡A¥þ¦b¬ü°ê¡C 2019¦~2¤ëªì¸Ñª¼¡A7¤Ñ«áñ¸p欧区±ÂÅv¦X约¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 06:54:06²Ä 5665 ½g¦^À³
|
¬ü¡B¥[¶}36Ó(30+6) ¿D¬w6/¦L«×8/纽¦èÄõ1/·s¥[©Y4,¤pp19Ó¤¤¤ß ¦Xp65Ó004 2b©Û¶Ò¤¤¤ß¡C 欧¬w¥»¦¸¤£©Û¶Ò¾÷²v«D±`¤j¡C 65Ó¤¤¤ß¨¬°÷¤w¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/30 ¤W¤È 06:37:05²Ä 5664 ½g¦^À³
|
www.clinicaltrials.gov/ct2/show/NCT05158023 004 ªº2b Á{§É¡A¤w¶}¥ß65Ó¦¬®×¤¤¤ß¡C 8¤ë30¤é¦Ü¤µ¥¼¨£²§°Ê¡C 欧·ù©M¬ü°êFDA¥»¦³Ã±¸pÁ{§É¹êÅç资®Æ¤¬¬Û©Ó»{¤§¦X约¡C ©Ò¥H¦b¬ü°ê¨ú±oÃĵý¤§Á{§É资¥iª½±µ®³¥h¥Ó½ÐÃĵý¡A¦p¤¤¸Îªº·R´þ¯fÃĵý¡C ¦b欧·ù¨ú±oÃĵý¤§Á{§É资®Æ¥ç¦P¥iª½±µ®³¥h¥Ó½Ð¬ü°êÃįg¡A¦pÃĵØÃĪºPVÃĵý¡C 8¤ë30¤é¶}¥ß¤§¤¤¤ß +2Ó¤ë©Û¶Ò+4Ó¤ëªvÀø¡C 预p2023¦~2¤ë©³~3¤ëªì¥i¸Ñª¼¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤U¤È 02:33:08²Ä 5663 ½g¦^À³
|
ASLAN004 2b´Á±æÈ¡G 004/2b ¤¤断²v ¦Plb¦b3/16=18% EASI75:(11+5)/22=73%¡K¡K¨ÌlbmITT+»´¯g½Õ¾ã预¦ô5/6 IGA0,1=EASI75 73%-16% =57% (¨ÌLebrikizumab 2b 2¬Û«ü¼Ð®t²§©Ò¦ô) ¬G2b ´Á±æȦô ¹êÅç组¤@¹ï·Ó组(¦PLeb. 2b¹ï·Ó组) EASI75 73% - 24%=49% IGA0,1 57% -15% =42% ¥H¤W¥i预´Á¥¼¨Ó3´Á¤Î³Q¨ÖÁÊ»ùȪº°Ñ¦Ò¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤U¤È 02:09:37²Ä 5662 ½g¦^À³
|
Ph3 ªº°ò½uEASI·|©Ô¤É¦Ü32-33. ¹ï·Ó组Àø®Ä¦ÛµM°§C¡C Ph3.ªº¤¤Â_²v¦b¹êÅç²Õ³q±`¶È7%-8% ¦ý¦b2b®É¡A³q±`±µªñ20%. ¦]¦¹2b©Mph3(¤T´Á)¡A¦©°£¹ï·Ó组ªº¥Dn«ü¼ÐÀø®Ä IGA0,1¤ÎEASI75 ·|¬Ûªñ¡C Lebrikizumab ¦]M0AÃö©ó¡A¤GÓ¤T´ÁÁ{§É®t²§30%Àø®Ä¡C Dupilumab 2Ó¤T´Á¡AIGA0,1¦©°£¹ï·Ó组«á¦P¬°28% ASLAN004 ¥¼¨Ó·|¦PDupilumab ,3´Á2ÓÁ{§ÉÀø®Ä¸û¤@P©Ê¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 11:58:19²Ä 5661 ½g¦^À³
|
Lebrikizumab 2b vs ph3 1.EASI75 ¹êÅç组-¹ï·Ó组 2b: 61% -24%=37% Ph3: Ad1 ,59%-16%=43% Ad2,51%-18%=33% 2.IGA0,1 2b : 45%-15%=30% Ph3: Ad1 ,43%-13%=30% Ad2 ,33%-11%=22% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 11:43:48²Ä 5660 ½g¦^À³
|
Immu ¤½¥q´¿±NImmu132 ADC¡A mTNBC ¤T½u¡A¤Î¨ä¥L¾AÀ³¯g¡C ¥þ²y¾P°âÅv¦b¨ú±oBTD¡A ¤Î¥H1/2´ÁÁ{§É资®Æ¥Ó½ÐÃĵý¡C ¥H20»õ¬ü¤¸±ÂÅv给¬ü°ê¦è©¤ªº¥t¤@®a¤½¥q¡C ªÑ»ù±q3-4¬ü¤¸(2015¦~ÀòBTD) 2016¦~±ÂÅv¡A¡K¡K16¬ü¤¸¡C «á¨Ó¤jªÑªF¤£¦P·N¡A¶}°£CEO¡A ¦Û¦æ¼W资¡A°µ§¹¤T´Á¡A2020¦~ªì¨ú±oÃÄ证¡C 2020¦~©³200»õ¬ü¤¸³Q¨ÖÁÊ¡AªÑ»ù90¬ü¤¸¥ª¥k¡C Tang 资¥»ºÞ²z¤w¨ú±o5555¤dªÑ¡Aªñ8%¡A µ´¹ï¦³¯à¤O¼vÅT¤½¥q¨Mµ¦¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 11:21:43²Ä 5659 ½g¦^À³
|
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/#!po=33.4821 Lebrikizumab 2b Á{§É资®Æ¦p¤W¡C ¹ï·Ó组 °ò½uEASI28.7 ¹êÅç组 °ò½uEASI25.5 EASI75 24% IGA 0,1 15% ÁÙ¬O¥i¤Þ¥Î¡C ¦]¦¹004/2b ªº¥Ø¼ÐÀø®Ä¡A维«ù¤§«e EASI 75 =73% vs 24%,¦©°£¹ï·Ó组¬°49% IGA0,1 =57% vs 15%,¦©°£¹ï·Ó组¬°42% ¡K¡K¡K¡K Dupilumab 3´ÁSOLO1/SOLO2¡A¦©°£¹ï·Ó组 EASI75 36%(51%-15%=36%)/32%(44%-12%=32%) IGA0,1=28%(38%-10%=28%)/28%(36%-8%=28%) Pk(¦©°£¹ï·Ó组) ASLAN004 2b ´Á±æÈvs Dupilumab 3´Á¥§¡ EASI75 49%/34%=144% IGA0,1 42%/28%=150% ASLAN004 Àu©óDupilumab 3´ÁSOLO1/SOLO2 ¤§ÁͶաC «H¬°ºÖ¼w¤§¤ð¡C °ß¬ì¾Ç¼Æ¾Ú¯à«H¤§¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 10:06:59²Ä 5658 ½g¦^À³
|
CAPITAL MANAGEMENT ¡A«ùÄò¶R¶i¤J¥DASLN¡A ¬O¥i¯àªº¡C ªÑ»ù©Ô20¬ü¤¸¡A´Nµu½u¤jÁȤ@ªi¡C ............¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 2b¥Ø¼ÐÀø®Ä×¥¿¡C(¹ï·Ó组) °ò½u EASI (31.2¡Ñ16+19¡Ñ6)/22=27.9.¡K¡K1b/aslan004 ¥§¡ ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Leb. 2b, EASI75= 24%....¹ï·Ó组,°ò½u EASI25.5 Leb. P3 EASI75=16%......¹ï·Ó组¡A°ò½u¦ôEASI31 (24%-16%)/(31-25.5)=1.46 内´¡ªk ASLAN004 2b EASI 27.9 ¹ï·Ó组EASI75¦ô20% EASI27.9=24%-2.4%¡Ñ1.6=20% ASLAN004(°ò½uEASI28) ¥Ø¼Ð EASI 75 =73% vs 20%//®t²§ 53% IGA0,1=57% vs 12%//®t²§ 45% |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/29 ¤W¤È 09:22:22²Ä 5657 ½g¦^À³
|
¦Ñ·àn¾Ç¥xÆW¯«ÃÄ°êXªº¸gÀç¯à¤O¡A¸Ñª¼¥¢±ÑÁÙ¯à±NªÑ»ù¼µ¦b60¶ô¥H¤W¡A¥Nªí»â¾É¶¥¼h¦³¤ßºû«ù¥«È; ¬Ý¨ÓTANG CAPITAL MANAGEMENT«Ü¦³³¥¤ß,«ùªÑ¤]°ª,µo°Ê©_ŧ¨Ó·í»â¾É¶¥¼h¤]¬O¤£¿ù~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 08:41:37²Ä 5656 ½g¦^À³
|
¥Ñ©óDupilumab +TCS ¤ñ¥¼¥[TCSªºDupilumab, ¦bEASI75¼W¥[45%ªºÀø®Ä¡C ¬G须¥ÎSOLO1/SOL2 q2w ¡A 16¶g¥§¡ ESSI75 47.5%¬°°ò¦¡C¡K¡K¡K¡K¡K¡KA IGA0,1 ¥§¡37%¡K¡K16¶g IGA0,1 ¥§¡35%¡K¡K52¶g(¨ÌDupilumab+TCS 52/16¶g´î2.5%)¡K¡K¡K¡KB B/A=74%. ¬G60¶g¤jpK¼Ò¦¡¤G¡A¦p¤U¡C Dupilumab 74% vs Leb. 75% vs Tra. 50% ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K 60¶g维«ù²v¡C(¤T´ÁADÁ{§ÉÀø®Ä)¤jPK 1.IGA0,1 Dupilumab+TCS 52% vs Leb. 75% vs Tra. 50% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 08:15:56²Ä 5655 ½g¦^À³
|
60¶g维«ù²v¡C(¤T´ÁADÁ{§ÉÀø®Ä)¤jPK 1.IGA0,1 Dupilumab+TCS 52% vs Leb. 75% vs Tra. 50% 2.EASI 75 60¶g维«ù²v Dupilumab+TCS 95% vs Leb. 80% vs Tra. 55% µù¡G IGA0,1 -52¶g/EASI75-16¶g=60¶gºû«ù²v¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¤@¡BDupilumab+TCS 52¶g维«ù²v 1.IGA0,1 QW//Q2W//¹ï·Ó²Õ--% 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5---A 2.EASI75(%) QW//Q2W//¹ï·Ó²Õ--% 16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6 ¡K¡KB 52¶g/16¶g=95%, ¥§¡°h5%¡A维«ù²v95%. 3.IGA0,1 ºû«ù²v ,Q2W, A/B=36/68.9=52% ¤G¡BLebrikizumab 52 ¶g维«ù²v¡C ¨Ì16¶g,¹FEASI75 OR IGA0,1¬°¤ÏÀ³ªÌ¬°°ò¦¡A¥t¦æ18-52¶gªvÀø¡C 1¡PADvocate 1(¦b²Ä16¶g¦³59%¹FEASI75¡^ Lebrikizumab 250 mg Q4W//Q2W IGA (0,1) 74 %//76 % EASI¤@75 79%//79% 2¡PADvocate2¡]¦b²Ä16¶g51%¹FEASI75¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 % ¤T¡BTralokinumab 52¶gºû«ù²v ¨Ì16¶g,¹FEASI75 OR IGA0,1¬°¤ÏÀ³ªÌ,¥t¶i¦æ18~52¶g Q2W/Q4W/Q2W¦w¼¢¾¯ (1)ECZTRA 1 Q2W//Q4W/Q2W¦w¼¢¾¯ A.IGA0,1 51%//39%//47% B.EASI-75 60%//49%//33% (2)ECZTRA 2 Q2W//Q4W/Q2W¦w¼¢¾¯ A.IGA0,1 59%//45%//25% B.EASI-75 56%//51%//21% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/28 ¤U¤È 09:16:21²Ä 5654 ½g¦^À³
|
ir.aslanpharma.com/static-files/712eae9b-859b-45f2-81d2-08a2de03bc86 Ãö©óÂà¦Ü¯Ç´µ¹F§J¸ê¥»¥«³õ¤W¥«ªº³qª¾ 2022 ¦~ 9 ¤ë 14 ¤é¡AASLAN Pharmaceuticals Limited¡]¡§¤½¥q¡¨¡^¦V¯Ç´µ¹F§JªÑ²¼¥«³õ¡]¡§¯Ç´µ¹F§J¡¨¡^¤W¥«¸ê®æ³¡´£¥æ¤F±N¨ä¥Nªí´¶³qªÑªº¬ü°ê¦s°UªÑ²¼¡]¡§ADS¡¨¡^ÂàÅý¤W¥«ªº¥Ó½Ð¤½¥q±q¯Ç´µ¹F§J¥þ²y¥«³õ¨ì¯Ç´µ¹F§J¸ê¥»¥«³õ¡C 2022 ¦~ 9 ¤ë 27 ¤é¡A¤½¥q¦¬¨ì¯Ç´µ¹F§J³qª¾¡A¨ä ADS ÂàÅý¤W¥«¥Ó½Ð¤wÀò§åã¡CÂàÅý±N©ó 2022 ¦~ 9 ¤ë 29 ¤é¶}·~®É¥Í®Ä¡C¤½¥q±NÄ~Äò¥H¡§ASLN¡¨ªº¥N½X¶i¦æ¥æ©ö¡C ¯Ç´µ¹F§J¸ê¥»¥«³õ¬O¤@Ó³sÄò¥æ©ö¥«³õ¡A¨ä¹B§@¤è¦¡»P¯Ç´µ¹F§J¥þ²y¥«³õ¬Û¦P¡C©Ò¦³¦b¯Ç´µ¹F§J¸ê¥»¥«³õ¤W¥«ªº¤½¥q³£¥²¶·º¡¨¬¬Y¨Ç°]°Èn¨D¨Ã¿í¦u¯Ç´µ¹F§Jªº¤½¥qªv²z¼Ð·Ç¡C¤½¥q»{¬°¡A¥¦²Å¦X¦b¯Ç´µ¹F§J¸ê¥»¥«³õÄ~Äò¤W¥«ªº©Ò¦³¾A¥Î¼Ð·Ç¡A¦ý²Å¦X 1.00 ¬ü¤¸ªº§ë¼Ð»ù®æn¨D¡A¥¿¦p¤½¥q¥ý«e¦b 2022 ¦~ 4 ¤ë 1 ¤é´£¥æªºªí®æ 6-K ¤¤«Å¥¬ªº¨º¼Ë¡C¤½¥q²Å¦X±ø¥óÃB¥~ªº 180 ¤Ñ¡]©Îª½¨ì 2023 ¦~ 3 ¤ë 27 ¤é¡^¥H«·s¿í¦u³Ì§C§ë¼Ð»ù®æ¡A³on¨D¤½¥q ADS ªº¦¬½L§ë¼Ð»ù®æ¥²¶·¦b¦Ü¤Ö³sÄò¤QÓ¤u§@¤é¤º¦Ü¤Ö¬°¨CªÑ 1.00 ¬ü¤¸.¦pªG¤½¥qµLªk¦bÃB¥~ªº 180 ¤Ñ¦X³W´Á¤º«ì´_¦X³W¡A¤½¥q¥´ºâ¦b¥²n®É¶i¦æ¤Ï¦VªÑ²¼©î¤À©Î ADS ¤ñ²vÅܧó¡C ¥»ªí®æ 6-K ¤¤¥]§tªº«H®§¯S¦¹³q¹L¤Þ¥Î¨Ö¤J¤½¥qÃö©óªí®æ F-3 ªºµù¥UÁn©ú¡]¤å¥ó¸¹ 333-234405¡^¡Bªí®æ F-3 ªºµù¥UÁn©ú¡]¤å¥ó¸¹ 333-252575¡^¡Bµù¥UF-3 ªí®æÁn©ú¡]¤å¥ó½s¸¹ 333-254768¡^¡BS-8 ªí®æµn°OÁn©ú¡]¤å¥ó½s¸¹ 333-252118¡^©M S-8 ªí®æµn°OÁn©ú¡]¤å¥ó½s¸¹ 333-263843¡^ Notice of Transfer of Listing to The Nasdaq Capital Market On September 14, 2022, ASLAN Pharmaceuticals Limited (the ¡§Company¡¨) submitted to the Listing Qualifications Department of the Nasdaq Stock Market (¡§Nasdaq¡¨) an application to transfer the listing of its American Depositary Shares (¡§ADSs¡¨) representing ordinary shares of the Company from The Nasdaq Global Market to The Nasdaq Capital Market. On September 27, 2022, the Company received notice from Nasdaq that its application to transfer listing of its ADSs had been approved. The transfer will be effective at the opening of business on September 29, 2022. The Company will continue to trade under the symbol ¡§ASLN.¡¨ The Nasdaq Capital Market is a continuous trading market that operates in the same manner as The Nasdaq Global Market. All companies listed on The Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq¡¦s corporate governance standards. The Company believes it is in compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, but for the $1.00 bid price requirement, as previously announced on Form 6-K filed by the Company on April 1, 2022. The Company is eligible for an additional 180-day period (or until March 27, 2023) to regain compliance with the minimum bid price, which requires that the closing bid price of the Company¡¦s ADSs must be at least $1.00 per share for a minimum of ten consecutive business days. In the event that the Company is not able to regain compliance during the additional 180-day compliance period, the Company intends to effect a reverse stock split or ADS ratio change, if necessary. The information contained in this Form 6-K is hereby incorporated by reference into the Company¡¦s Registration Statement on Form F-3 (File No. 333- 234405), Registration Statement on Form F-3 (File No. 333-252575), Registration Statement on Form F-3 (File No. 333-254768), Registration Statement on Form S-8 (File No. 333-252118) and Registration Statement on Form S-8 (File No. 333-263843). |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/28 ¤U¤È 07:24:56²Ä 5653 ½g¦^À³
|
ASLAN Pharmaceuticals ¦b²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¬ã¨s¾Ç·|¦~·|¤W¥H¨â±i³Ì·sªº¹q¤l®ü³ø®i¥Ü Eblasakimab ªº·s¼Æ¾Ú ¨È´µÄõÃÄ·~¦³¤½¥q 2022 ¦~ 9 ¤ë 28 ¤é¡A¬P´Á¤T¡A±ß¤W 7:00 ¦b¥»¤å¤¤¡G Shawn Kwatra ³Õ¤h©M Madan Kwatra ³Õ¤h¦X§@ªº²Ä¤@§å¼Æ¾ÚÅã¥Ü¡A¯SÀ³©Ê¥Öª¢ (AD) ±wªÌ¥Ö½§¼Ë¥»¤¤ªÎ¤j²ÓM©M¶Ý»Ä©Ê²É²ÓMªº IL-13R£\1 ªí¹F¼W¥[¡A¼W±j¤F IL-13R£\1 ªº®Ö¤ß§@¥Î Eblasakimab ÅãµÛ°§C¤F¥Ñ¤£¦Pªº IL-4 ©M IL-13 æ±Äo³~®|¤Þ°_ªº¯«¸g¤¸æ±Äo±Ó·P©Ê¡A¨Ã¥B½T©w¤F IL-13R£\1 «H¸¹¦b¤¶¾É AD ¥H¥~ªº¯«¸g¤¸¿³¾Ä©Ê©M±Ó·P©Ê¤¤ªº·s¿³§@¥Î ¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2022 ¦~ 9 ¤ë 28 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤F¦b²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·| (ESDR) ·|ij¤W¤¶²Ð·sªºÂà¤Æ©Ê¨Ì¥¬©Ô³ß³æ§Ü¼Æ¾Ú¡C 2022 ¦~ 9 ¤ë 28 ¤é¦Ü 10 ¤ë 1 ¤é¦b²üÄõªü©i´µ¯S¤¦Á|¦æªº¤j·|´Á¶¡¡A¨â´T®ü³ø¥H¹q¤l®ü³øªº§Î¦¡§e²{¡C ¡§¦b ESDR ¤W®i¥Üªº·sÂà¤Æ¼Æ¾Ú¬° AD ¤¤ IL-13R£\1 ¤¶¾Éªº²ÓM¦]¤l«H¸¹¶Ç¾É´£¨Ñ¤F·s¿o©M®t²§¤Æªº¾÷¨î¨£¸Ñ¡C§ÚÌ»P Shawn Kwatra ³Õ¤h©M Madan Kwatra ³Õ¤h¦X§@ªºªì¨B¼Æ¾ÚÅã¥Ü¡AIL-13R£\1 ¦bªÎ¤j²ÓM©M¶Ý»Ä©Ê²É²ÓM¤¤ªºªí¹F¸û°ª¡A³o¬O AD ª¢¯gªºÃöÁäÅX°Ê¦]¯À¡A¦bµoª¢¥Ö½§ªº¯fÅܳ¡¦ì¡A¥[±j¤F IL-13R£\1 ¦b±À°Ê AD ¯f²z¾Ç¡A¡¨ASLAN Pharmaceuticals Âà¤Æ¬ì¾Çt³d¤H Ferda Cevikbas ³Õ¤h»¡¡C ¡§¦¹¥~¡A°ò¦]ªí¹FªºÅܤƪí©ú 1 «¬©M 2 «¬¨üÅ餧¶¡¦s¦b°ò¥»ªº«H¸¹¶Ç¾É®t²§¡A°w¹ï³o¨Ç¨üÅ骺ÃĪ«¥i¯à¨ã¦³¤£¦Pªº¤U´å®ÄÀ³¡A±q¦Ó¾ÉP¤£¦PªºÁ{§Éµ²ªG¡C¨Ó¦Û¯«¸g¤¸¬ã¨sªº¼Æ¾ÚÃÒ¹ê¤F§Ṳ́§«eªºµo²{¡A§Y IL-13R£\1 «H¸¹¶Ç¾É¹ï©ó¯«¸g¤¸³q¹L¯S©wæ±Äo¨üÅé¹ïæ±Äo³~®|ªº±Ó·P©Ê«Ü«n¡A¨Ãº¦¸ªí©ú IL-13R£\1 «H¸¹¶Ç¾É¥i¯à¦b¤¶¾É AD ¥H¥~ªº¯«¸g¤¸¿³¾Ä©Ê©M±Ó·P©Ê¤è±µo´§ÃöÁä§@¥Î¡C³o¨Ç¼Æ¾Ú¤ä«ù¤F IL-13R£\1 §@¬° AD ¹vÂIªº«n©Ê¡A¬° eblasakimab ´î»´ AD ±wªÌªºª¢¯g©Mæ±Äo´£¨Ñ¤F¤@ºØ¼ç¦bªº®t²§¤Æ¤èªk¡C¡¨ 2022 ESDR ¹q¤l®ü³ø¸Ô±¡ ®ü³ø 1 IL-13R£\1«H¸¹¦b¯SÀ³©Ê¥Öª¢¤¤ªºªÅ¶¡©w¦ì©M¥\¯à§@¥Î ¡]ºKn½s¸¹¡GLB060¡^ °Q½× AD ¬O¤@ºØºC©Êª¢¯g©Ê¥Ö½§¯f¡A¦ñ¦³©úÅ㪺æ±Äo¡]æ±Äo¡^1¡C³o¬OAD±wªÌ³ø§iªº³ÌÁc«ªº¯gª¬¡C IL-4/IL-13 ¨üÅé¨t²Î¬O¸gÁ{§ÉÅçÃÒªº AD ªvÀø¹vÂI¡A¥Ñ 1 «¬¡]IL-14R£\1 ©M¤½¦@ £^ Ãì¡^©M 2 «¬¡]¥Ñ IL-4R£\1 ©M IL-13R£\1 ²Õ¦¨¡^¨üÅé²Õ¦¨2 .®ü³ø®i¥Ü¤F¹ï AD ±wªÌ¥Ö½§¤¤ IL-13R£\1 ªí¹F¼Ò¦¡ªº¤ÀªRµ²ªG¡A¨Ã»P°·±d¹ï·Ó²Õ¶i¦æ¤F¤ñ¸û¡A¸Ó¬ã¨s¦®¦b³q¹L§K¬Ì²Õ´¤Æ¾Ç (IHC) ©MªÅ¶¡©w¦ì§ó¦n¦a¤F¸Ñ IL-13R£\1 ¦b AD ¤¤ªº§@¥Î¨Ï¥Î¤ñ¸ûÂà¿ý²Õ¾Ç¨Ó´yz 1 «¬©M 2 «¬¨üÅ骺¥\¯à¡C µ²ªG ¼Æ¾ÚÅã¥Ü¡A»P¤Ç°tªº°·±d¹ï·Ó¬Û¤ñ¡A·l¶Ë (L) (P<0.001) ©M«D·l¶Ë (NL) (P=0.45) AD ¥Ö½§¤¤ IL-13R£\1 ªí¹FÅãµÛ¼W¥[¡C¦¹¥~¡A»P¤Ç°tªº¹ï·Ó¬Û¤ñ¡AL¡]¤À§O¬° P = 0.034 ©M P = 0.024¡^©M NL¡]¤À§O¬° P = 0.031 ©M P = 0.046¡^AD ¥Ö½§ªºªÎ¤j²ÓM©M¶Ý»Ä©Ê²É²ÓM¤Wªº IL-13R£\1 ªí¹FÅãµÛ¼W¥[¡C¥Î§Ü±`¨£ £^ Ãì§ÜÅé§í¨î 1 «¬¨üÅé¾ÉP MMP9 ªºªí¹F¼W¥[¡]P<0.001¡^¡A³o¬O¤@ºØ½¦ì酶¡A¦b AD ±wªÌ¤¤¤É°ª¡A¨Ã¥i¯à¥[¼@ª¢¯g«P¶i²Õ´¤ô¸~ 3¡B4¡C eblasakimab ¹ï 2 «¬¨üÅ骺§í¨î»¤¾É¤F¹ï¥]¬A½G¯À¤¶¾Éªº 2 «¬¦s¬¡©M²ÓM¦]¤l²£¥Í©Ò»Ýªº XBP1¡]P<0.001¡^©M CXCL8¡]P=0.046¡^¦b¤ºªº°ò¦]ªº§í¨î¡A¨ä¤ô¥»P AD ÄY«µ{«×¬ÛÃö6¡C ®ü³ø 2 ®ü³ø 2 ¨Ì¥¬©Ô¨ä³æ§Ü¹v¦V¥Õ²ÓM¤¶¯À 13 ¨üÅé £\ 1 (IL-13R£\1) ¬}¹î·sªºæ±Äo³~®|©M¦Ûµo¯«¸g¤¸¬¡°Ê ¡]ºKn½s¸¹¡GLB061¡^ °Q½× IL-4 ©M IL-13 ¹ïæ±Äo³~®|©M¯«¸g¤¸¿³¾Ä©Ê¦³©úÅ㪺¼vÅT¡A¥i¥H³q¹L¹v¦V IL-13R£\17,8 ¨Ó§í¨î¡C Eblasakimab ¥H°ª¿Ë©M¤O»P¤H 2 «¬¨üÅé¨È°ò IL-13R£\1 µ²¦X¡Aªý¤î IL-4 ©M IL-13 ³q¹L¦b¤@¨t¦C§K¬Ì©M«D§K¬Ì²ÓM¡]¥]¬A·Pı¯«¸g¤¸¡^¤Wªí¹Fªº 2 «¬¨üÅéµo¥X«H¸¹ 7,9¡C·Pı¯«¸g¤¸ªºP±Ó§Î¦¨¤F¦hºØÂßÅé·Pı»Ùꪺ²ÓM©M¤À¤l°ò¦¡A¨Ò¦pºC©Êæ±Äo¡B¯«¸g·½©Êª¢¯g©M¯kµh¥\¯à»Ùꪺ§Î¦¡¡C®ü³ø®i¥Ü¤F¤@¶µ¬ã¨sªºµ²ªG¡A¸Ó¬ã¨s¦®¦b½T©w¤HÃþI®Ú¯«¸g¸` (hDRG) ¯«¸g¤¸¦b¦UºØ±ø¥ó¤U¹ïæ±Äo커¾Éªºæ±Äo«H¸¹ªº¯«¸g¤¸¤ÏÀ³¡C¦b§t¦³½w¿E肽©M«e¦C¸¢¯Àªºª¢¯g´ö (IS) »¤¾Éªº hDRG ¯«¸g¤¸¤¤¡AIL-4 ©M IL-13 ¹ï¦Ûµo¯«¸g¤¸¬¡°Ê (SA) ªº¼vÅT¡A¦b¨Ï¥Î©M¤£¨Ï¥Î¨Ìblasakimab §@¬°·Pı¯«¸g¤¸¶W±Ó¤Æ¼Ò«¬ªº±¡ªp¤U¶i¦æ¤F´ú¶q¡C µ²ªG ¦¹®ü³ø¤¤´£¨Ñªº¼Æ¾ÚÃÒ¹ê¤F eblasakimab §í¨î¥Ñ IL-4 ©M IL-13 ¹ï¤HÃþ¯«¸g¤¸¤Þ°_ªº¯«¸g¤¸P±Óªº¥ý«eµ²ªG¡C¦¹¥~¡AIL-13 ¨Ï hDRG ¯«¸g¤¸¹ï«PµÇ¤W¸¢Åè½è¯À肽 1-20 (PAMP20) ±Ó·P¡AÃÒ©ú¤FÄo¯S²§©Ê MRGPRX2 ¨üÅé¦b¤HÃþ·Pı¯«¸g¤¸¤¤ªí¹F¨Ãµo´§§@¥Î¡Aªí©ú 2 «¬²ÓM¦]¤l¦b¦hºØ²ÓM¦]¤l¤¤ªº¼W±j§@¥Î»Pæ±Äo¬ÛÃöªº¯e¯f¡C¦bª¢¯g±ø¥ó¤U¡AIL-4 ¦b hDRG ¯«¸g¤¸¤¤»¤¾É¦Ûµo¬¡°Ê (SA)¡A¦Ó eblasakimab ÅãµÛ°§C¤F¦Ûµo¬¡°Ê¡C³o¥i¯à¬Oª¢¯g±ø¥ó¤U¯«¸g¤¸±Ó·P©Ê§ïÅܪº¾÷¨î°ò¦¡C³o¨Ç¼Æ¾Úªí©ú¡AIL-13 ©M IL-4 ¥i¯à¦b¼vÅT¯«¸g¤¸¬¡°Ê¤¤µo´§¤£¦Pªº§@¥Î¡A¦Ó¨Ì¥¬©Ô¦è³æ§Ü³QÃÒ©ú¥i¥HªýÂ_³o¨âºØ²ÓM¦]¤lªº§@¥Î¡C ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting finance.yahoo.com/news/aslan-pharmaceuticals-presents-data-eblasakimab-110000948.html |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/9/28 ¤U¤È 05:12:11²Ä 5652 ½g¦^À³
|
«X¯Q¾Ôª§¼vÅT ¼Ú¬w¾ãÅé¸gÀÙ¤£¼ÖÆ[ ¤µ¦~¥V¤Ñ¥i¯àÃø¼õ¤F ¼Ú¬w°Ï¥i¯à¤£¶}¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/28 ¤U¤È 04:17:46²Ä 5651 ½g¦^À³
|
www.clinicaltrials.gov/ct2/show/NCT05158023 8¤ë30¤é 004 2b¤w¶}65Ó¤¤¤ß. 欧¦{°Ï¥i¯à¤£¶}¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/28 ¤W¤È 10:59:51²Ä 5650 ½g¦^À³
|
¤@.ASLAN004 2b 16¶g´Á±æÈ ASLAN004 VS¹ï·Ó²Õ//®t²§(¦©°£¹ï·Ó²Õ) IGA 0,1= 57% VS 15%//®t²§42%(57%-15%=42%) EASI75= 73% VS 24%//®t²§49%(73%-24%=49%) ¤G.Tralokinumab °w¾¯,¥h¦~12¤ë ÀòFDA ,¤¤-«AD¬ü°êÃĵý(DUPILUMAB «áªº¥@¬É²Ä¤G¤ä,DUPILUMAB). MOA:§@¥Î¦bIL13 °tÅéA,DÁ³±Û¤W,¨Ï±oIL13 °T¸¹µLªk³Q¶Ç»¼.¦ýIL4 °T¸¹¥i¥¿±`¶Ç»¼. (¤@).ECZTRA 1 1.IGA0,1 Q2W//Q4W VS ¹ï·Ó²Õ //¦©°£¹ï·Ó²Õ«á 16¶g 15.8%//-- VS 7.1% // 8.7% 52¶g 8.1%//6.2% 2.EASI75 16¶g 25%//-- VS 12.7%//12.3% 52¶g 15%//12.3% (¤G).ECZTRA 2 1.IGA 0,1 Q2W//Q4W VS ¹ï·Ó²Õ //¦©°£¹ï·Ó²Õ«á 16¶g 22.2%//--VS 10.9% //11.3% 52¶g 13.1%//10.0% 2.EASI75 16¶g 32.2%//--VS 11.4%//20.8% 52¶g 18.0%//16.4% pubmed.ncbi.nlm.nih.gov/33000465/ Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) 1.At week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0 or 1: 15¡P8% vs. 7¡P1% in ECZTRA 1 [difference 8¡P6%, 95% confidence interval (CI) 4¡P1-13¡P1; P = 0¡P002] and 22¡P2% vs. 10¡P9% in ECZTRA 2 (11¡P1%, 95% CI 5¡P8-16¡P4; P < 0¡P001) and EASI 75: 25¡P0% vs. 12¡P7% (12¡P1%, 95% CI 6¡P5-17¡P7; P < 0¡P001) and 33¡P2% vs. 11¡P4% (21¡P6%, 95% CI 15¡P8-27¡P3; P < 0¡P001). www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/ (¤T)Tralokinumab 52¶gºû«ù²v ¨Ì16¶g,¹FEASI75 OR IGA0,1¬°¤ÏÀ³ªÌ,¥t¶i¦æ18~52¶g Q2W/Q4W/Q2W¦w¼¢¾¯ (1)ECZTRA 1 Q2W//Q4W/Q2W¦w¼¢¾¯ A.IGA0,1 51%//39%//47% B.EASI75 60%//49%//33% (2)ECZTRA 2 Q2W//Q4W/Q2W¦w¼¢¾¯ A.IGA0,1 59%//45%//25% B.EASI75 56%//51%//21% ¦b¨â¶µ¬°´Á 52 ¶g¡BÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº III ´Á¸ÕÅç ECZTRA 1 ©M ECZTRA 2 ¤¤¡A¤¤«×¦Ü««× AD ªº¦¨¤H³QÀH¾÷ (3:1) ±µ¨ü¨C 2 ¶g 300 mg ªº tralokinumab ¥Ö¤Uª`®g¡C Q2W¡^©Î¦w¼¢¾¯¡C ¥Dn²×ÂI¬O²Ä 16 ¶g®É¬ã¨sªÌªº¾ãÅéµû¦ô (IGA) µû¤À¬° 0 ©Î 1¡A²Ä 16 ¶g®ÉÀã¯l±¿n©MÄY«©Ê«ü¼Æ (EASI 75) §ïµ½≥ 75%¡C IGA µû¤À¬° 0 ©Î 1 ©M/©Î EASI 75 ªº±wªÌ ¦b²Ä 16 ¶g¨Ï¥Î tralokinumab ªº±wªÌ³Q«·sÀH¾÷¤À°t¦Ü tralokinumab Q2W ©Î¨C 4 ¶g¤@¦¸©Î¦w¼¢¾¯¡A«ùÄò 36 ¶g¡C ³o¨Ç¸ÕÅç¤w¦b ClinicalTrials.gov µù¥U¡GNCT03131648 ©M NCT03160885¡C In two 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Primary endpoints were Investigator¡¦s Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. Patients achieving an IGA score of 0 or 1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. The trials were registered with ClinicalTrials.gov: NCT03131648 and NCT03160885. ¤T.ASLAN004 2b ´Á±æÈ VS Tralokiumab 3´Á(16¶g) ¦©°£¹ï·Ó²Õ 1.ASLAN004 2b ´Á±æÈ IGA 0,1= 57% VS 15%//®t²§42%----A EASI75= 73% VS 24%//®t²§49%----B vs 2.Tralokiumab 3´Á(16¶g)---¦©°£¹ï·Ó²Õ IGA 0,1= ®t²§8.7%~11.3%,¥§¡10%---C EASI75= ®t²§12.3%~20.8%,¥§¡16.6%---D 3.16¶gPK IGA 0,1 A/C=42%/10%=420% EASI75 B/D=49%/16.6%=295% ¥|:µ²½×ASLAN004 ´Á±æÈ,¤T´Á¥Dn«ü¼Ð IGA0,1 //EASI75 ¤ñ¤w¦b¬ü/¼Ú¤W¥«ªºTralokiumab(¥@¬É²Ä¤G¤W¥«°w¾¯) Àø®Ä°ª¥X320%//195%. ASLAN004 ADÃĵý §ä¤£¨ì²z¥Ñ®³¤£¨ì. ¦ý»ùȦ³¦h°ªnPKªº¤´¬O Dupilumab ¤T´Á Q2W IGA 0,1= 38% VS 10%//®t²§28%----SOLO1 =36% VS 8% //®t²§28%----SOLO2 EASI75= 51% VS 15%//®t²§36%----SOLO1 = 44% VS 12%//®t²§32%----SOLO2 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/26 ¤W¤È 09:01:55²Ä 5649 ½g¦^À³
|
Leb. PK Dupilumab¡A(©Ò¦³¤T´Á¡A©Î¥[TCS¡A©Î16/52¶g)¡A¦©°£¹ï·Ó组¼vÅT Leb. 40% Àu©óDup. ©Î Leb. 39% ¦H©óDup. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/26 ¤W¤È 08:15:11²Ä 5648 ½g¦^À³
|
Lebrikizumab ¤QTCS¡Ñ16¶g ¤T´Á¡A¦©°£¹ï·Ó组 @% IGA. 41-22=19 EASI75 70-42=28 ¤G¡BDupilumab +TCS 16¶g¡A¦©°£¹ï·Ó组 @% IGA. 38.7-14.2=24.5 EASI75 68.9-23.2=45.7 ¤T¡APK Leb./Dup. @% IGA. 19/24.5=78 EASI75 28/45.7=61 结½× ¥[TCS«á¡ALeb. ¦H©ó Dup. ¦bIGA.¦H22%, ¦bEASI75 ¦H39%. Leb.¤QTCS ©MLeb.AD2 ¤T´Á/16¶gêq®Ä°ò¦¸û¬Ûªñ¡C Leb. AD2 16¶g¡C IGA. 33-11=22 EAS75 51-18=33 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/26 ¤W¤È 07:14:50²Ä 5647 ½g¦^À³
|
Dupilumab+TCS vs Dupilumab (SOLO1/2 Q2W), EASI75(%) pk¡A¡K¡K¤T´ÁÁ{§É 1.Dep.+TCS QW//Q2W//¹ï·Ó²Õ--% 16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6 52¶g/16¶g=95%, ¥§¡°h5% 2.Dup. SOLO 1/2 Q2W--% 16¶g 51/44,¥§¡47.5 3.pk 68.9/47.5=145...16¶g Dupilumab¤Q TCS¡A¦b²Ä16¶g¬Û¹ï©ó¥¼¥[TCS, EASI75,¼W¥[45%ªºÀø®Ä¡C ¥B52¶g¥u°5%. ¤G¡BLebrikizumab ¤QTCS ¤T´ÁÁ{§Éx16¶gªvÀø¡A 2022/4/22 µ²ªG¡C¤½§G 1.Leb.+TCS vs ¹ï·Ó组 1.IGA0,1 41 vs 22 2.EASI75 70 vs 42 3.Leb.+TCS pK Lebrikizumab 1EASI76, 16 ¶g AD1/AD2 59/51,¥§¡55 70/55=127%,¼W¥[27% TCS ¼W¥[EADI75 27%Àø®Ä ........................... News Release Lilly¡¦s Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis April 11, 2022 Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key secondary endpoints INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS. Today¡¦s ADhere data, together with results from the ADvocate monotherapy studies, demonstrate the potential for lebrikizumab to reduce disease burden and provide relief for people with uncontrolled atopic dermatitis when used either alone or combined with topicals, said Eric Simpson, M.D., M.C.R., Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland, and principal investigator of ADhere. Lebrikizumab specifically targets the IL-13 pathway, which plays the central role in this chronic inflammatory disease. These results strengthen our understanding of lebrikizumab in atopic dermatitis and help establish it as a possible new treatment option. Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin 13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R£\1/IL-4R£\ (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.1-5 IL-13 plays the central role in Type 2 inflammation in AD.6,7 In AD, IL-13 underlies the signs and symptoms including skin barrier dysfunction, itch, infection and hard, thickened areas of skin.8 Among patients taking lebrikizumab plus TCS, 41 percent achieved clear or almost clear skin (IGA) at 16 weeks compared to 22 percent of patients taking placebo plus TCS. At 16 weeks, 70 percent of patients taking lebrikizumab plus TCS achieved an EASI-75 response compared to 42 percent taking placebo plus TCS. Differences between patients receiving lebrikizumab in combination with TCS and placebo with TCS were observed as early as four weeks for EASI-75. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/25 ¤U¤È 03:42:55²Ä 5646 ½g¦^À³
|
¤j§ó¥¿Ãö©óLebrikizumab ¤T´Á52¶gªº¼Æ¾Ú°ò¦ÅTÀ³ªÌ©w¸q ¬O16¶g®É¹F EASI75 ,«DEASI50(¤@¯ëAD ªvÀø«á Responders¤§©w¸q¬°EASI50) * Responders were defined as those achieving a 75% reduction in the Eczema Area and Severity Index from baseline (EASI-75) or an IGA 0 or 1 (clear or almost clear) with a 2-point improvement and without rescue medication use at Week 16. * ÅTÀ³ªÌ©w¸q¬°Àã¯l±¿n©MÄY«µ{«×«ü¼Æ±q°ò½u (EASI-75) ´î¤Ö 75% ©Î IGA 0 ©Î 1¡]¡§²M°£¡¨©Î¡§´X¥G²M°£¡¨¡^¡A§ïµ½ 2 ¤À¥B¥¼¶i¦æ±Ï´©ªº¤H ²Ä 16 ¶gªºÃĪ«¨Ï¥Î±¡ªp¡C Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly¡¦s Phase 3 Monotherapy Atopic Dermatitis Trials September 8, 2022 finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html ¤@.Lebrikizumab 52¶gªºªvÀø®ÄªG---¨Ì°ò½u²Ä¤@¶g¦ôp°ò¦--------¤j×¥¿¦p¤U: 1¡AAD1. 52¶gQ4W//Q2W IGA ¡G59%(EASI75)x74%//76% =47%//45% Vs 16¶gÀø®Ä 43%¡A¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉIGA 4%//2% EASI75: 59%(EASI75)x79%//79%% =47% Vs 16¶gÀø®Ä 59%¡A¸g18¡ã52¶gªvÀø«á¦ôpEASI75,Ë°h12%¡C 2.AD2 IGA ¡G51%(EASI75)x81%//65% =41%//33% Vs 16¶gÀø®Ä 33%¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉIGA 8%//0% EASI75: 51%¡]EASI75)x85%//77% =43%//39% Vs 16¶gÀø®Ä 51%¸g18¡ã52¶gªvÀø«á¦ôp Ë°hEASI75 8%//12% µ²½×¡G±q16¶g©µªø¨ì52¶g§MÀø¹ïIGA ®ÄªG ¥§¡´£¤É3.5%¡A ¦ý¹ïEASI75 ¥§¡¤U°11%¡C ¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@ Lebrikizumab Week 52 Results 1¡PADvocate 1(¦b²Ä16¶g¦³59%¹FEASI75¡^ Lebrikizumab 250 mg Q4W//Q2W IGA (0,1) 74 %//76 % EASI¤@75 79%//79% Pruritis (Itch) NRS 80 %//81 % 2¡PADvocate2¡]¦b²Ä16¶g51%¹FEASI75¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 % Pruritis (Itch) NRS 88 %//90 % Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁÁ{§Éµ²ªG clinicaltrials.gov/ct2/show/results/NCT04146363 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2) clinicaltrials.gov/ct2/show/results/NCT04178967?term=ADvocate2+lebrikizumab&draw=2&rank=1 ¤@.Lebrikizumab(16¶g)¡A¤T´Á ¹êÅç²Õvs¹ï·Ó²Õ In ADvocate 1, (IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B In ADvocate 2, (IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D -------------------------------------------- ¤G..Lebrikizumab PK DUupilumab+TCS 52¶gÀø®ÄPK ---¨Ì°ò½u²Ä¤@¶g¦ôp°ò¦--------¤j×¥¿¦p¤U: ¤T´Á¥Dn«ü¼ÐIGA0,1 ¤jPk 1¡B16¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 38.7%-14.2%=24.5%¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^//¥t¥~2Ó¥¼¥[TCSªºSolo1/2 ¦©°£¹ï·Ó²Õ«á¬°28%¡^ vs 43%-13%=30%¡K.Leb. AD1¡KB 33%-11%=22%¡KLeb. .AD2...C ¡]¥h¦~©³¸ê°T¡^ B/A=30%/24.5%=122%(Leb.22%ÀuDupilumab)¡K..D C/A=22%/24.5%=90%¡]Leb. 10%¦H©óDupilumab)¡K.E ASLN004©M Lebrikizumab ¦P¨Ì¾aIL13-Ra1 ¡]ª½±µ¡þ¶¡±µ¡^¦Y¶º¡C ¦bASLN004Á{§É ITT¤ÀªR¥¼¶W¶VLebrikizumab(²¼gLeb.¡^«e¡A¤ÀªR®v¨ÌLeb.³Q¨ÖÁÊ»ùÈ11»õ¬ü¤¸¦ôºâASLAN004»ùÈ¡A¹êÄÝ¥¿±`¡C 9¤ë15¤é ASLN R&D ³ø§i¡A150¤H¥«½Õ³ø§i¡A¨Ì¾Ú8%Àu©óDupilumab°µ¥«½Õ°ò¦¡C«Ü¤j¥i¯à¨Ó¦ÛLeb.¤T´Á¡]SOLO1/2)¼Æ¾Ú¬°°ò¦¡C ³o¼ËDupilumab ¥é¥ÍÃĨÌ80%»ù®æ¾P°â¡AASLAN004ªº¥«³õ±N¦³«Ü¦hÄvª§ªÌ¡C ²H°¨¿ü¯à·Q¨ìªº´N¬O¦p¦¹¤F¡C¬GµL«ù¦¹¼W¥[«ùªÑ¤]¦X²z¡C 2.52¶g IGA0,1 PK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F 46%-13%=33%¡K.Leb. AD1¡KG ¡]2022/9/8 ¸ê°T¦ôp¡^ 37%-11%=26%⋯Leb. AD2¡KH ¡]2022/9/8¤½¥¬¸ê°T¦ôp¡^ G/F=33%/23.5%=140%¡KJ¡]Leb. 40%Àu©óDupilumab) H/F=26%/23.5%=111%¡K..K (Leb 11% Àu©óDupilumab) ¤T.16¶g VS 52 ¶g 1. Lebrikizumab ¤T´ÁÁ{§É A.IGA0,1 AD1//AD2/(¹ï·Ó²Õ)---% 16¶g43//33//(13~11) 52¶g46//37//(°²³]¦P16¶g 13~11).------(2022/09/08 ¤½§G) 52¶g/16¶g=111%,¥§¡´£¤É11% B.EASI75 AD1//AD2/(¹ï·Ó²Õ)---% 16¶g59//51//(16~18) 52¶g47//41//(°²³]¦P16¶g 16-18 ).------(2022/09/08 ¤½§G) 52¶g/16¶g=80%, ¥§¡°h20%. 2..Dupilumab+TCS ¤T´ÁÁ{§É A.IGA0,1 QW//Q2W//¹ï·Ó²Õ--% 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------(2017/10 ¤½§G) 52¶g/16¶g=97.5%,¥§¡°h2.5% B.EASI75(%) QW//Q2W//¹ï·Ó²Õ--% 16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6 52¶g/16¶g=95%, ¥§¡°h5% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤U¤È 06:48:25²Ä 5645 ½g¦^À³
|
¤T.¸É¥R Lebrikizumab 52¶g PK Dupilumab 16¶g ,¤T´Á¥Dn«ü¼ÐIGA0,1 SOLO1/SOLO2 Dupilumab 16¶g ¦©°£¹ï·Ó²Õ0,1=28%----L ( G/L=42.5%/28%=152%¡KM¡]Leb. 52%Àu©óDupilumab) H/L=36%/28%=129%¡K..N (Leb 29% Àu©óDupilumab) ¤G.52¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F 55.5%-13%=42.5%¡K.Leb. AD1¡KG ¡]2022/9/18 ¸ê°T¦ôp¡^ ¡]51%+43%¡^/2-11%=36%⋯Leb. AD2¡KH ¡]2022/9/18¤½¥¬¸ê°T¦ôp¡^ G/F=42,5%/23.5%=180%¡KJ¡]Leb. 80%Àu©óDupilumab) H/F=36%/23.5%=156%¡K..K (Leb 56% Àu©óDupilumab) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤U¤È 06:36:53²Ä 5644 ½g¦^À³
|
»Û£Âû´ö, ASLN 100%³Q¨ÖÁÊ. ¦]¬°nµo®iªºÁ{§ÉAD/ý³Ý/EOE/COPD...¦h¤S¤j. 2¦~«eDupilumab ¤w§ë¤J50»õ¬ü¤¸¬ãµo. |
|
|
·|û¡G»Û£Âû´ö10151217 µoªí®É¶¡:2022/9/24 ¤U¤È 06:25:31²Ä 5643 ½g¦^À³
|
ð ¤@ª½¶Rªº½T·Pı¨Æ±¡¤£³æ¯Â ¥BÀ£§C¦b¶R... ®z®zªº½Ð±Ð ¤Ñ©R¤j »{¬°³Q¨ÖÁʪº¾÷²v¬O? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤U¤È 03:25:29²Ä 5642 ½g¦^À³
|
×¥¿2 38.7%-14.2%=24.5%¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^ //¥t¥~2Ó¥¼¥[TCSªºSolo1/2 ¦©°£¹ï·Ó²Õ«á¬Ò¬°28%(solo1 38%-10%=28%//solo2 36%-8%=28%¡^ Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤U¤È 03:10:16²Ä 5641 ½g¦^À³
|
¬Ü¨¤¦b¦¹¡K×¥¿l ¤T´Á¥Dn«ü¼ÐIGA0,1 ¤jPk ¤@¡B16¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 38.7%-14.2%=24.5%¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^//¥t¥~2Ó¥¼¥[TCSªºSolo1/2 ¦©°£¹ï·Ó²Õ«á¬°30%¡^ vs 43%-13%=30%¡K.Leb. AD1¡KB 33%-11%=22%¡KLeb. .AD2...C ¡]¥h¦~©³¸ê°T¡^ B/A=30%/24.5%=122%(Leb.22%ÀuDupilumab)¡K..D C/A=22%/24.5%=90%¡]Leb. 10%¦H©óDupilumab)¡K.E ASLN004©M Lebrikizumab ¦P¨Ì¾aIL13-Ra1 ¡]ª½±µ¡þ¶¡±µ¡^¦Y¶º¡C ¦bASLN004Á{§É ITT¤ÀªR¥¼¶W¶VLebrikizumab(²¼gLeb.¡^«e¡A¤ÀªR®v¨ÌLeb.³Q¨ÖÁÊ»ùÈ11»õ¬ü¤¸¦ôºâASLAN004»ùÈ¡A¹êÄÝ¥¿±`¡C 9¤ë15¤é ASLN R&D ³ø§i¡A150¤H¥«½Õ³ø§i¡A¨Ì¾Ú8%Àu©óDupilumab°µ¥«½Õ°ò¦¡C«Ü¤j¥i¯à¨Ó¦ÛLeb.¤T´Á¡]SOLO1/2)¼Æ¾Ú¬°°ò¦¡C ³o¼ËDupilumab ¥é¥ÍÃĨÌ80%»ù®æ¾P°â¡AASLAN004ªº¥«³õ±N¦³«Ü¦hÄvª§ªÌ¡C ²H°¨¿ü¯à·Q¨ìªº´N¬O¦p¦¹¤F¡C¬GµL«ù¦¹¼W¥[«ùªÑ¤]¦X²z¡C ¤G.52¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F 55.5%-13%=42.5%¡K.Leb. AD1¡KG ¡]2022/9/18 ¸ê°T¦ôp¡^ ¡]51%+43%¡^/2-11%=36%⋯Leb. AD2¡KH ¡]2022/9/18¤½¥¬¸ê°T¦ôp¡^ G/F=42,5%/23.5%=180%¡KJ¡]Leb. 80%Àu©óDupilumab) H/F=36%/23.5%=156%¡K..K (Leb 56% Àu©óDupilumab) Leb.52¶g±N¨ú¦¨¬°AD ·s¥D¤O¡C¡K..¦ôp2023¦~©³¨úFDAÃĵý¡C »ùȳs«°¡A¦ôAD¤W¥«5¦~¶W¶VDupilumab. ¦³40¡ã80»õ¬ü¤¸ªº¾P°â¹ê¤O¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K.. ½Ö¯à·Q¨ìLebrikizumab AD¤T´ÁÁ{§É2ÓÁ{§É52¶g¤jÃzµo¡C 16¶gIGA.0,1=43%~33%, 52¶gIGA,0.1=56%/55%~51%/44%.------Àø®Ä¤j´T´£¤É.(2022/09/08 ¤½§G) (Lebrikizumabý³Ý/COPD ¤T´ÁµL¦¨¥\) -------------------------------------- ¦ÓDupilumab+TCS ¤T´ÁÁ{§É QW//Q2W//¹ï·Ó²Õ 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------©M16©PÀø®Ä¬Û·í.(2017/10 ¤½§G) Lebrikizumab 52 ¶g IGA,0.1Àø®Ä¡A 16¶g ¥Ñ44%´£¤É¦Ü52¶g55%/56% 33%´£¤É¦Ü51%/43% 16¤Ñ«e¤~µo§G¡C ±N¥´±ÑDupilumab 52¶g36%¥é¥ÍÃÄ¡C (¤é«á¥´8§é¾P°â) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤U¤È 02:59:16²Ä 5640 ½g¦^À³
|
¬Ü¨¤¦b¦¹ ¤T´Á¥Dn«ü¼ÐIGA0,1 ¤jPk ¤@¡B16¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 38.7%-12.4%=26.4 ¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^ vs 43%-13%=30%¡K.Leb. AD1¡KB 33%-11%=22%¡KLeb. .AD2...C ¡]¥h¦~©³¸ê°T¡^ B/A=30%/26.4%=114%(Leb.14%ÀuDupilumab)¡K..D C/A=22%/30%=73%¡]Leb. 27%¦H©óDupilumab)¡K.E ASLN004©M Lebrikizumab ¦P¨Ì¾aIL13-Ra1 ¡]ª½±µ¡þ¶¡±µ¡^¦Y¶º¡C ¦bASLN004Á{§É ITT¤ÀªR¥¼¶W¶VLebrikizumab(²¼gLeb.¡^«e¡A¤ÀªR®v¨ÌLeb.³Q¨ÖÁÊ»ùÈ11»õ¬ü¤¸¦ôºâASLAN004»ùÈ¡A¹êÄÝ¥¿±`¡C 9¤ë15¤é ASLN R&D ³ø§i¡A150¤H¥«½Õ³ø§i¡A¨Ì¾Ú8%Àu©óDupilumab°µ¥«½Õ°ò¦¡C«Ü¤j¥i¯à¨Ó¦ÛLeb.¤T´Á¼Æ¾Ú¬°°ò¦¡C ³o¼ËDupilumab ¥é¥ÍÃĨÌ80%»ù®æ¾P°â¡AASLAN004ªº¥«³õ±N¦³«Ü¦hÄvª§ªÌ¡C ²H°¨¿ü¯à·Q¨ìªº´N¬O¦p¦¹¤F¡C¬GµL«ù¦¹¼W¥[«ùªÑ¤]¦X²z¡C ¤G.52¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F 55.5%-13%=42.5%¡K.Leb. AD1¡KG ¡]2022/9/18 ¸ê°T¦ôp¡^ ¡]51%+43%¡^/2-11%=36%⋯Leb. AD2¡KH ¡]2022/9/18¤½¥¬¸ê°T¦ôp¡^ G/F=42,5%/23.5%=180%¡KJ¡]Leb. 80%Àu©óDupilumab) H/F=36%/23.5%=156%¡K..K (Leb 56% Àu©óDupilumab) Leb.52¶g±N¨ú¦¨¬°AD ·s¥D¤O¡C¡K..¦ôp2023¦~©³¨úFDAÃĵý¡C »ùȳs«°¡A¦ôAD¤W¥«5¦~¶W¶VDupilumab. ¦³40¡ã80»õ¬ü¤¸ªº¾P°â¹ê¤O¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K.. ½Ö¯à·Q¨ìLebrikizumab AD¤T´ÁÁ{§É2ÓÁ{§É52¶g¤jÃzµo¡C 16¶gIGA.0,1=43%~33%, 52¶gIGA,0.1=56%/55%~51%/44%.------Àø®Ä¤j´T´£¤É.(2022/09/08 ¤½§G) (Lebrikizumabý³Ý/COPD ¤T´ÁµL¦¨¥\) -------------------------------------- ¦ÓDupilumab+TCS ¤T´ÁÁ{§É QW//Q2W//¹ï·Ó²Õ 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------©M16©PÀø®Ä¬Û·í.(2017/10 ¤½§G) Lebrikizumab 52 ¶g IGA,0.1Àø®Ä¡A 16¶g ¥Ñ44%´£¤É¦Ü52¶g55%/56% 33%´£¤É¦Ü51%/43% 16¤Ñ«e¤~µo§G¡C ±N¥´±ÑDupilumab 52¶g36%¥é¥ÍÃÄ¡C (¤é«á¥´8§é¾P°â) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤U¤È 02:03:25²Ä 5639 ½g¦^À³
|
²H°¨¿ü«ùªÑASLNªº¥§¡¦¨¥»¦b7¶ô¦h¬ü¤¸1678¤dªÑADR¡A¦n¤[¨S¼W«ù¤F¡C¡]2019¦~©³°h¥X¸³¨Æ¡^¡AÁ`¸g²z¡]Á`²zªº¤Ó¤Ó°h¥ð¡^¡AASLN¤w±N³Q¨ÖÁÊ¡C ³Ì¤jªÑªFð¸ê²£¤½¥qªº¥§¡¦¨¥»1¶ô3¤ò¡A³s¶R4©u¡A5555¤dªÑ«ùªÑ¡C¡]±M§ë·sÃĪѡ^ ¨º¤@®a¤ñ¸û±M·~¡H |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/24 ¤U¤È 01:05:57²Ä 5638 ½g¦^À³
|
¤Ñ©R¤j §Ú«üªº¬Oì©l¤jªÑªF ¦p²H°¨¿ü·s¥[©Y¥DÅv°òª÷µ¥ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤W¤È 10:20:55²Ä 5637 ½g¦^À³
|
Ãö©óASLNªÑ»ù¡G ASLN ³Ì¤jªÑªF¦b§C»ù®É³sÄò¶R¡C ¤½¥q°ª¼h°tªÑ¦b§C»ù®É°tªÑ§ó°ª¿³¡C ¤é«á³Ì°ª»ù¦b³Q¨ÖÁÊ»ù«Å¥¬·í¤é¡A°O±o½æ¥X¡C ¤½¥q¶Ò资®É¤è¯àÅã¥Ü·í®É»ùÈ¡C ¥H¤W¥«ASLN ADRªº¯S©Ê¡C Lebrikizumab 52¶gªºÀø®Ä±iÅãIL13-Ra1ªº»ùÈ¡C «D±`«D±`«n¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤W¤È 10:06:30²Ä 5636 ½g¦^À³
|
§í¨îIL13-Ra1¤ñ§í¨îIL4-RaÀu¶V©Ê ¥ÑLebrikizumab pk Dupilumab ¤T´ÁÁ{§Éµý©ú¤§¡C ASLAN004 ¬Oª½±µ§í¨îIL13-Ra1¡C ·|¸û¦³®Ä²v(¤£¥Î52¶g¡A´Á±æ¥Ø¼Ð16¶g´N¥iÅã²{¡C¹FIGA0.1Àø®Ä¡C Lebrikizumab ¬O¶¡±µ§í¨î¡C©Ò¥H¥u¯à¾a18-52¶g¨Ó´£¤ÉIGA0.1ªºÀø®Ä¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤W¤È 09:52:44²Ä 5635 ½g¦^À³
|
¤½¥qÀ³«·s©M¨é°Ó·¾³q ¨Ì¾ÚLebrikizumab 52 ¶gªºÀø®Ä´£¤É¡C ´£¤ÉASLNªº¥Ø¼Ð»ù¡C ¤½§G2b´Á¤¤³ø§i¡A´£°ª©Ó¾P¤è®×ªº»ù®æ¡C ¥B±Nª½±µ¥«³õ¾P°â¶Ò资¤è®×¡A§ï¬°¥]销¨î¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Lebrikizumab 52 ¶g IGA,0.1Àø®Ä¡A 16¶g ¥Ñ44%´£¤É¦Ü52¶g55%/56% 33%´£¤É¦Ü51%/43% 16¤Ñ«e¤~µo§G¡C ±N¥´±ÑDupilumab 52¶g36%¥é¥ÍÃÄ¡C (¤é«á¥´8§é¾P°â) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤W¤È 09:31:06²Ä 5634 ½g¦^À³
|
¤½¥q¤w·Ç³Æ¦n¶Ò资¤è®×¤§¤@¡C ¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤W¤È 10:21:16²Ä 5565 ½g¦^À³ ¥i¯à¶·¤½¥¬2bªº´Á¤¤³ø§i¡A¨Ã¦P®É¶Ò¶°¸êª÷¡C 0¡P8¡ã5.6¬ü¤¸¡]¥«»ù7¬ü¤¸x80%¡^¡þADR ¥»¦¸±Nµo¦æ27¡A564¤dªÑADR ªÑ¥»¡G97¡A308¤dªÑADR The offering Up to 486,543,875 ordinary shares (or 97,308,775 ADSs), including ordinary shares represented by ADSs (as more fully described in the notes following this table), assuming sales of 27,564,102 ADSs in this offering at an offering price of $0.78 per ADS, which was the last reported sale price of ADSs on Nasdaq on September 9, 2022. The actual number of ADSs issued will vary depending on the sales prices under this offering P.8 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤W¤È 09:21:51²Ä 5633 ½g¦^À³
|
Lebrikizumab 52 ¶g IGA,0.1Àø®Ä¡A 16¶g ¥Ñ44%´£¤É¦Ü52¶g55%/56% 33%´£¤É¦Ü51%/43% 16¤Ñ«e¤~µo§G¡C ±N¥´±ÑDupilumab 52¶g36%¥é¥ÍÃÄ¡C (¤é«á¥´8§é¾P°â) ¤½¥¬´Á¤¤³ø§i¡A¶Ò¤T´Á资ª÷+¼Ú¬w°Ï±ÂÅv ªÑ»ù¦ÛµM¤ÏÀ³¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/24 ¤W¤È 09:06:27²Ä 5632 ½g¦^À³
|
³¯¤j¡A ³Ì¤jªÑªF«ùªÑ5555¤dªÑ¡A³sÄò¶R4©u¡A«ùªÑªñ8%. ¡C ¤w¸g¹F¥i³Q¨ÖÁʪ¬ºA¡C ¤U¥«¥u·|¥[³t³Q¨ÖÁÊ¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/24 ¤W¤È 08:57:50²Ä 5631 ½g¦^À³
|
§Ú¬O»{¬°¦Ñ·à¨S±Ï¤F ªñ´Á¤½¥q¬°004°µ¤F«Ü¦h¸É¥R¸ÕÅç¤ÀªR¤Î»¡©ú¡A ¥«³õ¨Ì¤£¶R³æµL¤ÏÀ³¡A¬Æ¦ÜÁ٤ϦV¤ÏÀ³¡A ³s°ò¥»ªº1¤¸¬üª÷ªÑ»ù¤]¯¸¤£¤W ÅýªÑ²¼¦b¤U¥«Ãä½tÄÆÀú ªÑ»ùªø´Á¦b¾ú¥v§CÂI®¶Àú¡A¦pªG¤½¥q¯u¦³¥¼¨Ó»P«e´º ¬°¦ó¤jªÑªF¤£§Q¥Î¾÷·|¼W¥[«ùªÑ¡A¬O§_¹ï¤½¥q¥¼¨Ó¥ç¤£¨ã«H¤ß ³o®a¤½¥q¦h¦¸¦b¸Ñª¼«e«á¤£¤@P¨¥½×¡A³y¦¨¥«³õ¹ï¨äµoªí¤§µ²ªG³£©ê«ùÃhºÃºA«× ´Nºâ004 MOA¾÷¨î¦³®Ä¡A¤]¬O¸Ó¤½¥q¦Û¤v»¡ªº¡A¬O§_¥i«HÁÙn·r°u ¤]³\¹ÚÀ³¸Ó¿ô¤F |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/23 ¤U¤È 06:58:26²Ä 5630 ½g¦^À³
|
¥xÁÞ¤j´¿»¡§ë¸ê·sÃÄn¾aÂI¹B®ð, §¨Ó¤½¥q¥H11»õ¬ü¤¸¨ÖÁÊDERM ¤½¥q/Lebrikizumab ¤é«áÅK©w¤jÁÈ¿ú. ½Ö¯à·Q¨ìLebrikizumab AD¤T´ÁÁ{§É2ÓÁ{§É 16¶gIGA.0,1=43%~33%, 52¶gIGA,0.1=56%/55%~51%/44%.------Àø®Ä¤j´T´£¤É.(2022/09/08 ¤½§G) (Lebrikizumabý³Ý/COPD ¤T´ÁµL¦¨¥\) -------------------------------------- ¦ÓDupilumab+TCS ¤T´ÁÁ{§É QW//Q2W//¹ï·Ó²Õ 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------©M16©PÀø®Ä¬Û·í.(2017/10 ¤½§G) MOA Lebrikizumab µ²¦X¦bIL-13°tÅé B,C Á³±Û,¦ý¥i©MIL13-R£\1 µ²¦X µ²¦X¦bIL-13°tÅé B,C Á³±Û¦Ó¨ÏIL13-R£\1 µLªkµ²¦X¦Ó²Õ¦¨«¬II½Æ¦X¨üÅ餧Àø®Ä¯ÊÂI:IL4µ²¦XIL4-R£\¦A§ä¦³ªÅªºIL-13R£\1¬O¦³¾÷·|ªº. ¬G³y¦¨ý³Ý¤T´ÁÁ{§É¤@Ó¹F¼Ð/¤@Ó¥¼¹F¼Ð//AD¤T´Á2ÓÁ{§É16¶g IGA,0.1 Àø®Ä43%/33%.---®t30% ASLAN004 µ²¦X¦bIL-13R£\1 ¨ÏIL13µLªkµ²¦X IL-13R£\1 µ²¦X¦bIL-13R£\1 ¨ÏIL-13R£\1 µLªkµ²¦X¦Ó²Õ¦¨«¬II½Æ¦X¨üÅ餧Àø®ÄDupilumab µ²¦X¦bIL4-R£\1 ¨ÏIL4µLªkµ²¦XIL4-R£\//YC-R µ²¦X¦bIL4-R£\1 ¨ÏIL4-R£\ µLªkµ²¦XIL13+IL13-R£\¦Ó²Õ¦¨«¬II½Æ¦X¨üÅ餧Àø®Ä |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/23 ¤U¤È 03:37:37²Ä 5629 ½g¦^À³
|
§Æ±æ¦b¼Æ¾Ú´¦ÅS«e³£¯à¥¿±`¥æ©ö¡A«ô°Uªü«iô·dÓ¥¿¦V´Á¤¤¼Æ¾Úµ¹§ë¸ê¤H§a! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/23 ¤U¤È 03:11:08²Ä 5628 ½g¦^À³
|
¥¼¨Ó2b ASLAN004Àø®Ä¡Aok Lebrikizumab °²³]°ò缐¦PEASI25.5 EAS75 16%°ª©óLebrikizumab 2b¾÷²v«D±`°ª IGA 27%°ª©óLebrikizumab 2b ¾÷²v«D±`°ª EASI75 =73%¡K.ASLAN004 2b ´Á±æÈ ¡]°²³]¹ï·Ó²Õ¦PLebrikizumab ªºÀø®Ä24%) 73%/61%=116% IGA0,1 =57% ¡KASLAN004 2b´Á±æÈ¡]°²³]¦PLebrikizumab ªºÀø®Ä15%¡^ 57%/45%=127% ⋯Lebrikizumab 3´Á52¶gIGA0¡A1 ¤w¥§¡¹F51%¡]42%¡ã56%¡^ Dupilumab¤QTCS 3´Á52¶gIGA 0¡A1 ¹F36%¡]2¶g¤@°w¡^ ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/17 ¤U¤È 01:05:01²Ä 5600 ½g¦^À³ clinicaltrials.gov/ct2/show/results/NCT03443024 Lebrikizumab 2b AD Á{§É 2¶g¤@°wx16¶g¡AN=75:52¡A°ò½uEASI25¡P5 ¡G27¡P5 ©M¹ï·Ó²ÕÀø®Äpk 1.IGA0¡A1 45%¤@15%=30% 2EASI 75 61%¤@24%=37% |
|
|
|